Prof Andrew Phillips

Photo

Personal Profile

Name: Andrew Phillips Email: andrew.phillips@ucl.ac.uk
Title: Prof Tel:
Department: Infection & Population Health Fax:
Position: Professor of Epidemiology and Biostatistics Address: , , ,
Research Domain: Global Health, Infection, Immunology & Inflammation, Personalised Medicine, Populations & Lifelong Health Web Page:  

Profile

Research Description

Design and analysis of cohort studies and trials of HIV infection and the effect of antiretroviral therapy. Stochastic computer simulation models of HIV transmission, progression and the effect of antiretroviral therapy.

Research Activities

Epidemiology of HIV infection

HIV

Education Description

UCL Collaborators

Prof Peter Coveney; Prof Amanda Mocroft; Prof Nigel Klein; Prof Deenan Pillay; Prof Greg Towers

External Collaborators

Publications

    2014

    • Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB (2014). Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.. Lancet Glob Health, 2(1), e23 - e34. doi:10.1016/S2214-109X(13)70172-4
    • Williams I, Horne R, Phillips A, Sabin C, Edwards S, Waters L, Churchill D, Fisher M, Gilleece Y, Anderson J, Boffito M, Bower M, Nelson M, Pozniak A, Winston A, Cairns G, Trevelion R, Cwynarski K, Johnson M, Marshall N, Youle M, Fidler S, Freedman A, Geretti AM, Khoo S, Leen C, Orkin C, Paton N, Post F, Ustianowski A, Wilkins E, Walsh J (2014). British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight). HIV Medicine, 15(S1), 1 - 6. doi:10.1111/hiv.12119
    • Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, d'Arminio Monforte A, Phillips AN, Sabin CA, Lundgren JD (2014). Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet, , - .
    • Cori A, Fraser C, Eaton JW, Mishra S, Boily M-C, Mountain E, Pickles M, Hallett TB, Menzies NA, Salomon JA, Chindelevitch L, Humair S, Bärnighausen T, Bloom DE, Cohen T, Stover J, Gopalappa C, Pretorius C, Cambiano V, Phillips A, Hontelez JAC, Bakker R, de Vlas SJ, Nichols BE, van de Vijver DAMC, Mikkelsen E, Kerr CC, Pham QD, Wilson DP, Zhang L, Klein DJ, Bershteyn A, Chang ST, Wagner BG, Mitchell KM, Vickerman P, Martin NK, Platt L, Prudden HJ, Remme M, Terris-Prestholt F, Dodd PJ, White RG, Lundgren J, Blandford J, Sangrujee N, Meyer-Rath G, Revill P, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G (2014). Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: A combined analysis of 12 mathematical models. The Lancet Global Health, 2(1), - . doi:10.1016/S2214-109X(13)70172-4
    • Keebler D, Revill P, Braithwaite S, Phillips A, Blaser N, Borquez A, Cambiano V, Ciaranello A, Estill J, Gray R, Hill A, Keiser O, Kessler J, Menzies NA, Nucifora KA, Vizcaya LS, Walker S, Welte A, Easterbrook P, Doherty M, Hirnschall G, Hallett TB (2014). Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. LANCET GLOBAL HEALTH, 2(1), E35 - E43. doi:10.1016/S2214-109X(13)70048-2
    • Cambiano V, Mavedzenge SN, Phillips A (2014). Modelling the Potential Population Impact and Cost-Effectiveness of Self-Testing for HIV: Evaluation of Data Requirements.. AIDS Behav, , - . doi:10.1007/s10461-014-0824-x
    • Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips AN, De Wit S, Ristola M, Lundgren JD, Grarup J, Kirk O, for EuroSIDA in EuroCOORD (2014). A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.. Infection, , - . doi:10.1007/s15010-014-0630-4
    • Rodger AJ, Phillips A, Speakman A, Gilson R, Fisher M, Wilkins E, Anderson J, Johnson M, O'Connell R, Collins S, Elford J, Sherr L, Lampe FC, ASTRA (Antiretrovirals, Sexual Transmission Risk and Attitudes) Study Group (2014). Attitudes of People in the UK with HIV Who Are Antiretroviral (ART) Naïve to Starting ART at High CD4 Counts for Potential Health Benefit or to Prevent HIV Transmission.. PLoS One, 9(5), e97340 - . doi:10.1371/journal.pone.0097340
    • Miners A, Rodger A, Speakman A, Phillips A, Fisher M, Anderson J, Collins S, Hart G, Sherr L, Lampe F (2014). HIV and health-related quality-of-life in the UK - where are we now?. HIV MEDICINE, 15, 3 - 4.
    • Burch L, Oakes-Monger N, Smith C, Lampe F, Tsintas R, Chaloner C, Phillips A, Johnson M (2014). Socio-economic factors and late diagnosis of HIV in 2011-2013 in the Royal Free cohort. HIV MEDICINE, 15, 107 - 108.
    • Inshaw J, Leen C, Fisher M, Gilson R, Hawkins D, Fox J, Mclean K, Fidler S, Phillips A, Babiker A, Porter K (2014). The effect of HCV infection duration on HIV disease progression.
    • Parsons V, Phillips A, Gilson R, Fidler S, Fox J, Fisher M, Johnson A, Hawkins D, McLean K, Johnson M, Collins S, Hart G, Porter K (2014). Temporal trends in cART initiation amongst HIV seroconverters in the UK. HIV MEDICINE, 15, 3 - 3.
    • Brima N, Lampe F, Smith C, Phillips A, Copas A, Gilson R, Johnson M, Williams I, Milinkovic A, Burns F, Kinloch-de Loes S, Edwards S (2014). Early virological response to antiretroviral therapy: can we predict earlier who is unlikely to achieve a response at 6 months?. HIV MEDICINE, 15, 129 - 129.
    • Jose S, Chan K, Samji H, Cescon A, Hill T, Shurgold S, Phillips A, Hogg R, Sabin C (2014). A comparison of virological outcomes among HIV-positive individuals receiving HAART in Canada and the UK. HIV MEDICINE, 15, 121 - 121.
    • Phillips AN, Munderi P, Revill PA, El-Sadr WM, Lundgren JD (2014). Antiretroviral therapy recommendations for the global community: aspiration versus reality.. AIDS, 28(7), 939 - 941. doi:10.1097/QAD.0000000000000171
    • Hodcroft E, Hadfield JD, Fearnhill E, Phillips A, Dunn D, O'Shea S, Pillay D, Leigh Brown AJ, on behalf of the UK HIV Drug Resistance Database and the UK CHIC Study (2014). The Contribution of Viral Genotype to Plasma Viral Set-Point in HIV Infection.. PLoS Pathog, 10(5), e1004112 - . doi:10.1371/journal.ppat.1004112
    • Nakagawa F, Phillips AN, Lundgren JD (2014). Update on HIV in Western Europe.. Curr HIV/AIDS Rep, , - . doi:10.1007/s11904-014-0198-8
    • Johnston V, Cohen K, Wiesner L, Morris L, Ledwaba J, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD (2014). Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch. JOURNAL OF INFECTIOUS DISEASES, 209(5), 711 - 720. doi:10.1093/infdis/jit411
    • Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD, INSIGHT SMART and ESPRIT Study Groups and the SILCAAT Scientific Committee (2014). Factors Associated with D-Dimer Levels in HIV-Infected Individuals.. PLoS One, 9(3), e90978 - . doi:10.1371/journal.pone.0090978
    • Lundgren JD, Phillips A (2014). Antiretroviral dose reduction: good for patients and rollout.. Lancet, , - . doi:10.1016/S0140-6736(13)62556-8
    • Cambiano V, Bertagnolio S, Jordan MR, Pillay D, Perriëns JH, Venter F, Lundgren J, Phillips A (2014). Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation.. AIDS, 28 Suppl 1, S15 - S23. doi:10.1097/QAD.0000000000000082
    • Borges AH, Weitz JI, Collins G, Baker JV, Lévy Y, Davey RT, Phillips AN, Neaton JD, Lundgren JD, Deeks SG, INSIGHT SILCAAT Scientific Committee (2014). Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease.. AIDS, 28(12), 1791 - 1796. doi:10.1097/QAD.0000000000000344

    2013

    • Geretti AM, Cozzi-Lepri A, Vitiello P, King S, Owen A, Phillips A, Grp ERASS (2013). HIV-1 DNA decline during long-term first-line NNRTI-based ART with consistent plasma HIV-1 RNA suppression below 50 copies/ml.
    • Rodger AJ, Bruun T, Vernazza P, Collins S, Estrada V, Van Lunzen J, Corbelli GM, Phillips AN, Lundgren JD, PARTNER Study Group (2013). Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative.. Antivir Ther, 18(3), 285 - 287. doi:10.3851/IMP2609
    • van de Vijver DAMC, Nichols BE, Abbas UL, Boucher CAB, Cambiano V, Eaton JW, Glaubius R, Lythgoe K, Mellors J, Phillips A, Sigaloff KC, Hallett TB (2013). Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS, 27(18), 2943 - 2951. doi:10.1097/01.aids.0000433237.63560.20
    • Babiker AG, Emery S, Faetkenheuer G, Gordin FM, Grund B, Lundgren JD, Neaton JD, Pett SL, Phillips A, Touloumi G, Vjecha MJ, Grp INSIGHTSTARTS (2013). Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. CLINICAL TRIALS, 10, S5 - S36. doi:10.1177/1740774512440342
    • O'Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, Chadwick D, Fisher M, Ainsworth J, Gilson R, Mackie N, Anderson J, Orkin C, Nelson M, Kegg S, Leen C, Palfreeman A, Post F, Johnson M, Sabin CA, Phillips AN (2013). Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.. AIDS, , - . doi:10.1097/QAD.0000000000000165
    • Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter K, EuroCoord CASCADEC (2013). Symptomatic Illness and Low CD4 Cell Count at HIV Seroconversion as Markers of Severe Primary HIV Infection. PLOS ONE, 8(11), - . doi:10.1371/journal.pone.0078642
    • Cambiano V, O Connor J, Phillips A, Rodger A, Lodwick R, Pharris A, Lampe F, Nakagawa F, Smith C, van de Laar M (2013). Antiretroviral therapy for prevention of HIV transmission: implications for Europe.. Euro Surveill, 18(48), - .
    • Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, Wit SD, Phillips A, Lundgren JD, Sabin CA, D:A:D Study Group (2013). Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study.. BMC Infect Dis, 13, 471 - . doi:10.1186/1471-2334-13-471
    • Phillips A, Baker J, Lundgren J (2013). Are antiretrovirals enough for people living with HIV?. Lancet, 382(9903), 1466 - 1467. doi:10.1016/S0140-6736(13)62072-3
    • Geretti AM, Fox Z, Johnson JA, Lipscomb J, Booth C, Stuyver LJ, Tachedjian G, Baxter J, Touloumi G, Lehmann C, Owen A, Phillips A (2013). Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. PLoS ONE, 8(7), - . doi:10.1371/journal.pone.0069266
    • Lodi S, Phillips A, Fidler S, Hawkins D, Gilson R, McLean K, Fisher M, Post F, Johnson AM, Walker-Nthenda L, Dunn D, Porter K, on behalf of the UK Register of HIV (2013). Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure.. PLoS One, 8(9), e75608 - . doi:10.1371/journal.pone.0075608
    • Kaulich-Bartz J, Dam W, May MT, Lederberger B, Widmer U, Phillips AN, Grabar S, Mocroft A, Vilaro J, van SA, Moreno S, Dabis F, Monforte AD, Teira R, Ingle SM, Sterne JA (2013). Insurability of HIV positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS, , - . doi:10.1097/QAD.0b013e3283601199
    • Abgrall S, Ingle SM, May MT, Cornish R, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Sirvent JLG, Sterne JAC, Coll ATC (2013). Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS, 27(5), 803 - 813. doi:10.1097/QAD.0b013e32835cb997
    • Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, Monforte AD, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J (2013). Associations between immune depression and cardiovascular events in hiv infection.. AIDS, , - . doi:10.1097/01.aids.0000432457.91228.f3
    • Huang X, Li W, Li N, Wu H, Lodi S, Porter K, Fox Z, Phillips A, Johnson AM, Lutsar I, Kelleher A, Xu X (2013). Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: A comparison between the Beijing PRIMO and CASCADE cohorts. Journal of Acquired Immune Deficiency Syndromes, 62(4), 441 - 446. doi:10.1097/QAI.0b013e31827f5c9a
    • Cambiano V, Bertagnolio S, Jordan MR, Lundgren JD, Phillips A (2013). Transmission of Drug Resistant HIV and Its Potential Impact on Mortality and Treatment Outcomes in Resource-Limited Settings.. J Infect Dis, 207 Suppl 2, S57 - S62. doi:10.1093/infdis/jit111
    • Geretti AM, Vitiello P, King S, Cozzi-Lepri A, Phillips A, ERAS SG (2013). HIV-1 RNA and HIV-1 DNA persistence during long-term suppressive ART. HIV MEDICINE, 14, 9 - 9.
    • Rodger A, Phillips A, Sturgeon K, Sewell J, Asboe D, Fedele S, Nwokolo N, Gilson R, De Esteban N, Jennings L, Gompels M, Allan S, Clay S, Engler B, Wandolo E, Campbell L, Hobbs K, Fisher M, Perry N, Dhar J, Mashonganyika L, O'Connell R, Tawana C, Bruun T, Cambiano V, Collins S, Nightingale A, Lundgren J (2013). Continued high levels of condomless sex in serodifferent couples when the positive partner is on antiretroviral therapy: the PARTNER study.
    • O'Connor J, Smith C, Lampe F, Johnson M, Sabin C, Phillips A (2013). Failure to achieve an adequate CD4 count response despite regular engagement in HIV care and consistent viral suppression. HIV MEDICINE, 14, 25 - 26.
    • Lampe F, Speakman A, Sherr L, Phillips A, Collins S, Gilson R, Johnson M, Fisher M, Wilkins E, Anderson J, Daskalopoulou M, Edwards S, McDonnell J, Perry N, Jones M, O'Connell R, Lascar M, Hart G, Johnson A, Miners A, Geretti A, Burman W, Elford J, Rodger A (2013). Psychological and physical symptoms and sexual behaviour among HIV-diagnosed men who have sex with men (MSM) in the UK.
    • Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) , Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A, Lodwick R, Torti C, Dorrucci M, Günthard HF, Michalik C, Chrysos G, Castagna A (2013). Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.. J Infect Dis, 207(5), 759 - 767. doi:10.1093/infdis/jis752
    • Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD, EuroCOORD ES (2013). CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. AIDS, 27(6), 907 - 918. doi:10.1097/QAD.0b013e32835cb766
    • Rodger AJ, Lodwick R, Schecter M, Deeks S, Amin J, Gilson R, Paredes R, Bakowska E, Engsig FN, Phillips A (2013). Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT Trials compared to the general population. AIDS, 27, 973 - 979.
    • Kovari H, Sabin CA, Ledergerber B, Ryom L, Worm SW, Smith C, Phillips A, Reiss P, Fontas E, Petoumenos K, De Wit S, Morlat P, Lundgren JD, Weber R (2013). Antiretroviral Drug-Related Liver Mortality Among HIV-Positive Persons in the Absence of Hepatitis B or C Virus Coinfection: The Data Collection on Adverse Events of Anti-HIV Drugs Study. CLINICAL INFECTIOUS DISEASES, 56(6), 870 - 879. doi:10.1093/cid/cis919
    • Sabin CA, Ryom L, Kovari H, Kirk O, de Wit S, Law M, Reiss P, Dabis F, Pradier C, El-Sadr W, Monforte AD, Kamara D, Phillips AN, Lundgren JD (2013). Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study.. J Acquir Immune Defic Syndr, 63(4), 456 - 463. doi:10.1097/QAI.0b013e318291cd29
    • Phillips AN, Cambiano V, Nakagawa F, Brown AE, Lampe F, Rodger A, Miners A, Elford J, Hart G, Johnson AM, Lundgren J, Delpech VC (2013). Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic.. PLoS One, 8(2), e55312 - . doi:10.1371/journal.pone.0055312
    • Monforte AD, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, Worm SW, Law MG, Weber R, Kirk O, Pradier C, Phillips AN, Lundgren JD, Sabin CA (2013). Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.. AIDS, 27(3), 407 - 415. doi:10.1097/QAD.0b013e32835b2ef1
    • Peters B, Post F, Wierzbicki AS, Phillips A, Power L, Das S, Johnson M, Moyle G, Hughes L, Wilkins E, McCloskey E, Compston J, Di Angelantonio E (2013). Screening for chronic comorbid diseases in people with HIV: the need for a strategic approach. HIV MEDICINE, 14, 1 - 11. doi:10.1111/j.1468-1293.2012.01055.x
    • O'Connor JL, Gardner EM, Mannheimer SB, Lifson AR, Esser S, Telzak EE, Phillips AN, INSIGHT SMART Study Group (2013). Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial.. J Infect Dis, 208(1), 40 - 49. doi:10.1093/infdis/jis731
    • Nakagawa F, May M, Phillips A (2013). Life expectancy living with HIV: recent estimates and future implications.. Curr Opin Infect Dis, 26(1), 17 - 25. doi:10.1097/QCO.0b013e32835ba6b1
    • Speakman A, Rodger A, Phillips AN, Gilson R, Johnson M, Fisher M, Ed Wilkins , Anderson J, O'Connell R, Lascar M, Aderogba K, Edwards S, McDonnell J, Perry N, Sherr L, Collins S, Hart G, Johnson AM, Miners A, Elford J, Geretti AM, Burman WJ, Lampe FC (2013). The 'Antiretrovirals, Sexual Transmission Risk and Attitudes' (ASTRA) Study. Design, Methods and Participant Characteristics.. PLoS One, 8(10), e77230 - . doi:10.1371/journal.pone.0077230
    • Friis-Moller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, De Wit S, Monforte AD, Kirk O, Fontas E, Sabin C, Phillips A, Lundgren JD, Law M, Grp DADS (2013). An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons; the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) Study.

    2012

    • Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D, Phillips A (2012). Second line protease inhibitor (PI/r) based antiretroviral therapy (ART) after non-nucleoside reverse transcriptase inhibitor (NNRTI) failure: impact of nucleoside (NRTI) backbone. Antivir Ther, , - . doi:10.3851/imp2329
    • Cozzi-Lepri A, Paredes , Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD, EuroSIDA in EuroCoord (2012). The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.. HIV Med, 13(1), 62 - 72. doi:10.1111/j.1468-1293.2011.00943.x
    • Lampe F, Speakman A, Phillips A, Sherr L, Gilson R, Johnson M, Fisher M, Wilkins E, Anderson J, Edwards S, McDonnell J, Perry N, Aderogba K, Hart G, Johnson A, Collins S, Elford J, Miners A, Geretti A, Burman B, Rodger A (2012). ART use, viral suppression, and sexual behaviour among HIV-diagnosed MSM in the UK: results from the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study. doi:10.7448/IAS.15.6.18143
    • Sethi G, Edwards S, Soni S, Gilson R, Anderson J, Palfreeman A, Post F, Delpech V, Fisher M, Hill T, Walsh J, Gazzard B, Bansi L, Leen C, Dunn D, Johnson M, Phillips AN, Orkin C, Gompels M, Ainsworth J, Sabin CA, HIV UKC (2012). Uptake and Outcome of Combination Antiretroviral Therapy in Men Who Have Sex with Men According to Ethnic Group: The UK CHIC Study. doi:10.1097/QAI.0b013e318245c9ca
    • van de Vijver D, Nichols B, Abbas U, Cambiano V, Eaton J, Glaubius R, Lythgoe K, Mellors J, Phillips A, Sigaloff K, Hallett T (2012). Pre-exposure prophylaxis (PrEP) will have a limited impact on the prevalence of HIV-1 drug resistance in sub-Saharan Africa: comparison of mathematical models. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 15, 140 - 141.
    • Mocroft A, Phillips A, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Kirk O, Lundgren J (2012). CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use.. J Int AIDS Soc, 15(6), 18191 - .
    • Phillips A, Cambiano V, Nakagawa F, Brown A, Lampe F, Rodger A, Miners A, Elford J, Johnson A, Hart G, Lundgren J, Delpech V (2012). Increased HIV incidence in men who have sex with men despite high levels of ART use: analysis of an extensively documented epidemic.. J Int AIDS Soc, 15(6), 18174 - .
    • Lampe F, Speakman A, Phillips A, Sherr L, Gilson R, Johnson M, Fisher M, Wilkins E, Anderson J, Edwards S, McDonnell J, Perry N, Aderogba K, Hart G, Johnson A, Collins S, Elford J, Miners A, Geretti A, Burman B, Rodger A (2012). ART use, viral suppression, and sexual behaviour among HIV-diagnosed MSM in the UK: results from the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study..
    • (2012). Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect.Dis., 12(2), 119 - 127. doi:10.1016/S1473-3099(11)70248-1
    • Johnston V, Fielding K, Charalambous S, Mampho M, Churchyard G, Phillips A, Grant AD (2012). Second-Line Antiretroviral Therapy in a Workplace and Community-Based Treatment Programme in South Africa: Determinants of Virological Outcome. PLOS ONE, 7(5), - . doi:10.1371/journal.pone.0036997
    • Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, Bloom DE, Cambiano V, Fraser C, Hontelez JA, Humair S, Klein DJ, Long EF, Phillips AN, Pretorius C, Stover J, Wenger EA, Williams BG, Hallett TB (2012). HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa.. PLoS Med, 9(7), e1001245 - . doi:10.1371/journal.pmed.1001245
    • Cambiano V, Phillips AN (2012). The role of individual-based models in understanding the potential impact of antiretroviral therapy for prevention.. AIDS, 26(11), 1441 - 1442. doi:10.1097/QAD.0b013e3283546623
    • (2012). Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. Bmj, 345, e5253 - . doi:10.1136/bmj.e5253
    • Johnston V, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD (2012). Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program.. J Acquir Immune Defic Syndr, 61(3), 370 - 380. doi:10.1097/QAI.0b013e318266ee3f
    • von Wyl V, Cambiano V, Jordan MR, Bertagnolio S, Miners A, Pillay D, Lundgren J, Phillips AN (2012). Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.. PLoS One, 7(8), e42834 - . doi:10.1371/journal.pone.0042834
    • Rodger A, Bruun T, Weait M, Vernazza P, Collins S, Estrada V, Lunzen JV, Corbelli GM, Lampe F, Phillips A, Lundgren J, PARTNER study group (2012). Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods.. BMC Public Health, 12, 296 - . doi:10.1186/1471-2458-12-296
    • Jordan MR, Bennett DE, Wainberg MA, Havlir D, Hammer S, Yang C, Morris L, Peeters M, Wensing AM, Parkin N, Nachega JB, Phillips A, De Luca A, Geng E, Calmy A, Raizes E, Sandstrom P, Archibald CP, Perriens J, McClure CM, Hong SY, McMahon JH, Dedes N, Sutherland D, Bertagnolio S (2012). Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011. CLINICAL INFECTIOUS DISEASES, 54, S245 - S249. doi:10.1093/cid/cis206
    • Lodwick R, Johnson M, Smith C, Lipman M, Cambiano V, Tyrer M, Phillips A, Lampe F (2012). Effect of patient smoking status on CD4 count change after initiation of antiretroviral therapy. HIV MEDICINE, 13, 73 - 73.
    • Smith C, Lampe F, Chaloner C, Kinloch S, Tsintas R, Madge S, Phillips A, Johnson M (2012). Continued improvements in clinical outcomes in the current ART era: epidemiology of a complete clinic population. HIV MEDICINE, 13, 66 - 66.
    • Nakagawa F, Miners A, Smith C, Smith R, Lodwick R, Cambiano V, Lundgren J, Delpech V, Phillips A (2012). Projected lifetime healthcare costs associated with HIV infection. HIV MEDICINE, 13, 66 - 67.
    • Dolling D, Phillips AN, Delpech V, Pillay D, Cane PA, Crook AM, Shepherd J, Fearnhill E, Hill T, Dunn D, Database UKHIVDR, CHI UCHCU (2012). Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV MEDICINE, 13(5), 309 - 314. doi:10.1111/j.1468-1293.2011.00968.x
    • Lampe F, Speakman A, Phillips A, Sherr L, Gilson R, Johnson M, Fisher M, Anderson J, Wilkins E, Broussard C, McDonnell J, Perry N, Scourse R, George V, Hart G, Johnson A, Collins S, Miners A, Elford J, Geretti A-M, Burman W, Rodger A (2012). Depression and virological status among UK HIV outpatients: results from a multicentre study.
    • Muessig KE, Smith MK, Powers KA, Lo YR, Burns DN, Grulich AE, Phillips AN, Cohen MS (2012). Does ART prevent HIV transmission among MSM?. AIDS, 26(18), 2267 - 2273. doi:10.1097/QAD.0b013e328355713d
    • del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Perez-Hoyos S, Jarrin I, Phillips A, Lodi S, van Sighem A, de Wolf F, Sabin C, Bansi L, Justice A, Goulet J, Miro JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernan MA, Collaboration HIV-CAUSAL (2012). Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. CLINICAL INFECTIOUS DISEASES, 54(9), 1364 - 1372. doi:10.1093/cid/cis203
    • Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel N, Kirk O, Miro JM, Furrer H, Castagna A, De Wit S, Munoz J, Kjaer J, Colin C, Grarup J, Chene G, Bucher H, Furrer H, Miro J, Zangerle R, Antoniadou A, Ghosn J, Morlat P, Le Moing V, Reiss P, Fisher M, Sharland M, Mocroft A, Kirk O, Stephan C, Girardi E, Torti C, Mussini C, Galli L, Ledergerber B, Teira R, Zangerle R, Touloumi G, Warszawski J, Meyer L, Dabis F, Krause MM, Ghosn J, Leport C, de Wolf F, Reiss P, Prins M, Buecher H, Sabin C, Gibb D, Faetkenheuer G, Del Amo J, Obel N, Thorne C, Mocroft A, Kirk O, Stephan C, Perez-Hoyos S, Noguera-Julian A, Antinori A, Monforte AD, Brockmeyer N, Ramos J, Battegay M, Rauch A, Mussini C, Tookey P, Casabona J, Castagna A, Goetghebuer T, Torti C, Teira R, Garrido M, Haerry D, Weller I, Casabona J, Costagliola D, Battegay M, Prins M, Paulsen M, Bohlius J, Bouteloup V, Bucher H, Cozzi-Lepri A, Dorrucci M, Egger M, Engsig F, Furrer H, Kirk O, Lambotte O, Lewden C, Lodwick R, Matheron S, Meyer L, Mocroft A, Obel N, Paredes R, Phillips A, Puoti M, Reekie J, Sabin C, Scherrer A, Smit C, Sterne J, Thiebaut R, Thorne C, Torti C, von Wyl V, Wittkop L, EuroCoord COHERE, Grp EAIDST (2012). y CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. PLOS MEDICINE, 9(3), - . doi:10.1371/journal.pmed.1001194
    • Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A, Jansen K, Masquelier B, Garcia F, De Wit S, Stephan C, Obel N, Faetkenheuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Colin CF, Kjaer J, Chene G, Grarup J, Phillips A, Castagna A, Costagliola D, Cozzi-Lepri A, De Luca A, De Wit S, de Wolf F, Dorrucci M, Duval X, Faetkenheuer G, Garcia F, Ghosn J, Guenthard H, Jansen K, Jorgensen L, Judd A, Ledergerber B, Lo Caputo S, Lodwick R, Masquelier B, Meyer L, Mocroft A, Mussini C, Noguera-Julian A, Obel N, Paraskevis D, Paredes R, Perez-Hoyos S, Phillips A, Pillay D, Podzamczer D, Ramos JT, Stephan C, Tookey PA, Torti C, Touloumi G, van Sighem A, Warsawski J, Zangerle R, Zangerle R, Touloumi G, Warszawski J, Meyer L, Dabis F, Krause MM, Ghosn J, Leport C, de Wolf F, Reiss P, Prins M, Buecher H, Sabin C, Gibb D, Faetkenheuer G, Del Amo J, Obel N, Thorne C, Mocroft A, Kirk O, Stephan C, Perez-Hoyos S, Noguera-Julian A, Antinori A, Monforte AD, Brockmeyer N, Ramos J, Battegay M, Rauch A, Mussini C, Tookey P, Casabona J, Miro JM, Castagna A, de Wit S, Goetghebuer T, Torti C, Teira R, Garrido M, Haerry D, Grp COHERE, Comm AW, Team PLATOIIP, Comm COHERES, Grp EAIDST (2012). Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 59(3), 294 - 299. doi:10.1097/QAI.0b013e31823fe66b
    • Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, Phillips AN, Geretti AM (2012). Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy.. Clin Infect Dis, 54(5), 724 - 732. doi:10.1093/cid/cir936
    • Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh Thomas A, Anderson J, Post F, Pillay D, Gazzard B, Hill T, Johnson M, Gilson R, Bansi L, Easterbrook P, Fisher M, Walsh J, Orkin C, Ainsworth J, Leen C, Sabin C, UK Collaborative HIV Cohort (UK CHIC) Study (Appendix) (2012). Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?. J Infect Dis, 205(4), 540 - 547. doi:10.1093/infdis/jir380
    • Worm SW, Kamara DA, Reiss P, Fontas E, De Wit S, El-Sadr W, Monforte AD, Law M, Phillips A, Ryom L, Dabis F, Weber R, Sabin C, Lundgren JD, Grp DADS (2012). Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke. JOURNAL OF INFECTIOUS DISEASES, 205(4), 535 - 539. doi:10.1093/infdis/jir788
    • Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C, Walsh J, Fisher M, Sabin C, UK Collaborative HIV Cohort Study (2012). Biomarkers to monitor safety in people on art and risk of mortality.. J Acquir Immune Defic Syndr, 60(1), 51 - 58. doi:10.1097/QAI.0b013e31824d2134
    • Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A, Dunn D, Gazzard B, Gilson R, Post F, Phillips AN, Walsh J, Orkin C, Delpech V, Ainsworth J, Leen C, Sabin CA, UK Collaborative HIV Cohort (CHIC) Study (2012). Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK.. HIV Med, 13(1), 73 - 78. doi:10.1111/j.1468-1293.2011.00956.x
    • Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O, EuroSIDA study group (2012). Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.. AIDS, 26(3), 315 - 323. doi:10.1097/QAD.0b013e32834e8805
    • Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, Delpech V, Phillips AN (2012). Projected life expectancy of people with HIV according to timing of diagnosis.. AIDS, 26(3), 335 - 343. doi:10.1097/QAD.0b013e32834dcec9
    • Phillips A, Cambiano V, Nakagawa F, Brown A, Lampe F, Rodger A, Miners A, Elford J, Johnson A, Hart G, Lundgren J, Delpech V (2012). Increased HIV incidence in men who have sex with men despite high levels of ART use: analysis of an extensively documented epidemic. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 15, 15 - 15. doi:10.7448/IAS.15.6.18174

    2011

    • Worm SW, Kamara D, Reiss P, Law M, Monforte AD, Phillips A, Ryom L, Dabis F, Weber R (2011). Evaluation of sudden death and non-haemorrhagic stroke and their association with HIV protease inhibitor (PI) usage. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 25(6), V - V.
    • Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M, Phillips A, Johnson M, Gilson R, Easterbrook P, Leen C, Porter K, Gazzard B, Sabin C, UK CHIC Steering Committee (2011). Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.. HIV Med, 12(5), 289 - 298. doi:10.1111/j.1468-1293.2010.00881.x
    • Rodger A, Phillips A, Lundgren J (2011). Prevention of HIV-1 Infection with Antiretroviral Therapy. NEW ENGLAND JOURNAL OF MEDICINE, 365(20), 1934 - 1934.
    • Cozzi-Lepri A, Prosperi MC, Kjær J, Dunn D, Paredes R, Sabin CA, Lundgren JD, Phillips AN, Pillay D, EuroSIDA Study , United Kingdom CHIC/United Kingdom HDRD Study (2011). Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.. PLoS One, 6(11), e25665 - . doi:10.1371/journal.pone.0025665
    • Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Gunthard HF, Chene G, Monforte AD, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JAC, Saag MS, AIDS Clinical Trial Grp DACS 241 T , AIDS Clinical Trial Grp Study 5095 , AIDS Clinical Trial Grp Study 5142 , Antiretroviral Cohort Collaboratio (2011). Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study. JAIDS-J ACQ IMM DEF, 58(3), 253 - 260. doi:10.1097/QAI.0b013e318230372e
    • May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B, Hill T, Walsh J, Fisher M, Orkin C, Ainsworth J, Bansi L, Phillips A, Leen C, Nelson M, Anderson J, Sabin C (2011). Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.. BMJ, 343, d6016 - .
    • Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T, Walsh J, Fisher M, Johnson M, Post F, Easterbrook P, Gazzard B, Palfreeman A, Orkin C, Leen C, Gompels M, Dunn D, Delpech V, Pillay D, Sabin CA, UK CHIC Study Steering Committee (2011). Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.. Antivir Ther, 16(6), 805 - 814. doi:10.3851/IMP1818
    • Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiebaut R, Pantazis N, del Amo J, Johnson AM, Babiker A, Porter K, CASCADE Collaboration EuroCoord (2011). Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds < 200, < 350, and < 500 Cells/mm(3): Assessment of Need Following Changes in Treatment Guidelines. CLIN INFECT DIS, 53(8), 817 - 825. doi:10.1093/cid/cir494
    • Garcia F, Alvarez M, Fox Z, Garcia-Diaz A, Guillot V, Johnson M, Chueca N, Phillips A, Hernandez-Quero J, Geretti AM (2011). Predicting antiretroviral drug resistance from the latest or the cumulative genotype. ANTIVIR THER, 16(3), 373 - 381. doi:10.3851/IMP1753
    • Kamara DA, Worm SW, Reiss P, Rickenbach M, Phillips A, Kirk O, Monforte AD, Bruyand M, Law M, De Wit S, Smith CJ, Pradier C, Lundgren J, Sabin C, Data Collection Adverse Events (2011). The Impact of Fasting on the Interpretation of Triglyceride Levels for Predicting Myocardial Infarction Risk in HIV-Positive Individuals: The D:A:D Study. J INFECT DIS, 204(4), 521 - 525. doi:10.1093/infdis/jir329
    • Fox ZV, Cozzi-Lepri A, D'Arminio Monforte A, Karlsson A, Phillips AN, Kronborg G, Kjaer J, Clotet B, Lundgren JD, EuroSIDA (2011). Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA.. Antivir Ther, 16(5), 781 - 785. doi:10.3851/IMP1801
    • Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M, Phillips A, Johnson M, Gilson R, Easterbrook P, Leen C, Porter K, Gazzard B, Sabin C, for the UK CHIC Steering Committee (2011). Authors' response to Drs Scourfield, Jackson and Nelson.. HIV Med, 12(7), 450 - 451. doi:10.1111/j.1468-1293.2011.00932.x
    • Worm SW, Kamara DA, Reiss P, Kirk O, El-Sadr W, Fux C, Fontas E, Phillips A, D'Arminio Monforte A, De Wit S, Petoumenos K, Friis-Mller N, Mercie P, Lundgren JD, Sabin C (2011). Elevated triglycerides and risk of myocardial infarction in HIV-positive persons.. AIDS, 25(12), 1497 - 1504. doi:10.1097/QAD.0b013e32834917c6
    • Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G, EuroCoord-CHAIN study group (2011). Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.. Lancet Infect Dis, 11(5), 363 - 371. doi:10.1016/S1473-3099(11)70032-9
    • Lodwick R, Alioum A, Archibald C, Birrell P, Commenges D, Costagliola D, De Angelis D, Donoghoe M, Garnett G, Ghys P, Law M, Lundgren J, Ndawinz J, Presanis A, Sabin C, Salminen M, Sommen C, Stanecki K, Stover J, Supervie V, Sweeting M, van de Laar M, van Sighem A, Wand H, Wilson D, Yan P, Phillips A, Working Grp Estimation HIV Prevale (2011). HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV Working Group on Estimation of HIV Prevalence in Europe. AIDS, 25(8), 1017 - 1023. doi:10.1097/QAD.0b013e3283467087
    • Hughes RA, Sterne JA, Walsh J, Bansi L, Gilson R, Orkin C, Hill T, Ainsworth J, Anderson J, Gompels M, Dunn D, Johnson MA, Phillips AN, Pillay D, Leen C, Easterbrook P, Gazzard B, Fisher M, Sabin CA (2011). Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.. HIV Med, 12(10), 583 - 593. doi:10.1111/j.1468-1293.2011.00929.x
    • Mocroft A, Lifson AR, Touloumi G, Neuhaus J, Fox Z, Palfreeman A, Vjecha MJ, Hodder S, De Wit S, Lundgren JD, Phillips AN, INSIGHT SMART Study Group (2011). Haemoglobin and anaemia in the SMART study.. Antivir Ther, 16(3), 329 - 337. doi:10.3851/IMP1746
    • Kowalska JD, Friis-Møller N, Kirk O, Bannister W, Mocroft A, Sabin C, Reiss P, Gill J, Lewden C, Phillips A, D'Arminio Monforte A, Law M, Sterne J, De Wit S, Lundgren JD, CoDe Working Group , D:A:D Study Group (2011). The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology.. Epidemiology, 22(4), 516 - 523. doi:10.1097/EDE.0b013e31821b5332
    • Vitiello P, Garcia A, Booth C, Fox Z, Owen A, Johnson J, Phillips A, Geretti AM (2011). Drug levels and drug resistance after interruption of NNRTI-based HAART in the SMART trial. HIV MED, 12, 4 - 5.
    • Smith C, Phillips A, Johnson M, Lodwick R, Cambiano V, Lampe F (2011). Frequency of treatment interruptions over calendar time: the impact of the results of the SMART study. HIV MED, 12, 84 - 84.
    • Doyle T, Vitiello P, Smith C, Cambiano V, Owen A, Phillips A, Geretti AM (2011). Low-level viraemia below 50 copies/ml in treated HIV-infected patients predicts viral load rebound above 400 copies/ml independently of adherence levels. HIV MED, 12, 22 - 23.
    • Cambiano V, Phillips AN (2011). Modelling the impact of treatment with individual antiretrovirals.. Curr Opin HIV AIDS, 6(2), 124 - 130. doi:10.1097/COH.0b013e328343ad66
    • Lazarus JV, Jürgens R, Weait M, Phillips A, Hows J, Gatell J, Coenen T, Sönnerborg A, Raben D, Lundgren JD (2011). Overcoming obstacles to late presentation for HIV infection in Europe.. HIV Med, 12(4), 246 - 249. doi:10.1111/j.1468-1293.2010.00872.x
    • Smith CJ, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte AD, Kirk O, Friis-Moller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW (2011). Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study (vol 24, pg 1537, 2010). AIDS, 25(6), 883 - 883. doi:10.1097/QAD.0b013e328343f97f
    • Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Phillips AN, Sabin CA, UK Collaborative HIV Cohort CHIC (2011). HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. EUR J NEUROL, 18(3), 527 - 534. doi:10.1111/j.1468-1331.2010.03291.x
    • Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Palfreeman A, Gompels M, Phillips AN, Sabin CA, UK Collaborative HIV Cohort (CHIC) study (2011). Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease.. Neurology, 76(8), 693 - 700. doi:10.1212/WNL.0b013e31820d8b0b
    • Bansi L, Smith C, Phillips A, Kirk S, Geretti AM, Johnson M, Mackie N, Post F, Gazzard B, Dunn D, Sabin C, UK Collaborative HIV Cohort (CHIC) Study and the UK Collaborative Group on HIV Drug Resistance (HDRD) (2011). The impact of HIV drug resistance testing on changes to treatment.. AIDS, 25(5), 603 - 610. doi:10.1097/QAD.0b013e32834403a0
    • Cambiano V, Rodger AJ, Phillips AN (2011). 'Test-and-treat': the end of the HIV epidemic?. Curr Opin Infect Dis, 24(1), 19 - 26. doi:10.1097/QCO.0b013e3283422c8c
    • Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A, EuroSIDA group (2011). Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.. J Antimicrob Chemother, 66(4), 901 - 911. doi:10.1093/jac/dkr006
    • Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, Girardi E, Johnson M, Kirk O, Lundgren J, Mocroft A, Monforte AD, Phillips A, Raben D, Rockstroh JK, Sabin C, Sonnerborg A, de Wolf F, European Late Presenter Consensus (2011). Late presentation of HIV infection: a consensus definition. HIV MED, 12(1), 61 - 64. doi:10.1111/j.1468-1293.2010.00857.x
    • Phillips AN, Pillay D, Garnett G, Bennett D, Vitoria M, Cambiano V, Lundgren J (2011). Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings.. AIDS, 25(6), 843 - 850. doi:10.1097/QAD.0b013e328344037a
    • Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) , Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A (2011). Risk of triple-class virological failure in children with HIV: a retrospective cohort study.. Lancet, 377(9777), 1580 - 1587. doi:10.1016/S0140-6736(11)60208-0

    2010

    • Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M, Porter K, Schwenk A, Hill T, Leen C, Anderson J, Fisher M, Sabin C (2010). The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. Journal of Viral Hepatitis, 17(8), 569 - 577.
    • Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K, Wiercinska-Drapalo A, Reiss P, Kirk O, Lundgren JD, EuroSIDA Study Group (2010). Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.. Antivir Ther, 15(4), 563 - 570. doi:10.3851/IMP1559
    • Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, Vjecha MJ, Neaton JD, Cooper DA, Grp INSIGHTS, Grp ESPRITS, Grp SILCAATS (2010). Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS, 24(12), 1877 - 1886. doi:10.1097/QAD.0b013e32833b1b26
    • Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J, EuroSIDA Study Group (2010). Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.. J Acquir Immune Defic Syndr, 55(2), 262 - 270. doi:10.1097/QAI.0b013e3181e9be6b
    • Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) , Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucci M, Ledergerber B, Mocroft A, Podzamczer D, Cozzi-Lepri A, Obel N, Masquelier B, Staszewski S, García F, De Wit S, Castagna A, Antinori A, Judd A, Ghosn J, Touloumi G, Mussini C, Duval X, Ramos J, Meyer L, Warsawski J, Thorne C, Masip J, Pérez-Hoyos S, Pillay D, van Sighem A, Lo Caputo S, Günthard H, Paredes R, De Luca A, Paraskevis D, Fabre-Colin C, Kjaer J, Chêne G, Lundgren JD, Phillips AN (2010). Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.. Arch Intern Med, 170(5), 410 - 419. doi:10.1001/archinternmed.2009.472
    • Reekie J, Kosa C, Engsig F, Monforte AD, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A, EuroSIDA Study Group (2010). Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies.. Cancer, 116(22), 5306 - 5315. doi:10.1002/cncr.25311
    • Ray M, Logan R, Sterne JAC, Hernandez-Diaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Justice A, Gouler J, Lodi S, Phillips A, Seng R, Meyer L, Perez-Hoyos S, de Olalla PG, Herman MA, Phillips AN, Gilson R, Easterbrook P, Fisher M, Gazzard B, Johnson M, Walsh J, Leen C, Orkin C, Anderson J, Pillay D, Delpech V, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A, Sabin C, HIV-CAUSAL Collaboration (2010). The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS, 24(1), 123 - 137. doi:10.1097/QAD.0b013e3283324283
    • Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, Chiesi A, Pradier C, Machala L, Lundgren JD, EuroSIDA Study Group (2010). History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change.. HIV Med, 11(7), 469 - 478. doi:10.1111/j.1468-1293.2009.00816.x
    • Lundgren JD, Phillips AN (2010). Rescue of Severely Immunocompromised HIV-Positive Persons. J INFECT DIS, 202(10), 1467 - 1469. doi:10.1086/656719
    • Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG, DAD Study Grp (2010). Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. EUR J CARDIOV PREV R, 17(5), 491 - 501. doi:10.1097/HJR.0b013e328336a150
    • Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, Chêne G, Vanhems P, Porter K, CASCADE Collaboration (2010). CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era.. AIDS, 24(17), 2697 - 2704. doi:10.1097/QAD.0b013e32833ef6c4
    • Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D, UK Collaborative Grp HIV Drug Resi , UK Collaborative HIV Cohort Study (2010). The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS, 24(12), 1917 - 1922. doi:10.1097/QAD.0b013e32833c1d93
    • Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients , Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S, Obel N, Castagna A, Wasmuth JC, Gill J, Klein MB, Gange S, Riera M, Mussini C, Gutiérrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN (2010). Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.. Lancet, 376(9738), 340 - 345. doi:10.1016/S0140-6736(10)60932-4
    • Lampe FC, Duprez DA, KullerMd LH, Tracy R, Otvos J, Stroes E, Cooper DA, Hoy J, Paton NI, Friis-Moller N, Neuhaus J, Liappis AP, Phillips AN, INSIGHT SMART Study Grp (2010). Changes in Lipids and Lipoprotein Particle Concentrations After Interruption of Antiretroviral Therapy. JAIDS-J ACQ IMM DEF, 54(3), 275 - 284. doi:10.1097/QAI.0b013e3181d32158
    • Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD, EuroSIDA Study Grp (2010). Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS, 24(11), 1667 - 1678. doi:10.1097/QAD.0b013e328339fc53
    • Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group , Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte AD, Kirk O, Friis-Moller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW (2010). Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.. AIDS, 24(10), 1537 - 1548. doi:10.1097/QAD.0b013e32833a0918
    • Phillips AN, Lampe FC, Smith CJ, Geretti AM, Rodger A, Lodwick RK, Cambiano V, Tsintas R, Johnson MA (2010). Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion.. AIDS, 24(10), 1561 - 1567. doi:10.1097/QAD.0b013e32833a6056
    • Cozzi-Lepri A, Dunn D, Pillay D, Sabin CA, Fearnhill E, Geretti AM, Hill T, Kaye S, Bansi L, Smit E, Johnson M, Burns S, Gilson R, Cameron S, Easterbrook P, Zuckerman M, Gazzard B, Walsh J, Fisher M, Orkin C, Ainsworth J, Leen C, Gompels M, Anderson J, Phillips AN, Babiker A, Porter K, Sadiq T, Schwenk A, Mackie N, Winston A, Delpech V, UK Collaborative Grp HIV Drug Resi , UK CHIC Study Grp (2010). Long-Term Probability of Detecting Drug-Resistant HIV in Treatment-Naive Patients Initiating Combination Antiretroviral Therapy. CLIN INFECT DIS, 50(9), 1275 - 1285. doi:10.1086/651684
    • Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM, UK Resistance Database , UK Collaborative HIV Cohort Study (2010). Antiretroviral Drug Resistance in HIV-1-Infected Patients with Low-Level Viremia. J INFECT DIS, 201(9), 1303 - 1307. doi:10.1086/651618
    • Bansi L, Geretti AM, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A, Sabin C, UK Collaborative Grp HIV Drug Resi , UK Collaborative HIV Cohort CHIC S (2010). The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART). JAIDS-J ACQ IMM DEF, 53(5), 633 - 639. doi:10.1097/QAI.0b013e3181c070d2
    • Worm SW, Kamara A, Reiss P, Fontas E, De Wit S, El-Sadr W, Monforte A, Law M, Ryom L, Phillips A, Dabis F, Weber R, Sabin C, Lundgren JD, DAD Study Grp (2010). Evaluation of sudden death and non-haemorrhagic stroke and their association with HIV protease inhibitor (PI) usage.
    • Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M, Gazzard B, Gilson R, Johnson M, Leen C, Orkin C, Schwenk A, Walsh J, Winston A, Babiker A, Delpech V, UK Collaborative HIV Cohort Study Group (2010). Data linkage reduces loss to follow-up in an observational HIV cohort study.. J Clin Epidemiol, 63(10), 1101 - 1109. doi:10.1016/j.jclinepi.2009.12.007
    • Cambiano V, Lampe FC, Rodger AJ, Smith CJ, Geretti AM, Lodwick RK, Puradiredja DI, Johnson M, Swaden L, Phillips AN (2010). Long-term trends in adherence to antiretroviral therapy from start of HAART.. AIDS, 24(8), 1153 - 1162. doi:10.1097/QAD.0b013e32833847af
    • Sabin CA, Schwenk A, Johnson MA, Gazzard B, Fisher M, Walsh J, Orkin C, Hill T, Gilson R, Porter K, Easterbrook P, Delpech V, Bansi L, Leen C, Gompels M, Anderson J, Phillips AN, UK CHIC Steering Comm (2010). Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS, 24(5), 723 - 727. doi:10.1097/QAD.0b013e328333fa0f
    • Cambiano V, Lampe FC, Rodger AJ, Smith CJ, Geretti AM, Lodwick RK, Holloway J, Johnson M, Phillips AN (2010). Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.. HIV Med, 11(3), 216 - 224. doi:10.1111/j.1468-1293.2009.00771.x
    • Phillips A, Costagliola D, Sabin C, Sterne J (2010). Early initiation of treatment for HIV infection. LANCET, 375(9715), 639 - 639.
    • Lampe FC, Harding R, Smith CJ, Phillips AN, Johnson M, Sherr L (2010). Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy.. J Acquir Immune Defic Syndr, 54(5), 500 - 505. doi:10.1097/QAI.0b013e3181ce6afe
    • Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P, Gilson R, Johnson M, Porter K, Anderson J, Gompels M, Leen C, Ainsworth J, Orkin C, Nelson M, Rice B, Phillips A, UK Collaborative HIV Cohort (CHIC) Study and the Health Protection Agency (2010). Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.. HIV Med, 11(7), 432 - 438. doi:10.1111/j.1468-1293.2009.00809.x
    • Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Moller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J, D A D Study Grp (2010). Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J INFECT DIS, 201(3), 318 - 330. doi:10.1086/649897
    • Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D, UK Collaborative Grp HIV Drug Resi (2010). The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.
    • Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D, Standardization, Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research (2010). Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.. AIDS, 24(3), 365 - 371. doi:10.1097/QAD.0b013e32833338ba
    • Worm SW, Friis-Moller N, Bruyand M, Monforte AD, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C, DAD Study Grp (2010). High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS, 24(3), 427 - 435. doi:10.1097/QAD.0b013e328334344e
    • Phillips A, van Oosterhout J (2010). DART points the way for HIV treatment programmes.. Lancet, 375(9709), 96 - 98. doi:10.1016/S0140-6736(09)62103-6
    • Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, Phillips A, Chêne G, Babiker A, Thiébaut R, NEAT-WP4 (2010). Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.. Clin Trials, 7(1), 19 - 35. doi:10.1177/1740774509356117
    • RAY M, LOGAN R, STERNE J, HERNANDEZ-DIAZ S, ROBINS J, SABIN C, BANSI L, VAN SIGHEM A, DE WOLF F, COSTAGLIOLA D, LANOY E, BUCHER H, VON WYL V, ESTEVE A, CASABONA J, DEL AMO J, MORENO S, JUSTICE A, GOULER J, LODI S, PHILLIPS A, SENG R, MEYER L, PEREZ-HOYOS S, DE OLALLA P, HERMAN M, PHILLIPS A, GILSON R, EASTERBROOK P, FISHER M, GAZZARD B, JOHNSON M, WALSH J, LEEN C, ORKIN C, ANDERSON J, PILLAY D, DELPECH V, SCHWENK A, DUNN D, GOMPELS M, HILL T, PORTER K, BABIKER A, COLLABORATION H (2010). The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. , 24(1), 123 - 137.
    • WITTKOP L, SMITH C, FOX Z, SABIN C, RICHERT L, ABOULKER J, PHILLIPS A, CHENE G, BABIKER A, THIEBAUT R, NEAT-WP4 (2010). Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. , 7(1), 19 - 35.
    • Weber R, Sabin C, Reiss P, de Wit S, Worm SW, Law M, Dabis F, Monforte AD, Fontas E, El-Sadr W, Kirk O, Rickenbach M, Phillips A, Ledergerber B, Lundgren J, Data Collection Adverse Events (2010). HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. ANTIVIR THER, 15(8), 1077 - 1086. doi:10.3851/IMP1681
    • Worm SW, Kamara A, Reiss P, Fontas E, De Wits S, El-Sadr W, Monforte A, Law M, Ryom L, Phillips A, Dabis F, Weber R, Sabin C, Lundgren JD, D A D Study Grp (2010). Evaluation of sudden death and non-haemorrhagic stroke and their association with HIV protease inhibitor (PI) usage.
    • Waters L, Asboe D, Pozniak A, Bansi L, Orkin C, Smit E, Fearnhill E, Phillips A (2010). Outcomes of second-line ritonavir-boosted protease inhibitor (PI/r)-based ART after failure of a first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART. HIV MED, 11, 3 - 4.
    • Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D, UK Collaborative Grp HIV Drug , Chic, U (2010). The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.

    2009

    • Geretti AM, Phillips AN, Kaye S, Booth C, Mackie NE, UK HIV Drug Resistance Database , UK Collaborative HIV Cohort Study (2009). Detection of clinically relevant antiretroviral drug resistance mutations among treated patients undergoing testing at low levels of viremia.
    • Smith CJ, Phillips AN, Dauer B, Johnson MA, Lampe FC, Youle MS, Tyrer M, Staszewski S (2009). Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.. HIV Med, 10(1), 19 - 27. doi:10.1111/j.1468-1293.2008.00650.x
    • Phillips AN, Emery S (2009). Predicting the potential benefits of early initiation of ART: time to do a trial to find out. CURR OPIN HIV AIDS, 4(3), 165 - 166. doi:10.1097/COH.0b013e328329ec32
    • Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, Johnson M, Li JF, Heneine W, Johnson JA (2009). Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.. J Acquir Immune Defic Syndr, 52(5), 569 - 573. doi:10.1097/QAI.0b013e3181ba11e8
    • Grund B, Neuhaus J, Phillips A, INSIGHT SMART Study Grp (2009). Relative risk of death in the SMART study. LANCET INFECT DIS, 9(12), 724 - 725.
    • Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M, Hill T, Johnson M, Leen C, Orkin C, Phillips AN, Porter K, Post F, Walsh J, Sabin CA, United Kingdom Collaborative HIV C (2009). Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? United Kingdom Collaborative HIV Cohort Study Group. AIDS, 23(18), 2507 - 2515. doi:10.1097/QAD.0b013e3283320dfd
    • Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips A, Sabin C, on behalf of the UK Collaborative HIV Cohort CHIC Study (2009). Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. Journal of Acquired Immune Deficiency Syndromes, 52(3), 391 - 396. doi:10.1097/QAI.0b013e3181ab73cc
    • Lanoy E, May M, Mocroft A, Phillips A, Justice A, Chene G, Furrer H, Sterling T, Monforte AD, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne JAC, Costagliola D, Antiretroviral Therapy Cohort (2009). Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS, 23(16), 2199 - 2208. doi:10.1097/QAD.0b013e3283305a00
    • Abrams D, Levy Y, Losso MH, Babilker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D, INSIGHT-ESPRIT Study Grp , SILCAAT Sci Comm (2009). Interleukin-2 Therapy in Patients with HIV Infection. NEW ENGL J MED, 361(16), 1548 - 1559.
    • Weller I, Costagliola D, Ledergerber B, Lundgren J, Chene G, Touloumi G, Warszawski J, Meyer L, Dabis F, Krause MM, Leport C, de Wolf F, Reiss P, Porter K, Dorrucci M, Sabin C, Gibb D, Del Amo J, Obel N, Thorne C, Mocroft A, Kirk O, Staszewski S, Perez-Hoyos S, Almeda J, Antinori A, Monforte AD, de Martino M, Brockmeyer N, Fatkenheuer G, Ramos J, Battegay M, Mussini C, Tookey P, Casabona J, Miro JM, Castagna A, de Wit S, Torti C, Teira R, Garrido M, Dedes N, Sabin C, Phillips A, Furrer H, Kirk O, Egger M, Dabis F, Newell ML, Sterne J, Telenti A, Collaboration Observational HIV Ep , European AIDS Treatment Grp (2009). Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS, 23(15), 2029 - 2037. doi:10.1097/QAD.0b013e32832e531c
    • Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte AD, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD, EuroSIDA Study Group (2009). Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.. J Infect Dis, 200(5), 687 - 697. doi:10.1086/604731
    • Phillips AN, Gilks C, Lundgren JD (2009). Cost-effectiveness of Strategies for Monitoring the Response to Antiretroviral Therapy in Resource-Limited Settings. ARCH INTERN MED, 169(9), 904 - 904.
    • Sterne JAC, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miro JM, Justice AC, Ledergerber B, Fatkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR, Start Consortium (2009). Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. LANCET, 373(9672), 1352 - 1363. doi:10.1016/S0140-6736(09)60612-7
    • Lundgren JD, Phillips AN, Neaton J (2009). Uncertainty as to Whether the Use of Antiretroviral Therapy for Persons Recently Infected with HIV Has a Favorable Risk-to-Benefit Ratio. CLIN INFECT DIS, 48(8), 1162 - 1162. doi:10.1086/597495
    • Sabin CA, Phillips AN (2009). Should HIV therapy be started at a CD4 cell count above 350 cells/microl in asymptomatic HIV-1-infected patients?. Current Opinion in Infectious Diseases, 22(2), 191 - 197. doi:10.1097/QCO.0b013e328326cd34
    • Cambiano V, Lampe F, Rodger A, Smith C, Lodwick R, Holloway J, Johnson M, Phillips A (2009). Use of a prescription refill-based measure of antiretroviral therapy adherence to predict subsequent virological rebound in patients with stable undetectable HIV viral loads. HIV MED, 10, 21 - 21.
    • Strang AL, Johnson JA, Fox Z, Booth CL, Phillips AN, Li JF, Heneine W, Geretti AM (2009). Low-frequency mutations strengthen the impact of transmitted drug resistance (TDR) on virological responses to first-line efavirenz- or nevirapine-based antiretroviral therapy. HIV MED, 10, 6 - 7.
    • Deeks SG, Phillips AN (2009). HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BRIT MED J, 338, - . doi:10.1136/bmj.a3172
    • Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A (2009). Virological response to initial antiretroviral regimens containing abacavir or tenofovir. The Journal of Infectious Diseases, 200, 710 - 714.
    • Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K, Mackie N, Fisher M, Orkin C, Johnson M, Easterbrook P, Hill T, Phillips AN, UK Collaborative HIV Cohort CHIC Study (2009). The associations between age, the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.. HIV Medicine, 10(1), 35 - 43. doi:10.1111/j.1468-1293.2008.00654.x
    • Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips A, Bansi L, Gilson R, Easterbrook P, Johnson M, Gazzard B, Leen C, Pillay D, Schwenk A, Anderson J, Porter K, Gompels M, Sabin CA, for the UK Collaborative HIV Cohort CHIC Study (2009). CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK.. Haematologica, 94(6), 875 - 880. doi:10.3324/haematol.2008.002691
    • Ewings F, Copas A, Fidler S, McLean K, Fisher M, Phillips A, Porter K, Hawkins D, Gilson R, Johnson M (2009). HIV-infected individuals co-infected with hepatitis C appear to have faster CD4 decline in the absence of ART but similar response once combination ART is initiated..
    • BARBER T, HUGHES A, DINSMORE W, PHILLIPS A (2009). How does HIV impact on non-AIDS events in the era of HAART?. , 20(1), 1 - 3.
    • DORRUCCI M, PHILLIPS A (2009). Has Human Immunodeficiency Virus Become More Virulent?. , 48(9), 1293 - 1295.
    • ZWAHLEN M, HARRIS R, MAY M, HOGG R, COSTAGLIOLA D, DE WOLF F, GILL J, FATKENHEUER G, LEWDEN C, SAAG M, STASZEWSKI S, MONFORTE A, CASABONA J, LAMPE F, JUSTICE A, VON WYL V, EGGER M, CHENE G, DABIS F, KITAHATA M, LEDERGERBER B, LEPORT C, MOCROFT A, PHILLIPS A, REISS P, SABIN C, STERNE J, BECKTHOLD B, YIP B, DAUER B, FUSCO J, DARNEY E, RICKENBACH M, LAVIGNOLLE V, VAN LETH F, PEREIRA E, PEZZOTTI P, COLL ATC (2009). Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. , 38(6), 1624 - 1633.
    • Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN, INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2009). Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.. J Infect Dis, 200(6), 973 - 983. doi:10.1086/605447
    • Antiretroviral Therapy Cohort Collaboration , Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M (2009). Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.. Int J Epidemiol, 38(6), 1624 - 1633. doi:10.1093/ije/dyp306

    2008

    • Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren JD, EuroSIDA SG (2008). Loss to follow-up in an international, multicentre observational study. HIV Med, 9(5), 261 - 269. doi:10.1111/j.1468-1293.2008.00557.x
    • DE WIT S, SABIN C, WEBER R, al. E (2008). Incidence and risk factors for new-onset diabetes, in HIV-infected patients - The data collection on adverse events of Anti-HIV drugs (D : A : D) study. , 31(6), 1224 - 1229.
    • Lundgren JD, Neuhaus J, Babiker A, Cooper D, Duprez D, Ei-Sadr W, Emery S, Gordin F, Kowalska J, Phillips A, Prineas OJ, Reiss P, Sabin C, Tracy R, Weber R, Grund B, Neaton AD, SMART INSIGHT , DAD Study Grp (2008). Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS, 22(14), F17 - F24. doi:10.1097/QAD.0b013e32830fe35e
    • Strategies for Management of Antiretroviral Therapy (SMART) Study Group , Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R (2008). Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.. J Infect Dis, 197(8), 1133 - 1144. doi:10.1086/586713
    • Phillips AN, Neaton J, Lundgren JD (2008). The role of HIV in serious diseases other than AIDS. AIDS, 22(18), 2409 - 2418. doi:10.1097/QAD.0b013e3283174636
    • Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J, SMART Study Group (2008). Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.. AIDS, 22(17), 2279 - 2289. doi:10.1097/QAD.0b013e328311d16f
    • Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JDDCOAEOA-HDDADSG (2008). HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS, 22(16), 2143 - 2153. doi:10.1097/QAD.0b013e3283112b77
    • Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD, EuroSIDA SG (2008). Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS, 22(16), 2187 - 2198. doi:10.1097/QAD.0b013e328310e04f
    • Lee KJ, Dunn D, Porter K, Gilson R, Bansi L, Hill T, Phillips AN, Sabin CA, Schwenk A, Leen C, Delpech V, Anderson J, Gazzard B, Johnson M, Easterbrook P, Walsh J, Fisher M, Orkin C, for the United Kingdom Collaborative HIV Cohort CHIC Study (2008). Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS, 22(15), 1943 - 1950. doi:10.1097/QAD.0b013e32830e4cf3
    • The SMARTINSIGHTATDADSG (2008). Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS, 22(14), F17 - F24. doi:10.1097/QAD.0b013e32830fe35e
    • Sabin CA, Worm S, Phillips AN, Lundgren JD (2008). Abacavir and increased risk of myocardial infarction - Reply. LANCET, 372(9641), 804 - 805.
    • Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, Degruttola V, Miller V, Costagliola D, Standardization and Clinical Relevance of HIV Drug Resistance Testing Project of the Forum for Collaborative HIV Research (2008). Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response.. J Infect Dis, 198(4), 470 - 480. doi:10.1086/590156
    • Sabin CA, Smith CJ, Monforte AD, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A, Leport C, Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chene G, Lundgren J, Weller I, Costagliola D, Ledergerber B, Lundgren J, Chene G, Touloumi G, Warszawski J, Meyer L, Dabis F, Krause MM, Goujard C, Leport C, de Wolf F, Reiss P, Porter K, Dorrucci M, Sabin C, Amo J, Obel N, Mocroft A, Kirk O, Staszewski S, Perez-Hoyos S, Almeda J, Antinori A, Tovo PA, Salzberger B, Fatkenheuer G, Ramos J, Battegay M, Mussini C, Tookey P, Casabona J, Miro JM, Castagna A, Wit S, Teira R, Garrido M, Dedes N, Sabin C, Phillips A, Furrer H, Egger M, Newell ML, Sterne J, Telenti A, Collaboration Observational HIV Ep , COHERE Steering Comm , European AIDS Treatment Grp (2008). Response to combination antiretroviral therapy: variation by age - The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. AIDS, 22(12), 1463 - 1473.
    • Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD (2008). Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. Journal of Acquired Immune Deficiency Syndromes, 48(3), 324 - 333. doi:10.1097/QAI.0b013e31817ae5c0
    • Phillips AN, Pillay D, Miners A, Gilks CF, Lundgren JD (2008). Monitoring of antiretroviral therapy in low-resource settings - Reply. LANCET, 372(9635), 289 - 289.
    • Hamers FF, Phillips AN (2008). Diagnosed and undiagnosed HIV-infected populations in Europe. doi:10.1111/j.1468-1293.2008.00584.x
    • De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte A, Fontas E, Law MG, Friis-Møller N, Phillips ADCOAEOA-HDDADS (2008). Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.. Diabetes Care, 31(6), 1224 - 1229. doi:10.2337/dc07-2013
    • Lodwick RK, Smith CJ, Youle M, Lampe FC, Tyrer M, Bhagani S, Chaloner C, Sabin CA, Johnson MA, Phillips AN (2008). Stability of antiretroviral regimens in patients with viral suppression. AIDS, 22(9), 1039 - 1046. doi:10.1097/QAD.0b013e3282fec415
    • Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD (2008). Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observations alone: a computer simulation model. The Lancet, 371(9622), 1443 - 1451.
    • Strategies for Management of Antiretroviral Therapy (SMART) Study Group , Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN (2008). Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.. J Infect Dis, 197(8), 1145 - 1155. doi:10.1086/529523
    • Data COAEOA-HDSG (2008). Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid-Lowering Drugs in HIV-Infected Individuals and Impact on Myocardial Infarction. Clinical Infectious Diseases, 46(7), 1101 - 1110. doi:10.1086/528862
    • Madge S, Smith CJ, Lampe F, Sabin CA, Youle M, Johnson MA, Phillips AN (2008). An audit of viral load in one clinical population to describe features of viraemic patients on antiretroviral therapy.. HIV Med, 9(4), 208 - 213. doi:10.1111/j.1468-1293.2008.00548.x
    • Angus B, Lampe F, Tambussi G, Duvivier C, Katlama C, Youle M, Williams I, Clotet B, Fisher M, Post FA, Babiker A, Phillips A, TILT Trial Steering Committee (2008). TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.. AIDS, 22(6), 737 - 740. doi:10.1097/QAD.0b013e3282f511f1
    • Grover D, Copas A, Green H, Edwards SG, Dunn DT, Sabin C, Phillips A, Allen E, Pillay DOBOTUKCGOHIVDRAUKCHIVCSUKCHIC (2008). What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?. Journal of Antimicrobial Chemotherapy, 61(3), 705 - 713. doi:10.1093/jac/dkm522
    • Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K, CASCADE Collaboration (2008). Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Annals of Neurology, 63(2), 213 - 221. doi:10.1002/ana.21225
    • Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA, for the UK Collaborative HIV Cohort CHIC Study (2008). Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?. AIDS, 22(3), 349 - 356. doi:10.1097/QAD.0b013e3282f4709a
    • Ewings FM, Bhaskaran K, McLean K, Hawkins D, Fisher M, Fidler S, Gilson R, Nock D, Brettle R, Johnson M, Phillips A, Porter K, for the UK Register of HIV Seroconverters (2008). Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS, 22(1), 89 - 95. doi:10.1097/QAD.0b013e3282f3915e
    • Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin C, Anderson J, Schwenk A, Leen C, Sabin CA, on behalf of the UK Collaborative HIV Cohort CHIC Study Steering Committee (2008). Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Medicine, 9(1), 47 - 56.
    • D A D Study Group S, C A W, S W W, R R, P E-S, W D, F DW, S L, M DM, A F, M A I, N K, O P, C W, I P, A N L, J D (2008). Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. The Lancet, 371(9622), 1417 - 1426.
    • Antiretroviral TCC (2008). Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies in industrialized countries. Antiviral Therapy, 13(8), 959 - 967.
    • Phillips AN, Carr A, Neuhaus JEA (2008). Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antiviral Therapy, 13(2), 177 - 187.
    • Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chene G, Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, Monforte AD, May M, Egger M (2008). Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antiviral Therapy, 13(8), 959 - 967.
    • Gompels M, Sabin C, Phillips A, Dunn D, and TUKCHIVCCHICS (2008). The frequency and clinical implications of a discordant CD4 count and CD4 percentage.
    • Cozzi-Lepri A, Dunn D, Pillay D, Sabin C, Fearnhill E, Phillips A, and the UKHIV Drug Resistance Database and UKCHIC Study Groups (2008). Long-term probability of detecting HIV drug resistance in drug-naïve patients starting currently recommended first-line combination ART..
    • Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, Phillips A, von Wyl V, Yerly S, Gunthard HF, Pillay D (2008). Emergence of drug resistance after failure of first-line HAART is associated with intensity of virological monitoring: a systematic analysis of cohort and trial data specifically addressing the WHO public health approach to antiretroviral therapy.
    • Phillips A, Pillay D, Miners A, Bennett D, Gilks CF, Lundgren JD (2008). Predicting the effects on resistance of lack of viral load monitoring in resource-limited settings.
    • Dunn D, Geretti AM, Green H, Fearnhill E, Pozniak A, Churchill D, Pillay D, Sabin C, Phillips A, UK Collaborative Grp , HIV Drug Resistance & UK Collabora (2008). Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. ANTIVIR THER, 13(6), 771 - 777.
    • Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho RJ, Kjaer J, Van Laethem K, Phillips A, Moreau Y, Lundgren JD, Vandamme AM, EuroSIDA Study Group (2008). Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.. Antivir Ther, 13(3), 399 - 407.
    • Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S (2008). Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.. Antivir Ther, 13(7), 927 - 936.
    • Assoumou L, Cozzi-Lepri A, Brun-Vezinet F, DeGruttola V, Kuritzkes D, Phillips A, Zolopa A, Miller V, Costagliola D, Sta Cl R HIV Dr Res Test Pr For Co (2008). Initiatives for developing genotype interpretation systems: derivation and validation of a didanosine interpretation system using large derivation and large validation datasets.
    • Cozzi-Lepri A, Clotet B, Paredes R, Kjoer J, Phillips AN, Lundgren JD (2008). The rate of accumulation of NNRTI resistance in patients kept on a virologically failing regimen containing NNRTI: a EuroSIDA study.
    • Geretti AM, Phillips A, Kaye S, Booth C, Garcia A, Mackie N, Uk Resistance Database CHIC Study (2008). Prevalence and patterns of antiretroviral drug resistance at low plasma HIV RNA load levels.
    • ANGUS B, LAMPE F, TAMBUSSI G, DUVIVIER C, KATLAMA C, YOULE M, WILLIAMS I, CLOTET B, FISHER M, POST F, BABIKER A, PHILLIPS A (2008). TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals. , 22(6), 737 - 740.
    • DUNN D, GERETTI A, GREEN H, al. E (2008). Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. , 13(6), 771 - 777.
    • DUPREZ D, PHILLIPS A, CARR A, al. E (2008). Does interruption of antiretroviral therapy change the risk of cardiovascular disease in HIV-1 patients? Results from the SMART trial. , 51(10), A248 - A248.
    • EL-SADR W, GRUND B, NEUHAUS J, al. E (2008). Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy - a randomized trial. , 149(5), 289 - W62.
    • LUNDGREN J, NEUHAUS J, BABIKER A, al. E (2008). Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. , 22(14), F17 - F24.
    • MOCROFT A, KIRK O, ALDINS P, al. E (2008). Loss to follow-up in an international, multicentre observational study. , 9(5), 261 - 269.
    • NEATON J, BABIKER A, BAXTER J, al. E (2008). Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. , 197(8), 1133 - 1144.
    • Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, Porter K (2008). Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. JOURNAL OF INFECTIOUS DISEASES, 197(3), 398 - 404. doi:10.1086/524686
    • SMART Study Group , El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD (2008). Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.. Ann Intern Med, 149(5), 289 - 299.

    2007

    • Fox Z, Antunes F, Davey R, Gazzard B, Klimas N, Labriola A, Losso M, Neaton JD, Phillips AN, Ruxrungtham K, Staszewski S, Weiss L, Lundgren JD, Abrams DI, Cooper DA, Abrams DI, Cooper DA, Darbyshire JH, Duncan WR, Emery S, Lane HC, Lehrman S, Lundgren JD, Neaton JD, Aguilar L, Angel EB, Aquilia S, Belloso W, Benetucci J, Bittar V, Cahn P, Casiro A, Contarelli J, Corral J, Daciuk L, David D, Ferrari I, Fridman D, Galache V, Guaragna G, Ivalo S, Laplume H, Lanusse I, Lasala MB, Lattes R, Lasovsky J, Lopardo G, Losso M, Lourtau L, Lupo S, Maranzana A, Marson C, Massera L, Sanchez MD, Somenzini C, Tocci M, Algar S, Anderson J, Baker D, Blavius K, Bloch M, Boyle M, Bradford D, Britton P, Carrall L, Carr A, Chuah J, Curry M, D'Arcy-Evans C, Dobson P, Doong N, Egan C, Ferguson W, Finlayson R, French M, Frater A, Gold J, Habel P, Haig K, Holland R, Hyland N, Hoy J, Hudson J, James R, Leung J, Lowe K, MacRae K, McMurchie M, Medland N, Miller S, Murray J, Newman R, Orth D, Patching J, Primrose R, Ree H, Richardson R, Rogers G, Roney J, Roth N, Sarangapany J, Shaw D, Silberberg C, Skett J, Williams L, Soo TM, Sowden D, Street A, Vale R, Villella C, Walker A, Watson A, Wendt N, Wood H, Youds D, Aichelburg A, Rieger A, Vetter N, Clumeck N, De Wit S, Kabeya K, O'Doherty E, Amorim CD, Basso CR, Lewi DS, Pereira LC, da Silva M, Souza TNL, Angel J, Bouchard PR, Clark F, Cohen J, Dambreville M, Ellis M, Fiset S, Foster A, Fraser C, Gagnon S, Gilmour J, Guenette R, Haldane H, Hawley-Foss N, Hyndman S, Johnston L, Jubinville N, Juneau F, Kelleher L, LaPointe L, Latendre-Paquette J, Lindemulder A, Mashinter L, Lefebvre E, McFarland N, Morisseau C, O'Neill R, Piche A, Ralph E, Rouleau D, Routy JP, Sandre R, Schmidt S, Shafran S, Smaill F, Stromberg D, Trepanier JM, Trottier S, Veal S, Walmsley S, Weiss K, Williams K, Young M, Zaleschuk B, Zarowny D, Baadegaard B, Black F, Boedker K, Gerstoft J, Jensen L, Mathiesen L, Nielsen H, Pedersen C, Petersen D, Aboulker JP, Baakili A, Bengrait N, Bensalem M, Berthe H, Bloche M, Bazin C, Boue F, Bouvet E, Brancon C, Capitant C, Ceppi C, Cheneau C, Coutellier A, Chennebault JM, Coquet F, De Truchis P, Delavalle AM, Frixon-Marin V, Gastaut JA, Delfraissy F, Eliaszeicz M, Gallais H, Gataut JA, Gilquin J, Gonzalez-Canali G, Gaudebout C, Goujard C, Hoen B, Honore P, Jarousse B, Lang JM, Lefebvre B, Levy Y, Loison J, Maignan A, Meynard JL, Michon C, Mole M, Marsal L, Matheron S, Mortier E, Oksenhendler E, Poirier S, Picard-Dahan C, Ravaux I, Raffi F, Raguin G, Reynes J, Rozenbaum W, Salmon D, Simon A, Spiridon G, Viard JP, Vidal M, Weiss L, Zucman D, Bergmann F, Brockmeyer N, Faetkenheuer G, Fenske S, Gey D, Goebel FD, Goetsch M, Hartmann M, Klinker H, Kremer G, Mantzsch K, Mauss S, Rockstroh J, Rotty J, Rund E, Schneider K, Schuermann D, Staszweski S, Tilmann K, Vogel M, Bentwich Z, Drora G, Kedem E, Lang R, Levi I, Maayan S, Magen E, Mamorsky M, Pilpul A, Pollack S, Sthoeger Z, Vered H, Yust I, Lyons F, Mulcahy F, Rochford A, Auiti F, Angarano G, Bertelli D, Bini T, Bruno R, Cadeo GP, Carosi G, Monforte AD, Del Giacco S, Di Pietro M, Esposito R, Filice G, Gavazzeni G, Guaraldi G, Indiveri F, Lazzarin A, Mazzotta F, Minolli L, Montroni M, Moroni M, Nozza S, Pastor G, Poli G, Raise E, Romagnani S, Rusconi V, Sacchi P, Suter F, Tambussi G, Tirelli U, Fraser H, Iwamoto A, Kikuchi Y, Mori M, Nakamura T, Odawara T, Oka S, Shirasaka T, Takano M, To J, Ueta C, El Filali K, Erradey I, Himmich H, Blok W, Borleffs J, Bravenboer B, Bronveld W, Claessen F, Duurvoort M, Ferwerda J, Frissen P, Hulshoff N, Juttman J, Kauffmann R, Koopmans P, Kroon F, Lowe S, Leemhuis M, Meenhorst P, de Boer LP, Reiss P, Reinders-Folmer S, Richter C, Santegoets R, Schoemaker M, Schrey G, Sprenger H, Ten Veen J, Tessalaar J, van der Ende M, van der Vall H, van Eeden A, van Leeuwen R, Vermeulen J, ten (2007). Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count >= 300 cells/mu L who were assigned to 7.5 MIU interleukin-2. HIV MED, 8(2), 112 - 123.
    • MOCROFT A, STASZEWSKI S, WEBER R, al. E (2007). Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4(+) T-cell counts (vol 12, pg 325, 2007). , 12(4), 577 - 577.
    • Antiretroviral TCC (2007). Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 46(5), 607 - 615.
    • Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T, Fisher M, Walsh J, Pillay D, Bansi L, Gazzard B, Easterbrook P, Gilson R, Johnson M, Sabin CA, on behalf of the UK Collaborative HIV Cohort CHIC Study (2007). Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. The Lancet, 370(9603), 1923 - 1928. doi:10.1016/S0140-6736(07)61815-7
    • Phillips AN, Sabin C, Pillay D, Lundgren JD (2007). HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Medicine, 8(8), 536 - 546. doi:10.1111/j.1468-1293.2007.00507.x
    • Phillips AN, Gilson R, Easterbrook P, Fisher M, Gazzard B, Johnson M, Walsh J, Leen C, Orkin C, Anderson J, Pillay D, Delpech V, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A, Sabin C (2007). HIV diagnosis at CD4 count above 500 Cells/mm(3) and progression to below 350 Cells/mm(3) without Antiretroviral therapy. JAIDS-J ACQ IMM DEF, 46(3), 275 - 278.
    • Ceccherini-Silberstein F, Cozzi-Lepri A, Ruiz L, Mocroft A, Phillips AN, Olsen CH, Gatell JM, Gunthard HF, Reiss P, Perno CF, Clotet B, Lundgren JDESG (2007). Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients. The Journal of Infectious Diseases, 196(8), 1180 - 1190. doi:10.1086/521678
    • Fox ZV, Geretti AM, Kjaer J, Dragsted UB, Phillips AN, Gerstoft J, Staszewski S, Clotet B, von Wyl V, Lundgren JD (2007). The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.. AIDS, 21(15), 2033 - 2042. doi:10.1097/QAD.0b013e32825a69e4
    • Mocroft A, Ledergerber B, Zilmer K, Kirk O, Hirschel B, Viard JP, Reiss P, Francioli P, Lazzarin A, Machala L, Phillips AN, Lundgren JD, EuroSIDA SGATSHIVCS (2007). Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS, 21(14), 1867 - 1875. doi:10.1097/QAD.0b013e328270b877
    • Smith CJ, Sabin CA, Youle MS, Lampe FC, Bhagani S, Madge S, Puradiredja D, Johnson MA, Phillips AN (2007). Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of gender.. J Acquir Immune Defic Syndr, 46(1), 62 - 67. doi:10.1097/QAI.0b013e31813e5e20
    • Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A, UK Collaborative HIV Cohort Study (2007). Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS, 21(13), 1717 - 1721. doi:10.1097/QAD.0b013e32827038bf
    • Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgren JDESG (2007). Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. The Lancet, 370(9585), 407 - 413. doi:10.1016/S0140-6736(07)60948-9
    • Hoen B, Cooper DA, Lampe F, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Lazzarin A, Ponscarne D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegman L, Janossy G, Kinloch-de Loes S (2007). Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clinical Infectious Diseases, 45(3), 381 - 390. doi:10.1086/519428
    • UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study, and the UK Register of HIV Seroconverters (2007). Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS, 21(8), 1035 - 1039.
    • DAD SG, Friis-Møller , N , Reiss , P , Sabin , C A, Weber , R , Monforte , A , El-Sadr , W , Thiébaut , R , De W, S , Kirk , O , Fontas , E , Law , M G, Phillips , A , Lundgren , J D (2007). Class of antiretroviral drugs and the risk of myocardial infarction. New England Journal of Medicine, 356(17), 1723 - 1735. doi:10.1056/NEJMoa062744
    • Lampe FC, Smith CJ, Madge S, Kinloch-de Loes S, Tyrer M, Sabin CA, Chaloner C, Youle M, Johnson MA, Phillips AN (2007). Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Archives of Internal Medicine, 167(7), 692 - 700. doi:10.1001/archinte.167.7.692
    • Stöhr W, Dunn D, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P, Fisher M, Johnson M, Delpech V, Phillips A, Sabin C, UK CHIC Study (2007). CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. HIV Medicine, 8(3), 135 - 141. doi:10.1111/j.1468-1293.2007.00443.x
    • Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JDESG (2007). Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS, 21(6), 721 - 732. doi:10.1097/QAD.0b013e3280141fdf
    • Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JDESG (2007). Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Medicine, 8(2), 96 - 104. doi:10.1111/j.1468-1293.2007.00436.x
    • ESPRIT Research Group , Fox Z, Antunes F, Davey R, Gazzard B, Klimas N, Labriola A, Losso M, Neaton JD, Phillips AN, Ruxrungtham K, Staszewski S, Weiss L, Lundgren JD (2007). Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2.. HIV Med, 8(2), 112 - 123. doi:10.1111/j.1468-1293.2007.00440.x
    • Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, Geretti AM (2007). Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J ANTIMICROB CHEMOTH, 59(3), 517 - 524. doi:10.1093/jac/dkl501
    • Ramaswamy M, Waters A, Smith C, Hainsworth E, Hardy G, Johnson M, Ainsworth J, Phillips A, Geretti AM (2007). Reconstitution of herpes simplex virus-specific T cell immunity in HIV-infected patients receiving highly active antiretroviral therapy.
    • Chawla A, Murphy G, Donnelly C, Booth CL, Johnson M, Parry JV, PhillipS A, Geretti AM (2007). Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J CLIN MICROBIOL, 45(2), 415 - 420. doi:10.1128/JCM.01879-06
    • Antiretroviral TARTCC (2007). Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS, 21(9), 1185 - 1197.
    • Dorrucci M, Rezza G, Porter K, Phillips A, CASCADE Collaboration (2007). Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. The Journal of Infectious Diseases, 195(4), 525 - 534. doi:10.1086/510911
    • Cicconi P, Cozzi-Lepri A, Phillips A, Puoti M, Antonucci G, Manconi PE, Tositti G, Colangeli V, Lichtner M, Monforte AISG (2007). Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?. AIDS, 21(5), 599 - 606. doi:10.1097/QAD.0b013e328013db9c
    • Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD (2007). When should antiretroviral therapy for HIV be started?. BMJ (Clinical Research Ed.), 334(7584), 76 - 78. doi:10.1136/bmj.39064.406389.94
    • Shah S, Smith CJ, Lampe F, Youle M, Johnson MA, Phillips AN, Sabin CA (2007). Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: relationships with gender. HIV Medicine, 8(1), 38 - 45. doi:10.1111/j.1468-1293.2007.00434.x
    • Smith CJ, Phillips AN, Youle MS, Sabin CA, Lampe FC, Tsintas R, Tyrer M, Johnson MA (2007). Treatment outcomes amongst previously antiretroviral-naive HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital. HIV Medicine, 8(1), 55 - 63. doi:10.1111/j.1468-1293.2007.00431.x
    • Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Dunn D, Delpech V, Taylor GP, Walsh JC, Phillips ANOBOTUKCHIVCCHICS (2007). Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS, 21(11), 1423 - 1430. doi:10.1097/QAD.0b013e3281532ca7
    • Cozzi-Lepri A, Phillips AN, Martinez-Picado J, d'Arminio Monforte A, Katlama C, Eg Hansen AB, Horban A, Ruun J, Clotet B, Lundgren JDESG (2007). Rate of accumulation of thymidine analogue mutations (TAM) in patients left on virologically failing regimens containing zidovudine (ZDV) or stavudine (d4T)..
    • Fox ZV, Geretti AM, Clotet B, Cozzi-Lepri A, Hill T, Green H, Sabin CA, Ledergebner B, Lundgren JD, Phillips ANUKCGOHIVR, EuroSIDA AUKCHICS (2007). Association between resistance and CD4-count change in patients on ART with ongoing viraemia.
    • De Forche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho R, Kjaer J, van Laethem K, Phillips AN, Moreau Y, LundgrenJ D V, Group MES (2007). Proof-of-principle evaluation of predictive performance for therapy outcome of baseline estimated fitness and genetic barrier towards resistance in a clinical cohort of HIV-1-treated patients.
    • Lampe FC, Porter K, Kaldor J, Law M, Kinloch-de Loes S, Phillips AN, CASCADE Collaboration (2007). Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antiviral Therapy, 12(2), 189 - 193.
    • Mocroft A, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasiorowski J, Panos G, Monforte A, Rakhmanova A, Phillips AN, Lundgren JDESG (2007). Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antiviral Therapy, 12(3), 325 - 333.
    • Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte AD, Katlama C, Hansen ABE, Horban A, Braun J, Clotet B, Lundgren J, EuroSIDA Study Grp (2007). Rate of accumulation of thymidine analogue mutations (TAM) in patients left on virologically failing regimens containing zidovudine (ZDV) or stavudine (d4T).
    • Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte AD, Katlama C, Hansen ABE, Horban A, Bruun J, Clotet B, Lundgren J, EuroSIDA Study Grp (2007). Rate of accumulation of thymidine analogue mutations (TAM) in patients left on virologically failing regimens containing zidovudine (ZDV) or stavudine (d4T).
    • Fox ZV, Geretti AM, Clotet B, Cozzi-Lepri A, Hill T, Green H, Sabin CA, Ledergerber B, Lundgren JD, Phillips AN, UK Collaborat Grp HIVDR , EuroSIDA , UK CHIC Study (2007). Association between resistance and CD4-count change in patients on ART with ongoing viraemia.
    • Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho R, Kjaer J, Van Laethem K, Phillips AN, Moreau Y, Lundgren JD, Vandamme AM, EuroSIDA Study Grp (2007). Proof-of-principle evaluation of predictive performance for therapy outcome of baseline estimated fitness and genetic barrier towards resistance in a clinical cohort of HIV-1-treated patients.
    • MAY M, STERNE J, SHIPLEY M, al. E (2007). A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. , 36(6), 1309 - 1318.
    • Burns S, Cameron S, Cane P, Down P, Chrystie I, Churchill D, Delpech V, Pillay D, Dunn D, Fearnhill E, Green H, Porter K, Easterbrook P, Zuckerman M, Geretti AM, Gifford R, Kellam P, Pillay D, Phillips A, Sabin C, Goldberg D, Gompels M, Hale A, Kaye S, Leigh-Brown A, Orkin C, Pozniak A, Robb G, Smit E, Tilston P, Williams I, Ainsworth J, Anderson J, Babiker A, Delpech V, Dunn D, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M, Hill T, Johnson M, Leen C, Orkin C, Phillips A, Pillay D, Porter K, Sabin C, Sadiq T, Schwenk A, Walsh J, Babiker A, Brettle R, Darbyshire J, Delpech V, Easterbrook P, Fidler S, Gilson R, Goldberg D, Hawkins D, Jaffe H, Johnson A, Johnson M, McLean K, Phillips A, Pillay D, UK Collaborative Grp HIV Drug Re , UK CHIC Steering Comm , UK Register HIV Seroconverters Ste (2007). Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS, 21(8), 1035 - 1039.

    2006

    • Fox Z, Bak Dragsted U, Gerstoft J, Phillips AN, Kjaer J, Mathiesen L, Youle M, Katlama C, Hill A, Bruun JN, Clumeck N, Dellamonica P, Lundgren JD (2006). A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Antiviral Therapy, 11(6), 761 - 770.
    • Imrie J, Lambert NL, Mercer CH, Copas AJ, Phillips A, Dean G, Watson R, Fisher M (2006). Refocusing health promotion for syphilis prevention: results of a case-control study of men who have sex with men on England's south coast. Sexually Transmitted Infections, 82(1), 80 - 83.
    • Stöhr W, Dunn DT, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P, Fisher M, Johnson MA, Delpech VC, Phillips AN, Sabin CA, UK CS (2006). CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997–2003. HIV Medicine, 8(3), 135 - 141.
    • Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD (2006). Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Archives of Internal Medicine, 166(15), 1632 - 1641.
    • Antiretroviral TCC (2006). Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. The Journal of Infectious Diseases, 194(5), 612 - 622.
    • May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fatkenheuer G, Staszewski S, d'Arminio Monforte A, Egger MATARTCC (2006). HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. The Lancet, 368(9534), 451 - 458.
    • Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thiebaut R, Morfeldt L, de Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JDFTDADS (2006). The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Medicine, 7(4), 218 - 230.
    • Bannister WP, Kirk O, Gatell JM, Knysz B, Viard JP, Mens H, Monforte AD, Phillips AN, Mocroft A, Lundgren JDESG (2006). Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 42(2), 229 - 237.
    • Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M, Lazzarin A, Weber J, Clumeck N, Vetter N, Phillips A, Lundgren JDESG (2006). Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. The Journal of Infectious Diseases, 194(5), 633 - 641.
    • Bannister WP, Ruiz L, Loveday C, Vella S, Zilmer K, Kjaer J, Knysz B, Phillips AN, Mocroft AESG (2006). HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antiviral Therapy, 11(6), 707 - 715.
    • Mocroft A, Rockstroh J, Soriano V, Kirk O, Viard JP, Caplinskas S, Gasiorowski J, Chiesi A, Phillips AN, Lundgren JD, EuroSIDA SG (2006). Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scandinavian Journal of Infectious Diseases, 38(11-12), 1092 - 1097.
    • Mocroft A, Horban A, Clumeck N, Stellbrink HJ, d'Arminio Monforte A, Zilmer K, Kirk O, Gatell J, Phillips AN, Lundgren JDESG (2006). Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naive patients starting cART after January 1, 2000. HIV Clinical Trials, 7(6), 271 - 284.
    • Cozzi-Lepri A, Costagliola D, Brun Vezinet F, Miller V, Phillips AN, on BOTSACROHIVDRTPFTFFCHIVR (2006). Exploratory analysis for the development of a score-based interpretation system to predict abacavir susceptibility using the Forum for Collaborative HIV Research Database..
    • Benzie A, Bansi L, Sabin C, Walsh J, Phillips A, for the UKCHIC Study Group (2006). Viral rebound in patients on antiretroviral therapy with viral suppression: association with extent of previous virological failure and time with viral suppression.
    • Phillips AN, Lundgren JD (2006). The CD4 lymphocyte count and risk of clinical progression.. Curr Opin HIV AIDS, 1(1), 43 - 49. doi:10.1097/01.COH.0000194106.12816.b1
    • El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C (2006). CD4+ count-guided interruption of antiretroviral treatment. New England Journal of Medicine, 355(22), 2283 - 2296. doi:10.1056/NEJMoa062360
    • Phillips AN, Cohen C, Lundgren JD (2006). Issues in the design of trials comparing management strategies for heavily pretreated patients.. Curr Opin HIV AIDS, 1(6), 476 - 481. doi:10.1097/01.COH.0000247388.00862.bb
    • Cozzi-Lepri A, De Luca A, Phillips AN, Bongiovanni M, Di Giambenedetto S, Mena M, Moioli MC, Arlotti M, Sighinolfi L, Narciso P, Lichtner M, Cauda R, Monforte A (2006). A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads. The Journal of Infectious Diseases, 194(1), 20 - 28. doi:10.1086/504265
    • Lampe FC, Gatell J, Staszewski S, Johnson MA, Pradier C, Gill MJ, de Lazzari E, Dauer B, Youle M, Fontas E, Krentz H, Phillips AN (2006). Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Archives of Internal Medicine, 166(5), 521 - 528. doi:10.1001/archinte.166.5.521
    • Cicconi P, Cozzi-Lepri A, Puoti M, Antonucci G, Mannazzu M, Pastore G, Mena M, Phillips A, d'Arminio Monforte A, ICONA SG (2006). Is the increased risk of liver enzyme elevation in hepatitis co-infected patients greater in those on HAART than in antiretroviral-naïve patients?.
    • Cozzi-Lepri A, Ruiz L, Ceccherini-Silberstein F, Mocroft A, Phillips A, Gatell J, Ledergerber B, Reiss P, Clotet B, Lundgren J, EuroSIDA SG (2006). Mutation at reverse transcriptase codon 214 is antagonist to thymidine analogue mutations (TAM) type 2 profiles and predicts virological response to thymidine analogue-containing cART regimens only if TAM type 1 profiles are concomitantly detected.
    • Mocroft A, Neaton J, Bebchuk J, Staszewski S, Antunes F, Knysz B, Law M, Phillips AN, Lundgren JDESGESPRITSG (2006). The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. Clinical Trials, 3(2), 119 - 132.
    • Sabin CA, Smith CJ, Youle M, Lampe FC, Robertson Bell D, Puradiredja D, Lipman MC, Bhagani S, Phillips AN, Johnson MA (2006). Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS, 20(1), 67 - 71.
    • Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JDFTESG (2006). Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.. AIDS, 20(8), 1141 - 1150.

    2005

    • Gazzard BBHIVAWC (2005). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.. HIV Medicine, 6(suppl 2), 1 - 61.
    • GAZZARD B (2005). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). , 6, 1 - 61.
    • Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron-Kaczmarska A, Viksna L, Kirk O, Lundgren JD, EuroSIDA Study Group (2005). Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.. AIDS Res Hum Retroviruses, 21(6), 527 - 536. doi:10.1089/aid.2005.21.527
    • Monforte AD, Cozzi-Lepri A, Phillips A, De Luca A, Murri R, Mussini C, Grossi P, Galli A, Zauli T, Montroni M, Tundo P, Moroni M, Italian Cohort Antiretroviral Naiv (2005). Interruption of highly active antiretroviral therapy in HIV clinical practice - Results from the Italian cohort of antiretroviral-naive patients. JAIDS-J ACQ IMM DEF, 38(4), 407 - 416.
    • Sabin CA, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, Youle MS, Johnson MA, Fisher M, Scullard G, Easterbrook P, Gazzard B, Phillips AN (2005). Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ (Clinical Research Ed.), 330(7493), 695 - 699. doi:10.1136/bmj.38369.669850.8F
    • Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D (2005). Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.. AIDS, 19(5), 487 - 494.
    • Lambert NL, Fisher M, Imrie J, Watson R, Mercer CH, Parry JV, Phillips A, Iversen A, Perry N, Dean GL (2005). Community based syphilis screening: feasibility, acceptability, and effectiveness in case finding. Sexually Transmitted Infections, 81(3), 213 - 216.
    • Pillay D, Green H, Matthias R, Dunn D, Phillips A, Sabin C, Evans B (2005). Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. The Journal of Infectious Diseases, 192(6), 967 - 973.
    • Sabin CA, Phillips AN, Yee TT, Griffioen A, Lee CA (2005). Twenty five years of HIV infection in haemophilic men in Britain: an observational study. BMJ (Clinical Research Ed.), 331(7523), 997 - 998.
    • d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger MTATCC (2005). The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Archives of Internal Medicine, 165(4), 416 - 423.
    • Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fatkenheuer G, Sterne JAATCC (2005). Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clinical Infectious Diseases, 41(12), 1772 - 1782.
    • Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron-Kaczmarska A, Viksna L, Kirk O, Lundgren JDESG (2005). Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Research and Human Retroviruses, 21(9), 743 - 752.
    • Mocroft A, Oancea C, van Lunzen J, Vanhems P, Banhegyi D, Chiesi A, Vinogradova E, Maayan S, Phillips AN, Lundgren JESG (2005). Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. American Journal of Gastroenterology, 100(7), 1446 - 1454.
    • Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren JESG (2005). Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. The Journal of Infectious Diseases, 192(6), 992 - 1002.
    • Dorrucci M, Phillips AN, Longo B, Rezza GISS (2005). Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985-2002. AIDS, 19(3), 331 - 335.
    • Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Moller N, Weber J, Horban A, Staszewski S, Lundgren JD, Phillips ANESG (2005). Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS, 19(3), 319 - 330.
    • Phillips A, Lampe F (2005). When to start therapy. The Journal of Infectious Diseases, 191(5), 821 - .
    • d'Arminio Monforte A, Cozzi-Lepri A, Phillips A, De Luca A, Murri R, Mussini C, Grossi P, Galli A, Zauli T, Montroni M, Tundo P, Moroni MICOA-NPSG (2005). Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 38(4), 407 - 416.
    • Smith CJ, Sabin CA, Lampe FC, Shah S, Tyrer M, Youle MS, Cropley I, Johnson MA, Phillips AN (2005). The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimens. Antiviral Therapy, 10(3), 459 - 467.
    • Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, Goh LE, Andersson J, Tsoukas C, Sonnerborg A, Tambussi G, Girard PM, Bloch M, Battegay M, Carter N, El Habib R, Theofan G, Cooper DA, Perrin LQUESTSG (2005). Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. The Journal of Infectious Diseases, 192(4), 607 - 617.
    • Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JDESG (2005). Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antiviral Therapy, 10(7), 791 - 802.
    • Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E, Reiss P, Katlama C, Phillips AN, Lundgren JDESG (2005). Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?. Antiviral Therapy, 10(7), 779 - 790.
    • Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S, Gatell J, Clotet B, Phillips AN, Lundgren JDFTESG (2005). Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. AIDS, 19(18), 2117 - 2125.
    • Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, Enilia R, Cozzi-Lepri A, Phillips AN, Ortolani P, Bratt G, Eriksson LE, Sighinolfi L, Cossarizza A, d'Arminio Monforte A, De Luca A, Di Giambenedetto S, Antinori AISGOC-MTI (2005). CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l. AIDS, 19(3), 287 - 294.
    • Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, Pillay D, Porter K, Pozniak A, Sabin C, Smit E, Weber J, Zuckerman M, Hill T (2005). Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ, 331(7529), 1358 - .
    • Dahan S, Wiles S, La Ragione RM, Best A, Woodward MJ, Stevens MP, Shaw RK, Chong YW, Knutton S, Phillips A, Frankel G (2005). EspJ is a prophage-carried type III effector protein of attaching and effacing pathogens that modulates infection dynamics. Infection and Immunity, 73(2), 679 - 686.
    • CANE P, CHRYSTIE I, DUNN D, al. E (2005). Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. , 331(7529), 1368 - 1371.
    • Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K, Gilson R, Easterbrook P, Matthias R, Scullard G, Johnson MA, Sabin CA (2005). The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. The Journal of Infectious Diseases, 192(8), 1387 - 1397. doi:10.1086/466534

    2004

    • Bhaskaran K, Brettle R, Porter K, Walker AS, Beral V, Coutinho R, Darbyshire J, Del Amo J, Gill N, Lee C, Meyer L, Rezza G, Babiker A, Tyrer F, Dabis F, Thiebaut R, Chene G, Lawson-Ayayi S, Meyer L, Boufassa F, Vanhems P, Hamouda O, Pezzotti P, Rezza G, Touloumi G, Hatzakis A, Karafoulidou A, Katsarou O, del Amo J, del Romero J, Aguado IH, Perez-Hoyos S, Cayla J, de Olalla PG, Muga R, van Asten L, van Benthem B, Prins M, Coutinho R, Pedersen C, Eskild A, Bruun JN, Sannes M, Brettle R, Sabin C, Lee C, Phillips AN, Babiker A, Darbyshire JH, Gill N, Porter K, Day NE, de Angelis D, Francioli P, Vanhems P, Egger M, Rickenbach M, Cooper D, Kaldor J, Ashton L, Cooper D, Kaldor J, Ashton L, Vizzard J, Gill J, CASCADE Collaboration , Aquitaine cohort , SEROCO cohort , Lyon Primary Infection cohort , Italian Seroconversion Study , Greek Haemophilia cohort , Madrid cohort , Valencia IDU cohort , Barcelona IDU cohort , Badalona IDU hospital cohort , Amsterdam Cohort Studies among , Copenhagen cohort , Oslo and Ulleval Hospital cohorts , Edinburgh Hospital cohort , Royal Free haemophilia cohort , UK Register of HIV Seroconverters , MRC Biostatistic Unit , Swiss HIV cohort , Sydney AIDS Prospective Study , Sydney Primary HIV Infection , South Alberta clinic (2004). Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. AIDS, 18(4), 673 - 681. doi:10.1097/01.aids.0000111464.61782.64
    • BHASKARAN K, BRETTLE R, PORTER K, al. E (2004). Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. , 18(4), 673 - 681.
    • Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron-Kaczmarska A, Viksna L, Kirk O, Lundgren JD, EuroSIDA study grp (2004). Why do patients with HIV stop antiretrovirals used as part of an initial highly active antiretroviral regimen?.
    • Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, Cropley I, Johnson MA, Phillips AN (2004). Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. The Journal of Infectious Diseases, 190(10), 1860 - 1868. doi:10.1086/425075
    • Phillips A, Ledergerber B, Lundgren J, Hogg B, Monforte AD, Castelli F, Walker S, Staszewski S, Thiebaut R, Gazzard B, Saag M, Petoumenos K, Johnson M, Scullard G, Gill J, James I, Fisher M, Mussini C, Klein M, Costagliola D, Collaboration HIV Cohorts (2004). Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound.
    • Brun-Vezinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola V (2004). Clinically validated genotype analysis: guiding principles and statistical concerns. ANTIVIR THER, 9(4), 465 - 478.
    • Pillay D, Green H, Gazzard B, Pozniak A, Matthias R, Johnson M, Churchill D, Fisher M, Hill T, Geretti AM, Clarke J, Cane P, Loveday C, Scullard G, Easterbrook P, Porter K, Williams I, Gilson R, Sabin C, Phillips A, Dunn D, UK Collaborative Grp HIV Drug (2004). Estimating resistance in drug experienced patients in the UK.
    • Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, Monforte AD, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN, Castelli F, Fusco GP, Gill MJ, Hogg R, Lampe F, Law M, Ledergerber B, Lundgren JD, Monforte AD, Mussini C, Phillips AN, Reiss P, Staszewski S, Walker AS, Rooney P, Taylor S, Couldwell D, Austin D, Block M, Clemons J, Finlayson R, Law M, Petoumenos K, Quan D, Smith D, O'Connor C, Gorton C, Allen D, Mulhall B, Mutimer K, Smith D, Keeffe N, Cooper D, Carr A, Miller J, Pell C, Ellis D, Baker D, Kidd J, McFarlane R, Liang MT, Brown K, Huffam S, Savage J, Morgan S, Knibbs P, Sowden D, Walker A, Orth D, Lister G, Chuah J, Fankhauser W, Dickson B, Bradford D, Wilson C, Ree H, Magon H, Anderson J, Moore R, Russell D, McGovern G, McNair R, Bal J, Fairley K, Roth N, Eu B, Strecker S, Russell D, Wood H, Mijch A, Hoy J, Pierce A, McCormack C, Watson K, Medland N, Daye J, Mallal S, French M, Skett J, Maxwel D, Cain A, Montroni M, Scalise G, Costantini A, Giacometti A, Tirelli U, Nasti G, Pastore G, Ladisa N, Perulli ML, Suter F, Arici C, Chiodo F, Gritti FM, Colangeli V, Fiorini C, Guerra L, Carosi G, Cadeo GP, Castelli F, Minardi C, Vangi D, Rizzardini G, Migliorino G, Manconi PE, Piano P, Ferraro T, Scerbo A, Pizzigallo E, Ricci F, Santoro D, Pusterla L, Carnevale G, Galloni D, Vigano P, Mena M, Ghinelli F, Sighinolfi L, Leoncini F, Mazzotta F, Pozzi M, Lo Caputo S, Angarano G, Grisorio B, Ferrara S, Grima P, Tundo P, Pagano G, Piersantelli N, Alessandrini A, Piscopo R, Toti M, Chigiotti S, Soscia F, Taccooni L, Orani A, Perini P, Scasso A, Vincenti A, Scalzini A, Fibbia G, Moroni M, Lazzarin A, Cargnel A, Vigevani GM, Caggese L, Monforte AD, Tordato F, Novati R, Galli A, Merli S, Pastecchia C, Moioli C, Esposito R, Mussini C, Abrescia N, Chirianni A, Izzo C, Piazza M, De Marco M, Montesarchio V, Manzillo E, Nappa S, Colomba A, Abbadessa V, Prestileo T, Mancuso S, Ferrari C, Pzzaferri P, Filice G, Minoli L, Bruno R, Maserati R, Pauluzzi S, Baldelli F, Petrelli E, Cioppi A, Alberici F, Ruggieri A, Menichetti F, Martinelli C, De Stefano C, La Gala A, Zauli T, Ballardini G, Magnani G, Ursitti MA, Arlotti M, Ortolani P, Ortona L, Dianzani F, Ippolito G, Antinori A, Antonucci G, D'Elia S, Narciso P, Petrosillo N, Vullo V, De Luca A, Del Forno L, Zaccarelli M, De Longis P, Ciardi M, D'Offizi G, Noto P, Lichtner M, Capobianchi MR, Girardi E, Pezzotti P, Rezza G, Mura MS, Mannazzu M, Caramello P, Sinicco A, Soranzo ML, Gennero L, Sciandra M, Salassa B, Grossi PA, Basilico C, Poggio A, Bottari G, Raise E, Pasquinucci S, De Lalla F, Tositti G, Resta F, Chimienti A, Lepri AC, Bachmann S, Battegay M, Bernasconi E, Bucher H, Burgisser P, Cattacin S, Egger M, Erb P, Fierz W, Fischer M, Flepp M, Fontana A, Francioli P, Furrer HJ, Gorgievski M, Hirschel B, Kaiser L, Kind C, Klimkait T, Ledergerber B, Lauper U, Opravil M, Paccaud F, Pantaleo G, Perrin L, Piffaretti JC, Rickenbach M, Rudin C, Schupbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S, de Wolf F, van Sighem AI, van Valkengoed I, Gras L, Bronsveld W, Prins JM, Bos JC, Schattenkerk JKME, Godfried MH, Lange JMA, Lowe SH, van der Meer JTM, Nellen FJB, Pogany K, van der Poll T, Reiss P, Ruys TA, Sankatsing S, van der Valk M, van Vonderen MGA, Wit FWMN, van Eeden A, ten Veen JH, van Dam PS, Hillebrand-Haverkort ME, Brinkman K, Frissen PHJ, Weigel HM, Mulder JW, van Gorp ECM, Meenhorst PL, Mairuhu ATA, Veenstra J, Danner SA, Van Agtmael MA, Claessen FAP, Geerlings SE, Perenboom RM, Richter C, van der Berg J, van Leusen R, Vriesendorp R, Jeurissen FJF, Kauffmann RH, Koger ELW, Bravenboer B, ten Napel CHH, Mudrikova T, Sprenger HG, Miesen WMAJ, ten Kate RW, van Houte DPF, Leemhuis MP, Pole M, Kroon FP, Schippers EF, Schreij G, van de Ge (2004). Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. LANCET, 364(9428), 51 - 62.
    • Mocroft AJ, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, Antunes F, Stellbrink HJ, Phillips AN, Lundgren JD (2004). The changing pattern of Kaposi Sarcoma in patients with HIV, 1994-2003. Cancer, 100(12), 2644 - 2654. doi:10.1002/cncr.20309
    • Lundgren JD, Phillips AN (2004). Indirect comparisons: a novel approach to assessing the effect of anti-HIV drugs. BMJ (Clinical Research Ed.), 328(7434), 253 - 253.
    • Collaboration OHIVC, Lampe , F , Smith , C , Chaloner , C , Gumley , H , Ransom , D , Sabin , C A, Mocroft , A , Lipman , M , Phillips , A N, Youle , M , Johnson , M (2004). Nucleoside Analogue Use Before and During Highly Active Antiretroviral Therapy and Virus Load Rebound. The Journal of Infectious Diseases, 190(4), 675 - 687.
    • Phillips AN, Walker AS (2004). Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection. AIDS, 18(3), 365 - 370.
    • Phillips AN, Lendergerber B, Horban A, Reiss P, Chiesi A, Kirk O, Mulcahy F, Fisher M, Machala L, Lundgren JD (2004). Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.. AIDS, 18(13), 1795 - 1804.
    • d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Moller NWCOTDADSG (2004). Cardio- and cerebrovascular events in HIV-infected persons. AIDS, 18(13), 1811 - 1817.
    • Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjoer J, Lundgren J, Clotet B, Ruiz L (2004). Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. Antiviral Therapy, 9(5), 787 - 800.
    • Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN, Prinz B, Youle M, Johnson MA (2004). Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS, 18(16), 2145 - 2151.
    • Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vezinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L (2004). Updated European recommendations for the clinical use of HIV drug resistance testing. Antiviral Therapy, 9(6), 829 - 848.
    • Smith CJ, Staszewski S, Sabin CA, Nelson M, Dauer B, Gute P, Johnson MA, Phillips AN, Gazzard B (2004). Use of Viral Load Measured after 4 weeks of Highly Active Antiretroviral Therapy to Predict Virologic Outcome at 24 weeks for HIV-1 Positive Individuals. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 37(1), 1155 - 1159.
    • Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, Horban A, Hansen AB, Phillips AN, Lundgren JD (2004). Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. The Journal of Infectious Diseases, 190(11), 1947 - 1956.
    • Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, Vella S, Blaxhult A, Phillips AN, Lundgren JESG (2004). Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS, 18(17), 2333 - 2337.
    • Mocroft A, Phillips A, Lundgren JD (2004). HIV survival benefit associated with earlier antiviral therapy. Annals of Internal Medicine, 140(7), 578 - 579.
    • Garmendia J, Phillips A, Chong Y, Schuller S, Marches O, Dahan S, Oswald E, Shaw RK, Knutton S, Frankel G (2004). TccP is an enterohaemorrhagic E. coli O157:H7 type III effector protein that couples Tir to the actin-cytoskeleton. Cellular Microbiology, 6, 1167 - 1183.
    • Sabin C, Babiker A, Dunn D, Easterbrook P, Fisher M, Gilson R, Johnson M, Mortimer J, Peters B, Phillips A, Porter K, Scullard G, Gazzard B, Matthias R, Hill T (2004). The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Medicine, 5(2), 115 - 124.
    • Phillips A, CASCADE C (2004). Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS, 18(1), 51 - 58.
    • Lambert NL, Imrie J, Mercer CH, Fisher M, Dean G, Watson R, Phillips A, Copas AJ (2004). Syphilis and drug use among men who have sex with men..
    • Imrie J, Lambert NL, Phillips A, Mercer CH, Copas AJ, Watson R, Perry N, Dean G, Fisher M (2004). Demographic, sexual partnerships and sexual behaviours associated with recent syphilis diagnosis among men who have sex with men (MSM) on England’s south coast..
    • Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D (2004). Risk of development of drug resistance in patients starting antiretroviral therapy with three or more drugs in routine clinical practice.
    • Beral V, Coutinho R, Darbyshire J, Del Amo J, Gill N, Lee C, Meyer L, Rezza G, Porter K, Babiker A, Walker AS, Darbyshire J, Tyrer F, Dabis F, Thiebaut R, Chene G, Lawson-Ayayi S, Meyer L, Boufassa F, Vanhems P, Hamouda O, Fischer K, Pezzotti P, Rezza G, Touloumi G, Hatzakis A, Karafoulidou A, Katsarou O, Brettle R, Sabin C, Lee C, Johnson AM, Phillips AN, Babiker A, Darbyshire JH, Gill N, Porter K, Day NE, De Angelis D, Del Amo J, del Romero J, Aguado IH, Perez-Hoyos S, Muga R, van Asten L, van Benthem B, Prins M, Coutinho R, Kirk O, Pedersen C, Eskild A, Briuun JN, Sannes M, Francioli P, Vanhems P, Egger M, Rickenbach M, Cooper D, Kaldor J, Ashton L, Vizzard J, CASCADE Collaboration (2004). Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS, 18(1), 51 - 58. doi:10.1097/01.aids.0000096908.73209.5d

    2003

    • Martinez E, Bailey L, Milinkovic A, Blanco JL, Lonca M, Laguno M, Leon A, Mallolas J, Phillips AN, Gatell JM (2003). A prospective cohort study on the risk of lipodystrophy in HIV-1-infected patients treated with highly active antiretroviral therapy not containing protease inhibitors.
    • Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, Goebel FD, Phillips AN, Clotet B, Lundgren JD, EuroSIDA SG (2003). Virological rebound after suppression on highly active antiretroviral therapy. AIDS, 17(12), 1741 - 1751.
    • Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, Panos G, Katlama C, Vella S, Phillips A (2003). Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Medicine, 4(3), 255 - 262.
    • Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD, DATA SG (2003). Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS, 17(8), 1179 - 1193.
    • Phillips AN, Youle MS, Lampe F, Johnson M, Sabin CA, Cozzi-Lepri A, Loveday C (2003). Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection. AIDS, 17(7), 1009 - 1016.
    • Smith CJ, Sabin CA, Lampe FC, Kinloch-de-Loes S, Gumley H, Carroll A, Prinz B, Youle M, Johnson MA, Phillips AN (2003). The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy.. AIDS, 17(7), 963 - 969. doi:10.1097/01.aids.0000060352.78202.79
    • Cozzi-Lepri A, Phillips AN, Miller V, Katlama C, Ledergerber B, Vella S, Weber J, Bruun JN, Kirk O, Clotet B, Lundgrens JD (2003). Changes in viral load in people with virological failure who remain on the same HAART regimen. Antiviral Therapy, 8(2), 127 - 136.
    • Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, Colebunders R, Chiesi A, Lungren JD, Phillips AN (2003). Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 32(4), 452 - 461.
    • Sabin CA, Lampe FC, Chaloner C, Madge SJ, Lipman MC, Youle M, Phillips AN, Johnson MA (2003). An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. HIV Medicine, 4(2), 87 - 93.
    • Lampe FC, Johnson MA, Lipman M, Loveday C, Youle M, Ransom D, Sabin CA, Tyrer M, Phillips AN (2003). Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 years. AIDS, 17(5), 768 - 770.
    • Phillips AN, Pezzotti P (2003). Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS, 18(1), 51 - 58. doi:10.1097/00002030-200401020-00006
    • CASCADE Collaboration (2003). Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1 infected individuals with well-estimated dates of seroconversion. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 34(1), 76 - 83.
    • CASCADE C (2003). Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data. HIV Medicine, 4(4), 332 - 337.
    • CASCADE Collaboration (2003). Impact of tuberculosis on HIV disease progression in persons with well-documented time of HIV seroconversion. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 33(2), 184 - 190.
    • CASCADE C (2003). Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 32(3), 303 - 310.
    • Phillips A (2003). Commentary: Balancing quantity and quality when designing epidemiological studies. International Journal of Epidemiology, 32(1), 58 - 59.
    • Phillips A (2003). Trial and error: cross-trial comparisons of antiretroviral regimens. AIDS, 17(4), 619 - 623.
    • Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, Fisher M, Johnson M, Khoo S, Leen C, Loveday C, Moyle G, Nelson M, Peters B, Phillips A, Pillay D, Wilkins E, Williams I, Youle M (2003). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine, 4(Sup1), S1 - S41.
    • FRIIS-MOLLER N, KIRK O, REISS P, al. E (2003). Safety of non-nucleoside reverse transcriptase therapy: data from the EuroSIDA study. , 8(4), L20 - L20.
    • HUMPHRIES M, MURPHY J, PHILLIPS A, al. E (2003). Synthesis of functionalized piperidinones. , 68(6), 2432 - 2436.
    • KIRK O, GATELL J, MOCROFT A, al. E (2003). Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy (vol 162, pg 865, 2000). , 167(12), 1719 - 1719.
    • Martinez E, Domingo P, Galindo MJ, Milinkovic A, Arroyo JA, Baldovi F, de Lazzari E, Gatell JM (2003). Risk of metabolic abnormalities in HIV-infected patients starting lopinavir-ritonavir containing antiretroviral therapy: a prospective cohort study.
    • Del Amo J, Hernandez SPHI, Diez M, Castilla J, Porter K, Beral V, Coutinho R, Darbyshire J, Gill N, Lee C, Meyer L, Rezza G, Babiker A, Walker AS, Tyrer F, Dabis F, Thiebaut R, Lawson-Ayayi S, Boufassa F, Hamouda O, Fischer K, Pezzotti P, Touloumi G, Hatzakis A, Karafoulidou A, Katsarou O, Brettle R, del Romero J, Prins M, van Benthem B, Kirk O, Pedersen C, Aguado IH, Perez-Hoyos S, Eskild A, Bruun JN, Sannes M, Sabin C, Lee C, Johnson AM, Phillips AN, Francioli P, Vanhems P, Egger M, Rickenbach M, Cooper D, Kaldor J, Ashton L, Vizzard J, Bustamente RM, Day NE, De Angelis D, CASCADE Collaboration (2003). Impact of tuberculosis on HIV disease progression in persons with well-documented time of HIV seroconversion. JAIDS-J ACQ IMM DEF, 33(2), 184 - 190.
    • Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD (2003). Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine, 349(21), 1993 - 2003. doi:10.1056/NEJMoa030218
    • CASCADE Collaboration (2003). Determinants of survival following HIV-1 seroconversion after the introduction of HAART. The Lancet, 362(9392), 1267 - 1274. doi:10.1016/S0140-6736(03)14570-9
    • Murri R, Cozzi-Lepri A, Phillips AN, Girardi E, Nasti G, Ferrara S, Mura MS, Mussini C, Petrelli E, Arlotti M, De Stefano C, Vigano P, Novati R, Cargnel A, Monforte AD (2003). Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 34(2), 184 - 190.
    • Phillips AN, Cozzi-Lepri AC, Lampe F, Johnson M, Sabin CA (2003). When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS, 17(13), 1863 - 1869.
    • Staszewski S, Sabin C, Dauer B, Cozzi-Lepri A, Phillips A (2003). Definition of loss of virological response in trials of antiretroviral drugs. AIDS, 17(13), 1997 - 1998.
    • Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, d'Arminio MA, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME (2003). Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. The Lancet, 362(9385), 679 - 686.
    • Mocroft AJ, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. The Lancet, 362(9377), 22 - 29. doi:10.1016/S0140-6736(03)13802-0

    2002

    • Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA, Gazzard BG (2002). Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS, 16(1), 53 - 61.
    • Kirk O, Pedersen C, Law M, Gulick RM, Moyle G, Montaner J, Eron JJ, Phillips AN, Lundgren JD (2002). Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Antiviral Therapy, 7(4), 271 - 281.
    • Blaxhult A, Fox Z, Colebunders R, Francioli P, Ben Ishai Z, Fatkenheuer G, Parkin JM, Vanhems P, Phillips AN, Kirk O (2002). Regional and temporal changes in AIDS in Europe before HAART. Epidemiology and Infection, 129(3), 565 - 576. doi:10.1017/S0950268802007719
    • Johnson M, Phillips A, Wilkinson D (2002). HIV infection.. Clin Evid, (8), 693 - 701.
    • Sabin CA, Griffioen A, Yee TT, Emery VC, Herrero-Martinez E, Phillips AN, Lee CA (2002). Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study. The Lancet, 360(9345), 1546 - 1551. doi:10.1016/S0140-6736(02)11519-4
    • CASCADE Collaboration (2002). Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. International Journal of Epidemiology, 31(5), 951 - 958.
    • Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, Sabin CA, Doerr HW, Johnson MA, Loveday C, Miller V (2002). Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. The Journal of Infectious Diseases, 186(8), 1086 - 1091.
    • Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, Miller V, Francioli P, Furrer H, Battegay M, Vernazza P, Bernasconi E, Gunthard HF, Hirschel B, Phillips AN, Telenti A (2002). Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS, 16(14), 1967 - 1969.
    • Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, Ormaasen V, Gargalianos-Kakolyris P, Vella S, Lundgren JD (2002). Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. The Journal of Infectious Diseases, 186(2), 189 - 197.
    • Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, d'Arminio Monforte A DW, F R, P L, J D J, A C S, S L, C H, R S S, C A G, M J S, B S, J A (2002). Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. The Lancet, 360(9327), 119 - 129.
    • Lundgren JD, Mocroft A, Gatell JM, Phillips AN (2002). Is the poorer rate of survival among patients with human immunodeficiency virus infection and anemia linked to immune activation? Reply. J INFECT DIS, 186(1), 142 - 143.
    • Perrin L, Cooper DA, Hoen B, Kinloch S, Phillips A, Tsoukas C, Andersson J, Lampe F, Autran B, Janossy G, Miller V, Racz P, Sekaly R (2002). Therapeutic vaccination in primary HIV infection, the Quest trial. Vaccine, 20(15), 2004 - 2006. doi:10.1016/S0264-410X(02)00087-7
    • Phillips AN, Youle M, Lampe F, Sabin CA, Hill A, Ransom D, Gumley H, Loveday C, Lipman M, Johnson M (2002). CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy. AIDS, 16(7), 1073 - 1075.
    • Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, Piersantelli N, Orani A, Petrosillo N, Leoncini F, Scerbo A, Tundo P, Abrescia N, Moroni M (2002). Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. The Journal of Infectious Diseases, 185(8), 1062 - 1069. doi:10.1086/339821
    • Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, Piersantelli N, Orani A, Petrosillo N, Leoncini F, Scerbo A, Tundo P, Abrescia N, Moroni M, Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study Group (2002). Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study.. J Infect Dis, 185(8), 1062 - 1069. doi:10.1086/339821
    • Barry SM, Lloyd-Owen SJ, Madge SJ, Cozzi-Lepri A, Evans AJ, Phillips AN, Johnson MA (2002). The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000. HIV Medicine, 3(2), 129 - 134.
    • Mocroft A, Phillips AN, Friis-Moller N, Colebunders R, Johnson AM, Hirschel B, Saint-Marc T, Staub T, Clotet B, Lundgren JDESG (2002). Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antiviral Therapy, 7(1), 21 - 30.
    • Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, D'Arminio Monforte A, Hermans P, Goebel FD, Blaxhult A, Kirk O, Phillips ANESG (2002). A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. The Journal of Infectious Diseases, 185(2), 178 - 187.
    • Moore AL, Sabin CA, Johnson MA, Phillips AN (2002). Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 29(2), 197 - 202.
    • Paddam L, Sabin C, Cozzi-Lepri A, Phillips A (2002). Early assessment of anti-HIV drug efficacy. The Lancet, 359(9318), 1696 - 1697.
    • Wilde JT, Lee CA, Darby SC, Kan SW, Giangrande P, Phillips AN, Winter M, Spooner R, Ludlam CA (2002). The incidence of lymphoma in the UK haemophilia population between 1978 and 1999. AIDS, 16(13), 1803 - 1807.
    • Youle M, Tyrer M, Fisher M, Lampe F, Wilson D, Ransom D, Story A, Mocroft A, Loveday C, Johnson MA, Phillips AN (2002). Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 29(1), 58 - 61.
    • PHILLIPS A, YOULE M, LAMPE F, al. E (2002). Theoretical rationale for the use of single drug sequential antiretroviral therapy regimens. , 7, S80 - S80.
    • Moore AL, Youle M, Lipman M, Cozzi-Lepri A, Lampe F, Madge S, Nesaratnam S, Tyrer M, Cuthbertson Z, Ransom D, Loveday C, Johnson MA, Phillips AN (2002). Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?. AIDS, 16(4), 615 - 618.

    2001

    • Phillips AN, Youle M, Johnson M, Loveday C (2001). Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS, 15(17), 2211 - 2220.
    • Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Cadeo G, Tositti G, Pasquinucci S, Pauluzzi S, Scalzini A, Salassa B, Vincenti A, Phillips AN, Dianzani F, Appice A, Angarano G, Monno L, Ippolito G, Moroni M, d' Arminio Monforte A (2001). Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. The Journal of Infectious Diseases, 184(8), 983 - 991.
    • Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, Antunes F, Ledergerber B, Kirk O, Lundgren JD, EuroSIDA SG (2001). Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS, 15(18), 2385 - 2395.
    • Phillips AN, Miller V, Sabin C, Cozzi-Lepri A, Klauke S, Bickel M, DOERR HW, Hill A, Staszewski S (2001). Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS, 15(18), 2379 - 2384.
    • Babiker A, Darbyshire N, Pezzotti P, Porter K, Rezza G, Walker S, Beral V, Coutinho R, Del Amo J, Gill N, Lee C, Meyer L, Tyrer F, Dabis F, Thiebaut R, Lawson-Ayayi S, Meyer L, Boufassa F, Hamouda O, Lorenzo JI, Touloumi G, Hatzakis A, Karafoulidou A, Katsarou O, Brettle R, del Romero J, Prins M, Coutinho RA, van Benthem B, Coutinho RA, Kirk O, Pedersen C, Aguado IH, Perez-Hoyos S, Eskild A, Bruun JN, Sannes M, Sabin C, Johnson AM, Phillips AN, Darbyshire JH, Francioli P, Vanhems P, Egger M, Rickenbach M, Cooper D, Kaldor J, Vizzard J, Tusell JM, Ruiz I, Cayla JA, de Olalla PG, Day NE, De Angelis D, CASCADE Collaboration (2001). Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?. J ACQ IMMUN DEF SYND, 28(2), 158 - 165.
    • KAZA A, KRON I, LEUWERKE S, al. E (2001). Keratinocyte growth factor enhances post-pneumonectomy lung growth by alveolar proliferation.. , 104(17), 522 - 522.
    • BABIKER A, DARBYSHIRE N, PEZZOTTI P, al. E (2001). Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?. , 28(2), 158 - 165.
    • Sabin CA, Cozzi-Lepri A, Devereux H, Phillips AN, Loveday C, Lee CA (2001). Relationships among the detection of p24 antigen, human immunodeficiency virus (HIV) RNA level, CD4 cell count, and disease progression in HIV-infected individuals with hemophilia. The Journal of Infectious Diseases, 184(4), 511 - 514.
    • Miller V, Vandamme AM, Loveday C, Staszewski S, Lundgren J, Youle M, Ait-Khaled M, Boucher C, Brun-Vezinet F, Dedes N, Giaquinto C, Hertogs K, Houyez F, Perrin L, PILLAY D, Schmit JC, Schuurman R, Lange J, Banhegyi D, Biondi G, Broekhuizen A, Bush-Donovan C, Camacho R, Carlier H, Clavel F, Clotet B, Clumeck N, Colebunders R, De Clerq K, De Jaegher JJ, De Schrijver G, De Smet K, Hall W, Harrigan R, Hatzakis A, Hellmann N, Hoetelmans R, Holtzer C, Katlama C, Larder D, Loriaux E, McCreedy B, Mulcahy F, Opravil M, Phillips A, Ruiz N, Shulse E, Sonnerborg A, Soriano V, Steel H, Vella S, Williams A (2001). Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. AIDS, 15(3), 309 - 320.
    • Davey Smith G, Phillips AN (2001). Re: "cigarette smoking and suicide: a prospective study of 300,000 male active-duty army soldiers". American Journal of Epidemiology, 153(3), 307 - 308.
    • Cozzi-Lepri AC, Miller V, Phillips AN, Rabenau H, Sabin CA, Staszewski S (2001). The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load. AIDS, 15(1), 47 - 54.
    • Mocroft A, Phillips AN, Miller V, Gatell J, van Lunzen J, Parkin JM, Weber R, Roge B, Lazzarin A, Lundgren JD (2001). The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS, 15(2), 201 - 209.
    • Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Cozzi-Lepri A, Tyrer M, Chaloner C, Wilson D, Loveday C, Johnson MA, Phillips AN (2001). Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS, 15(2), 185 - 194.
    • Moore AL, Mocroft A, Madge S, Devereux H, Wilson D, Phillips AN, Johnson M (2001). Gender differences in virologic response to treatment in an HIV- positive population: a cohort study. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 26(2), 159 - 163.
    • Miller V, Vandamme AM, Loveday C, Staszewski S, Lundgren J, Youle M, Ait-Khaled M, Boucher C, Brun-Vezinet F, Dedes N, Giaquinto C, Hertogs K, Houyez F, Perrin L, Pillay D, Schmit JC, Schuurman R, Lange J, Banhegyi D, Biondi G, Broekhuizen A, Bush-Donovan C, Camacho R, Carlier H, Clavel F, Clotet B, Clumeck N, Colebunders R, De Clerq K, De Jaegher JJ, De Schrijver G, De Smet K, Hall W, Harrigan R, Hatzakis A, Hellmann N, Hoetelmans R, Holtzer C, Katlama C, Larder D, Loriaux E, McCreedy B, Mulcahy F, Opravil M, Phillips A, Ruiz N, Shulse E, Sonnerborg A, Soriano V, Steel H, Vella S, Williams A, EuroGuidelines Grp HIV Resistance (2001). Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS, 15(3), 309 - 320.
    • Martinez E, Mocroft AJ, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, Gatell JM (2001). Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. The Lancet, 357(9256), 592 - 598. doi:10.1016/S0140-6736(00)04056-3
    • Sabin CA, Phillips AN (2001). Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. Journal of Antimicrobial Chemotherapy, 47(4), 371 - 375.
    • Pezzotti P, Pappagallo M, Phillips AN, Boros S, Valdarchi C, Sinicco A, Zaccarelli M, Rezza G (2001). Response to highly active antiretroviral therapy according to duration of HIV infection. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 26(5), 473 - 479.
    • Lepri AC, Phillips AN, Monforte AD, Castelli F, Antinori A, de Luca A, Pezzotti P, Alberici F, Cargnel A, Grima P, Piscopo R, Prestileo T, Scalise G, Vigevani M, Moroni M, ICONA Study Grp (2001). When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS, 15(8), 983 - 990.
    • Kirk O, Mocroft A, Pradier C, Bruun JN, Hemmer R, Clotet B, Miller V, Viard JP, Phillips AN, Lundgren JD, EuroSIDA SG (2001). Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. AIDS, 15(8), 999 - 1008.
    • Cozzi-Lepri A, Phillips AN, d'Arminio A, Monforte A, Castelli F, Antinori A, De Luca A, Pezzotti P, Alberici F, Cargnel A, Grima P, Piscopo R, Prestileo T, Scalise G, Vigevani M, Moroni M (2001). When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS, 15(8), 983 - 990. doi:10.1097/00002030-200105250-00006
    • Sabin CA, Phillips AN (2001). Cohort studies in sexual health. Sexually Transmitted Infections, 77(3), 174 - 178.
    • Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips A, Gatell JM (2001). Hepatotoxicity in HIV-1-infected patients receiving nevirapine- containing antiretroviral therapy. AIDS, 15(10), 1261 - 1268.
    • Phillips A (2001). Will the drugs still work? Transmission of resistant HIV. Nature Medicine, 7(9), 993 - 994.
    • Goh LE, Perrin L, Hoen B, Cooper D, Phillips A, Janossy G, Sonnenborg A, Tsoukas C, Lampe F, Kinloch SQUESTSG (2001). Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: The QUEST study. HIV Clinical Trials, 2(5), 438 - 444.
    • Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN, Studd JW, Johnson MA (2001). Reduced bone mineral density in HIV-positive individuals. AIDS, 15(13), 1731 - 1733.
    • Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Cadeo G, Tositti G, Pasquinucci S, Pauluzzi S, Scalzini A, Salassa B, Vincenti A, Phillips AN, Dianzani F, Appice A, Angarano G, Monno L, Ippolito G, Moroni M, Monforte AD, Italian Cohort Naive Antiretrovira (2001). Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.
    • Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B (2001). HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA, 286(20), 2560 - 2567. doi:10.1001/jama.286.20.2560

    2000

    • Collaborative GOAIDSIAHIVSITCASCADEEUCACAOSTAIDSADIE (2000). Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re- analysis. The Lancet, 355(9210), 1131 - 1137.
    • DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J (2000). The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy, 5(1), 41 - 48.
    • Foisy MM, Gough K, Quan CM, Harris K, Ibanez D, Phillips A (2000). Hospitalization due to adverse drug reactions and drug interactions before and after HAART. Canadian Journal of Infectious Diseases, 11(4), 193 - 201.
    • Miller V, Cozzi-Lepri A, Hertogs K, Gute P, Larder B, Bloor S, Klauke S, Rabenau H, Phillips A, Staszewski S (2000). HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antiviral Therapy, 5(1), 49 - 55.
    • Mocroft A, Katlama C, Johnson AM, Pradier C, Mulcahy F, Chiesi A, Phillips AN, Kirk O, Lundgren JD (2000). AIDS across Europe, 1994-1998: the EuroSIDA study. The Lancet, 356(9226), 291 - 296.
    • Sabin CA, Cozzi-Lepri AC, Phillips A (2000). A Practical Guide to Applying the Intention-to-Treat Principle to Clinical Trials in HIV Infection. HIV Clinical Trials, 1(2), 31 - 38.
    • CASCADE Collaboration (2000). Survival after introduction of HAART in people with known duration of HIV-1 infection. The Lancet, 355(9210), 1158 - 1159.
    • Sabin CA, Devereux H, Phillips AN, Hill A, Janossy G, Lee CA, Loveday C (2000). Course of viral load throughout HIV-1 infection. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 23(2), 172 - 177.
    • Marang-van de Mheen PJ, Smith GD, Hart CL, Hole DJ, Phillips AN (2000). The influence of gender, social circumstances and smoking on survival: the Renfrew and Paisley study. Public Health, 114(2), 117 - 122.
    • Cozzi-Lepri A, Sabin CA, Staszewski S, Hertogs K, Muller A, Rabenau H, Phillips AN, Miller V (2000). Resistance profiles in patients with viral rebound on potent antiretroviral therapy. The Journal of Infectious Diseases, 181(3), 1143 - 1147.
    • Monforte AD, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M, ICONA Study Grp (2000). Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS, 14(5), 499 - 507.
    • d'Arminio Monforte A, Cozzi-Lepri A, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M (2000). Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS, 14(5), 499 - 507.
    • Babiker A, Darby S, De Angelis D, Kwart D, Porter K, Beral V, Darbyshire J, Day N, Gill N, Coutinho R, Prins M, van Benthem B, Coutinho R, Dabis F, Marimoutou C, Ruiz I, Tusell J, Altisent C, Evatt B, Jaffe H, Kirk O, Pedersen C, Rosenberg P, Goedert J, Biggar R, Melbye M, Brettie R, Downs A, Hamouda O, Touloumi G, Karafoulidou A, Katsarou O, Donfield S, Gomperts E, Hilgartner M, Hoots K, Schoenbaum E, Beral V, Zangerle R, Del Amo J, Pezzotti P, Rezza G, Hutchinson S, Day N, De Angelis D, Gore S, Kingsley L, Schrager L, Rosenberg P, Goedert J, Melnick S, Koblin B, Eskild A, Bruun J, Sannes M, Evans B, Lepri AC, Sabin C, Buchbinder S, Vittinghoff E, Moss A, Osmond D, Winkelstein W, Goldberg D, Boufassa F, Meyer L, Egger M, Francioli P, Rickenbach M, Cooper D, Tindall B, Sharkey T, Vizzard J, Kaldor J, Cunningham P, Vanhems P, Vizzard J, Kaldor J, Learmont J, Farewell V, Berglund O, Mosley J, Operskalski E, van den Berg M, Metzger D, Tobin D, Woody G, Rusnak J, Hendrix C, Garner R, Hawkes C, Renzullo P, Garland F, Darby S, Ewart D, Giangrande P, Lee C, Phillips A, Spooner R, Wilde J, Winter M, Babiker A, Darbyshire J, Evans B, Gill N, Johnson A, Phillips A, Porter K, Lorenzo JI, Schechter M, Collaborative Grp AIDS Incubation (2000). Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. LANCET, 355(9210), 1131 - 1137.
    • Sabin CA, Devereux HL, Clewley G, Emery VC, Phillips AN, Loveday C, Lee CA, Griffiths PD (2000). Cytomegalovirus seropositivity and human immunodeficiency virus type 1 RNA levels in individuals with hemophilia. The Journal of Infectious Diseases, 181(5), 1800 - 1803.
    • Sabin CA, Yee TT, Devereux H, Griffioen A, Loveday C, Phillips AN, Lee CA (2000). Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy.. AIDS, 14(8), 1001 - 1007.
    • Sabin CA, Yee TT, Devereux H, Griffioen A, Loveday C, Phillips AN, Lee CA (2000). Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy. AIDS, 14(8), 1001 - 1007.
    • Vanhems P, Hirschel B, Phillips AN, Cooper DA, Vizzard J, Brassard J, Perrin L (2000). Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS. The Journal of Infectious Diseases, 182(1), 334 - 337.
    • Mocroft A, Devereux H, Kinloch-de-Loes S, Wilson D, Madge S, Youle M, Tyrer M, Loveday C, Phillips AN, Johnson MA (2000). Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS, 14(11), 1545 - 1552. doi:10.1097/00002030-200007280-00010
    • Mocroft A, Devereux H, Kinloch-de-Loes S, Wilson D, Madge S, Youle M, Tyrer M, Loveday C, Phillips AN, Johnson MA (2000). Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS, 14(11), 1545 - 1552.
    • Mocroft A, Gill MJ, Davidson W, Phillips AN (2000). Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 24(5), 475 - 482.
    • Youle M, Janossy G, Turnbull W, Tilling R, Loveday C, Mocroft A, Tyrer M, Madge S, Wilson D, Dykhoff A, Johnson M, Phillips AN, Royal Free Centre HIV Med (2000). Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. AIDS, 14(12), 1717 - 1720.
    • Youle M, Janossy G, Turnbull W, Tilling R, Loveday C, Mocroft A, Tyrer M, Madge S, Wilson D, Dykhoff A, Johnson M, Phillips AN (2000). Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Royal Free Centre for HIV Medicine. AIDS, 14(12), 1717 - 1720.
    • Rezza G, Lepri AC, Monforte AD, Pezzotti P, Castelli F, Dianzani F, Lazzarin A, De Luca A, Arlotti M, Leoncini F, Manconi PE, Rizzardini G, Minoli L, Poggio A, Ippolito G, Phillips AN, Moroni M, ICONA Study Grp (2000). Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection. J ACQ IMMUN DEF SYND, 25(1), 56 - 62.
    • Rezza G, Cozzi-Lepri A, d'Arminio Monforte A, Pezzotti P, Castelli F, Dianzani F, Lazzarin A, De Luca A, Arlotti M, Leoncini F, Manconi PE, Rizzardini G, Minoli L, Poggio A, Ippolito G, Phillips AN, Moroni M (2000). Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection. I.CO.N.A. Study Group. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 25(1), 56 - 62.
    • Kirk O, Gatell JM, Mocroft A, Pedersen C, Proenca R, Brettle RP, Barton SE, Sudre P, Phillips AN (2000). Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. American Journal of Respiratory and Critical Care Medicine, 162(3 Pt 1), 865 - 872.
    • Miller V, Sabin CA, Phillips AN, Rottmann C, Rabenau H, Weidmann E, Rickerts V, Findhammer S, Helm EB, Staszewski S (2000). The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS, 14(14), 2129 - 2136.
    • Moore AL, Vashist A, Mocroft A, Phillips AN, Studd J, Johnson MA (2000). Reduced bone mineral density in HIV positive individuals. AIDS, 14, S11 - S11.
    • Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren J, Ledergerber B (2000). Viral toad changes in response to antiretroviral therapy according to the baseline CD4 lymphocyte count and viral load. AIDS, 14, S3 - S3.
    • De Luca A, Lepri AC, Monforte AD, Phillips AN, Alberici F, Vigevani M, Sinicco A, Colangeli V, Menichetti F, Ghinelli F, Moroni M (2000). Virological suppression in patients starting a second-line HAART regimen after stopping their first HAART regimen. AIDS, 14, S35 - S35.
    • Lepri AC, Phillips AN, Monforte AD, Muro S, De Luca A, Pezzotti F, Vigano P, Orani A, d' Elia S, Moroni M (2000). When to start HAART in chronically HIV-infected patients? A collection of pieces of evidence from the I.CONA study. AIDS, 14, S3 - S3.
    • Ullum H, Cozzi-Lepri A, Katzenstein TL, Phillips AN, Skinhoj P, Gerstoft J, Pedersen BK (2000). Prognostic value of single measurements of beta-2-microglobulin, immunoglobulin A in HIV disease after controlling for CD4 lymphocyte counts and plasma HIV RNA levels. Scandinavian Journal of Infectious Diseases, 32(4), 371 - 376.
    • Goh LE, McDade H, Kinloch S, Perrin L, Cooper D, Phillips A, Hoen B, Autran B, Sonnerborg A, Tsoukas C (2000). The QUEST trial, a paradigm of HIV collaborative research. Nature Medicine, 6(11), 1194 - .
    • Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S (2000). Virological and immunological effects of treatment interruptions in HIV- 1 infected patients with treatment failure. AIDS, 14(18), 2857 - 2867.
    • Porter K, Babiker A, Walker S, Darbyshire J, Gill N, Beral V, Coutinho R, Darbyshire J, Gill N, Lee C, Meyer L, Rezza G, Porter K, Babiker A, Walker S, Darbyshire J, Tyrer F, Dabis F, Marimoutou C, Meyer L, Boufassa F, Hamouda O, Brunn M, Pezzotti P, Rezza G, Lorenzo JI, Touloumi G, Hatzakis A, Karafoulidou A, Katsarou O, Brettle R, Del Amo J, del Romero J, Prins M, Coutinho RA, van Benthem B, Coutinho RA, Kirk O, Pedersen C, AGuado IH, Perez-Hoyos S, Eskild A, Bruun JN, Sannes M, Sabin C, Lee C, Johnson AM, Phillips AN, Babiker A, Darbyshire JH, Gill N, Porter K, Egger M, Francioli P, Rickenbach M, Cooper D, Kaldor J, Cooper D, Kaldor J, Vizzard J, Tusell JM, Ruiz I, Cayla JA, de Olalla PG, Day NE, De Angelis D, CASCADE Collaboration (2000). Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE. AIDS, 14(13), 1899 - 1906.
    • Madge S, Mocroft A, Wilson D, Youle M, Lipman MC, Phillips A, Tyrer M, Cozzi-Lepri A, Swaden L, Johnson MA (2000). Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years. HIV Medicine, 1(4), 212 - 218.

    1999

    • Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M, EuroSIDA , French Hosp Database HIV , Swiss HIV Cohort Study Grp (1999). Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. AIDS, 13(15), 2075 - 2082.
    • ABRAMS D, ALLAN D, ANTUNES F, al. E (1999). Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. , 353(9169), 2014 - 2025.
    • Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzalez-Lahoz J, Monforte AD, Proenca R, Phillips AN, Lundgren JD, Reiss P, EuroSIDA Study Gr (1999). Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. LANCET, 353(9161), 1293 - 1298.
    • Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M (1999). Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS, 13(15), 2075 - 2082.
    • Phillips AN (1999). HIV Dynamics: Lessons from the use of antiretrovirals. In Dalgleish AG, Weiss RA (Ed.), HIV and the New Viruses (pp. 59 - 74). : Academic Press.
    • Abrams D, Allan D, Antunes F, Breckenridge A, Bruun J, Cameron W, Carbon C, Chalmers I, Chang H, Chodakewitz J, Clendenin N, Clumeck N, Collier A, Collins G, Cooper E, Cooper D, Danner S, D'Aquila R, DeGruttola V, DeMasi R, Dee L, Deyton L, Dixon D, Farthing C, Feinberg J, Fischl M, Flepp M, Gartland M, Gatell J, Gazzard B, Goebel F, Gotzsche P, Gringeri A, Hall D, Hamilton J, Hammer S, Hartigan P, Heath-Chiozzi M, Henry K, Hill A, Hirschel B, Ioannidis J, Kahn J, Katlama C, Katzenstein D, Killen J, King E, de Loes SK, Kravcik S, Lange J, Leavitt R, Leonard J, Maeland A, Mannucci P, Mathiesen L, McDade H, Meibohn A, Melander H, Merigan T, Mulder J, Myers M, Neaton J, Nessling M, Perrin L, Pettinelli C, Phair J, Phillips A, Pinching A, Poppa A, Power L, Reiss P, Richman D, Rooney J, Rousseau F, Rutherford G, Salgo M, Sandstrom E, Saravolatz L, Savidge G, Schnittman S, Schooley R, Seligmann M, Simberkoff M, Skowron G, Slade P, Smith D, Smith RP, Soriano V, Stanley K, Stingl G, Stoffels P, Struthers L, Tierney C, Thompson M, Van der Broeck R, Van Leeuven R, Van Weverling G, Veenstra J, Vella S, Volberding P, Weber J, Winslow D, Yeni P, Yeo J, Dormont J, Sande M, Weller I, Babiker A, Collins R, Darbyshire J, Duncan W, Foulkes M, Hughes M, Peto R, Peto T, Walker S, HIV Trialists' Collaborative Grp (1999). Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. LANCET, 353(9169), 2014 - 2025.
    • Devereux H, Loveday C, Burke A, Dann L, Johnson M, Phillips A (1999). The prevalence of non-B subtype HIV-1 in a London HIV/AIDS outpatient clinic. AIDS, 13(1), 142 - 142.
    • Petruckevitch A, Del Amo J, Phillips AN, Stephenson JM, Johnson AM, De Cock KM (1999). Risk of cancer in patients with HIV disease. London African HIV/AIDS Study Group. International Journal of STD and AIDS, 10(1), 38 - 42.
    • Porter K, Johnson AM, Phillips AN, Darbyshire JH (1999). The practical significance of potential biases in estimates of the AIDS incubation period distribution in the UK register of HIV seroconverters. AIDS, 13(14), 1943 - 1951.
    • Phillips AN, McLean AR, Loveday C, Tyrer M, Bofill M, Devereux H, Madge S, Dykoff A, Drinkwater A, Burke A, Huckett L, Janossy G, Johnson MA (1999). In vivo HIV-1 replicative capacity in early and advanced infection. AIDS, 13(1), 67 - 73.
    • Aladdin H, Ullum H, Cozzi-Lepri A, Leffers H, Katzenstein T, Gerstoft J, Gjedde SB, Phillips AN, Skinhoj P, Pedersen BK (1999). Bulk culture levels of specific cytotoxic T-cell activity against HIV-1 proteins are not associated with risk of death. Scandinavian Journal of Immunology, 50(2), 223 - 227. doi:10.1046/j.1365-3083.1999.00585.x
    • Blaxhult A, Mocroft A, Phillips A, van Lunzen J, Bentwich Z, Stergiou G, Colebunders R, Benfield TL, Mulcahy F, Lundgren JD, EuroSIDA SG (1999). Does European or non-European origin influence health care and prognosis for HIV patients in Europe?. HIV Medicine, 1(1), 2 - 9. doi:10.1046/j.1468-1293.1999.00002.x
    • Chiesi A, Mocroft A, Dally LG, Miller V, Katlama C, Ledergerber B, Pedersen C, Phillips AN, Arcieri R, Lundgren JD, EuroSIDA SG (1999). Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. AIDS, 13(16), 2281 - 2288. doi:10.1097/00002030-199911120-00010
    • Del Amo J, Petruckevitch A, Phillips AN, De Cock KM, Stephenson J, Desmond N, Hanscheid T, Low N, Newell A, Obasi A, Paine K, Pym A, Theodore C, Johnson AM (1999). Risk factors for tuberculosis in patients with AIDS in London: a case-control study. International Journal of Tuberculosis and Lung Disease, 3(1), 12 - 17.
    • Devereux H, Loveday C, Burke A, Dann L, Johnson M, Phillips A (1999). The prevalence of non-B subtype HIV-1 in a London HIV/AIDS outpatient clinic. AIDS, 13(1), 142 - .
    • Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzales-Lahoz J, d'Arminio Monforte A, Proenca R, Phillips AN, Lundgren JD, Reiss P, EuroSIDA SG (1999). Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection.. The Lancet, 353(9161), 1296 - 1298.
    • Emery VC, Atkins MC, Bowen EF, Clark DA, Johnson MA, Kidd IM, McLaughlin JE, Phillips AN, Strappe PM, Griffiths PD (1999). Interactions between beta-herpesviruses and human immunodeficiency virus in vivo: evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6. Journal of Medical Virology, 57(3), 278 - 282. doi:10.1002/(SICI)1096-9071(199903)57:3<278::AID-JMV11>3.0.CO;2-3
    • Griffiths PD, Ait-Khaled M, Bearcroft CP, Clark DA, Quaglia A, Davies SE, Burroughs AK, Rolles K, Kidd IM, Knight SN, Noibi SM, Cope AV, Phillips AN, Emery VC (1999). Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. Journal of Medical Virology, 59(4), 496 - 501.
    • Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, van Lunzen J, Antunes F, Phillips AN, Lundgren JD, EuroSIDA SG (1999). Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Annals of Internal Medicine, 130(7), 570 - 577.
    • Miller V, Staszewski S, Nisius G, Cozzi-Lepri A, Sabin C, Phillips AN (1999). Risk of new AIDS diseases in people on triple therapy. The Lancet, 353(9151), 463 - .
    • Miller V, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E, Rabenau H, Hill A, Cozzi-Lepri A, Phillips AN (1999). CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. The Journal of Infectious Diseases, 180(2), 530 - 533.
    • Mocroft A, Sabin CA, Youle M, Swaden L, Tyrer M, Wilson D, Madge S, Johnson MA, Phillips AN (1999). Changing treatment patterns among patients with HIV: Royal Free Hospital 1987-97. HIV Medicine, 1(1), 32 - 39.
    • Mocroft A, Sabin CA, Youle M, Madge S, Tyrer M, Devereux H, Deayton J, Dykhoff A, Lipman MC, Phillips AN, Johnson MA (1999). Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 21(5), 401 - 407.
    • Mocroft A, Barry S, Sabin CA, Cozzi-Lepri A, Kinloch S, Drinkwater A, Lipman M, Youle M, Johnson MA, Phillips AN (1999). The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. AIDS, 13(10), 1255 - 1261.
    • Mocroft A, Sabin C, Phillips AN (1999). Impact of Kaposi's sarcoma on HIV disease progression. AIDS, 13(2), 286 - .
    • Phillips AN (1999). HIV viral load and its prognostic significance in women compared with men. Medscape HIV/AIDS ejournal, , - .
    • Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidemann E, Hill A, Phillips A (1999). Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS, 13(8), 951 - 956.
    • Staszewski S, Miller V, Sabin C, Carlebach A, Berger AM, Weidmann E, Helm EB, Hill A, Phillips A (1999). Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS, 13(3), 367 - 373.
    • UK Register of HIV Seroconverters Steering Committee (1999). How soon after HIV seroconversion is antiretroviral therapy initiated?. AIDS, 13(10), 1241 - 1247.
    • Ullum H, Cozzi-Lepri A, Aladdin H, Katzenstein T, Victor J, Phillips AN, Gerstoft J, Skinhoj P, Klarlund Pedersen B (1999). Natural immunity and HIV disease progression. AIDS, 13(5), 557 - 563.
    • Wilkinson D, Phillips AN (1999). HIV Infection. In (Ed.), Clinical Evidence (pp. - ). : BMJ Publishing Group.
    • Study GFTMRCCSOHIVIIW (1999). Survival and progression of HIV disease in women attending GUM/HIV clinics in Britain and Ireland. Sexually Transmitted Infections, 75(4), 247 - 252. doi:10.1136/sti.75.4.247
    • Mocroft A, Barry S, Sabin CA, Lepri AC, Kinloch S, Drinkwater A, Lipman M, Youle M, Johnson MA, Phillips AN, Royal Free Ctr HIV Med (1999). The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. AIDS, 13(10), 1255 - 1261.

    1998

    • PHILLIPS A, KATLAMA C, BARTON S, al. E (1998). Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. , 17(3), 239 - 244.
    • PHILLIPS A, LOVEDAY C, JOHNSON M (1998). HIV suppression and risk of drug resistance mutations. , 12(14), 1930 - 1930.
    • WILDE J, LEE C, DARBY S, al. E (1998). The incidence of lymphoma in the UK haemophilia population over a 20 year period.. , 101, 68 - 68.
    • Madge S, Phillips AN, Griffioen A, Olaitan A, Johnson MA (1998). Demographic, clinical and social factors associated with human immunodeficiency virus infection and other sexually transmitted diseases in a cohort of women from the United Kingdom and Ireland. MRC Collaborative Study of women with HIV.. Int J Epidemiol, 27(6), 1068 - 1071.
    • Madge S, Phillips AN, Griffioen A, Olaitan A, Johnson MA, MRC Collaborative Study Women HIV (1998). Demographic, clinical and social factors associated with human immunodeficiency virus infection and other sexually transmitted diseases in a cohort of women from the United Kingdom and Ireland. INT J EPIDEMIOL, 27(6), 1068 - 1071.
    • Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD (1998). Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.. Lancet, 352(9142), 1725 - 1730.
    • Lepri AC, Sabin CA, Phillips AN, Lee CA, Pezzotti P, Rezza G, Italian Seroconversion Study (1998). The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. EPIDEMIOL INFECT, 121(2), 369 - 376.
    • Lepri AC, Phillips AN, Pezzotti P, Mocroft A, Sabin CA, Porter K, Rezza G, Italian Seroconversion Study (1998). Evaluating the effect of year of seroconversion on HIV progression in cohort studies. AIDS, 12(11), 1353 - 1360.
    • Cozzi-Lepri A, Smith GD, Mocroft A, Sabin CA, Morris RW, Phillips AN (1998). A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responses. AIDS, 12(10), 1155 - 1161.
    • Wannamethee SG, Sirivichayakul S, Phillips AN, Ubolyam S, Ruxrungtham K, Hanvanich M, Phanuphak P (1998). Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand. International Journal of Epidemiology, 27(2), 289 - 295.
    • Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD, Emery VC, Cozzi-Lepri A, Smith GD, Mocroft A, Sabin CA, Morris RW, Phillips AN (1998). Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplantation, 21(6), 597 - 605.
    • Mocroft A, Youle M, Phillips AN, Halai R, Easterbrook P, Johnson MA, Gazzard B (1998). The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Archives of Internal Medicine, 158(5), 491 - 497.
    • Phillips AN, Katlama C, Barton S, Vella S, Blaxhult A, Clotet B, Goebel FD, Hirschel B, Pedersen C, Lundgren JD (1998). Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 17(3), 239 - 244.
    • Phillips AN (1998). Cytotoxic-T-cell responses in early HIV-1 infection. New England Journal of Medicine, 338(9), 622 - 623.
    • Sabin CA, Mocroft A, Bofill M, Janossy G, Lee CA, Johnson M, Phillips AN (1998). Changes in lymphocyte subsets in human immunodeficiency virus-positive persons with < 5 CD4 T lymphocytes/mm3. The Journal of Infectious Diseases, 178(4), 1166 - 1169.
    • Mocroft A, Gill MJ, Davidson W, Phillips AN (1998). Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS, 12(16), 2161 - 2167.
    • Staszewski S, Miller V, Sabin C, Berger A, Hill AM, Phillips AN (1998). Rebound of HIV-1 viral load after suppression to very low levels. AIDS, 12(17), 2360 - .
    • Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD, EuroSIDA SG (1998). Changing patterns of mortality across Europe in patients infected with HIV-1.. The Lancet, 352(9142), 1725 - 1730.
    • Cozzi-Lepri A, Katzenstein TL, Phillips ANU (1998). The relative prognostic value of HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS, 12, 1639 - 1643.
    • Staszewski S, Miller V, Sabin C, Carlebach A, Berger AM, Weidmann E, Helm EB, Hill A, Phillips A (1998). Virological response to protease inhibitor therapy in an HIV Clinic Cohort. AIDS, 13(3), 367 - 373.
    • Del Amo J, Petruckevitch A, Phillips AN, Johnson AM, Stephenson J, Desmond N, Hanscheid T, Low N, Newell A, Obasi A, Paine K, Pym A, Theodore C, De Cock KM (1998). Disease progression and survival in HIV-1-infected Africans in London. AIDS, 12(10), 1203 - 1209.
    • Petruckevitch A, Del Amo J, Phillips AN, Johnson AM, Stephenson J, Desmond N, Hanscheid T, Low N, Newell A, Obasi A, Paine K, Pym A, Theodore C, De Cock KM (1998). Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London. AIDS, 12(9), 1007 - 1013.
    • Cozzi-Lepri A, Phillips AN, Pezzotti P, Mocroft A, Sabin CA, Porter K, Rezza G (1998). Evaluating the effect of year of seroconversion on HIV progression in cohort studies. Italian Seroconversion Study. AIDS, 12(11), 1353 - 1360.
    • UK Register of HIV Seroconverters Steering Committee (1998). The AIDS incubation period in the UK estimated from a national register of HIV seroconverters. AIDS, 12(6), 659 - 667.
    • Sabin CA, Devereux H, Phillips AN, Janossy G, Loveday C, Lee CA (1998). Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. AIDS, 12(11), 1347 - 1352.
    • Ullum H, Cozzi-Lepri A, Victor J, Aladdin H, Phillips AN, Gerstoft J, Skinhoj P, Pedersen BK (1998). Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1beta are associated with a decreased risk of HIV disease progression. The Journal of Infectious Diseases, 177(2), 331 - 336.
    • Madge S, Phillips AN, Griffioen A, Olaitan A, Johnson MA (1998). Demographic, clinical and social factors associated with human immunodeficiency virus infection and other sexually transmitted diseases in a cohort of women from the United Kingdom and Ireland. MRC Collaborative Study of women with HIV. International Journal of Epidemiology, 27(6), 1068 - 1071.
    • Sabin CA, Mocroft A, Cozzi-Lepri A, Phillips AN (1998). Cofactors and markers of disease progression in human immunodeficiency virus infection. Journal of the Royal Statistical Society: Series A (Statistics in Society), 161(2), 177 - 189.
    • EWART D, DARBY S, LEE C, al. E (1998). Immune status in HIV-1-infected men and boys with haemophilia in the United Kingdom. , 12(8), 956 - 958.
    • LUNDGREN J, MILLER V, BLAXHULT A, al. E (1998). CD4 count and viral load changes in response to >= 3-drug therapy in EuroSIDA: Association with clinical disease progression. , 12, S80 - S80.
    • MADGE S, PHILLIPS A, GRIFFIOEN A, al. E (1998). Demographic, clinical and social factors associated with human immunodeficiency virus infection and other sexually transmitted diseases in a cohort of women from the United Kingdom and Ireland. , 27(6), 1068 - 1071.
    • MILLER V, MOCROFT A, REISS P, al. E (1998). Disease progression in patients with HIV-1 infection - Relationship with antiretroviral treatment and increasing CD4 lymphocyte counts. , 12, S14 - S14.
    • MILLER V, MOCROFT A, REISS P, al. E (1998). Disease progression in patients with HIV-1 infection - Relationship with antiretroviral treatment and increasing CD4 lymphocyte counts. , 12, S40 - S40.
    • MILLER V, PHILLIPS A, ROTTMANN C, al. E (1998). Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: Association with therapy failure. , 177(6), 1521 - 1532.
    • MILLER V, SABIN C, ROTTMANN C, al. E (1998). Prognostic value of virus load levels in patients receiving HAART: The Frankfurt HIV-cohort. , 12, S14 - S14.
    • MILLER V, SABIN C, ROTTMANN C, al. E (1998). Prognostic valve of virus load levels in patients receiving HAART: The Frankfurt HIV-cohort. , 12, S68 - S68.
    • MOCROFT A, YOULE M, PHILLIPS A, al. E (1998). The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. , 158(5), 491 - 497.

    1997

    • Lundgren JD, Phillips AN, Vella S, Katlama C, Ledergerber B, Johnson AM, Reiss P, Gatell J, Clumeck N, Dietrich M, Benfield TL, Nielsen JO, Pedersen C (1997). Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 16(3), 153 - 160.
    • Lundgren JD, Phillips AN, Vella S, Katlama C, Ledergerber B, Johnson AM, Reiss P, Gatell J, Clumeck N, Dietrich M, Benfield TL, Nielsen JO, Pedersen C (1997). Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. J ACQ IMMUN DEF SYND, 16(3), 153 - 160.
    • Mocroft AJ, Lundgren JD, d'Armino Monforte A, Ledergerber B, Barton SE, Vella S, Katlama C, Gerstoft J, Pedersen C, Phillips AN (1997). Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group.. Int J Epidemiol, 26(2), 400 - 407.
    • Phillips AN, Sabin CA, Ribbans WJL (1997). Orthopaedic Surgery in Hemophilic Patients With Human Immunodefiency Virus. Clinical Orthopaedics and Related Research, 343, 81 - 87.
    • Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA (1997). The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. The Journal of Infectious Diseases, 175(1), 164 - 168.
    • Phillips AN, Eron J, Bartlett J, Kuritzkes DR, Johnson VA, Gilbert C, Johnson J, Keller A, Hill AM (1997). Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. AIDS, 11(2), 169 - 175.
    • Mocroft A, Johnson MA, Sabin CA, Bofill M, Janossy G, Phillips AN (1997). The relationship between beta-2-microglobulin, CD4 lymphocyte count, AIDS and death in HIV-positive individuals. Epidemiology and Infection, 118(3), 259 - 266.
    • Mocroft A, Youle M, Morcinek J, Sabin CA, Gazzard B, Johnson MA, Phillips AN (1997). Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. BMJ (Clinical Research Ed.), 314(7078), 409 - 413.
    • Cozzi-Lepri A, Sabin CA, Pezzotti P, England PD, Phillips AN, Rezza G (1997). Is there a general tendency for CD4 lymphocyte decline to speed up during human immunodeficiency virus infection? Evidence from the Italian Seroconversion Study. The Journal of Infectious Diseases, 175(4), 775 - 780.
    • Alliegro MB, Dorrucci M, Phillips AN, Pezzotti P, Boros S, Zaccarelli M, Pristera R, Rezza G (1997). Incidence and consequences of pregnancy in women with known duration of HIV infection. Italian Seroconversion Study Group. Archives of Internal Medicine, 157(22), 2585 - 2590.
    • Ullum H, Cozzi-Lepri A, Bendtzen K, Victor J, Gotzsche PC, Phillips AN, Skinhoj P, Klarlund Pedersen B (1997). Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. AIDS Research and Human Retroviruses, 13(12), 1039 - 1046.
    • Balslev U, D'Arminio Montforte A, Stergiou G, Antunes F, Mulcahy F, Pehrson PO, Phillips AN, Pedersen C, Lundgren JD (1997). Influence of age on rates of new AIDS-defining diseases and survival in 6546 AIDS patients. Scandinavian Journal of Infectious Diseases, 29(4), 337 - 343.
    • Brown AJ, Lobidel D, Wade CM, Rebus S, Phillips AN, Brettle RP, France AJ, Leen CS, McMenamin J, McMillan A, Maw RD, Mulcahy F, Robertson JR, Sankar KN, Scott G, Wyld R, Peutherer JF (1997). The molecular epidemiology of human immunodeficiency virus type 1 in six cities in Britain and Ireland. Virology, 235(1), 166 - 177.
    • Phillips AN, McLean A, Johnson MA, Tyrer M, Emery V, Griffiths P, Bofill M, Janossy G, Loveday C (1997). HIV-1 dynamics after transient antiretroviral therapy: implications for pathogenesis and clinical management. Journal of Medical Virology, 53(3), 261 - 265.
    • Alcabes P, Pezzotti P, Phillips AN, Rezza G, Vlahov D (1997). Long-term perspective on the prevalent-cohort biases in studies of human immunodeficiency virus progression. American Journal of Epidemiology, 146(7), 543 - 551.
    • Ullum H, Cozzi-Lepri A, Victor J, Skinhoj P, Phillips AN, Pedersen BK (1997). Increased losses of CD4+CD45RA+ cells in late stages of HIV infection is related to increased risk of death: evidence from a cohort of 347 HIV-infected individuals. AIDS, 11(12), 1479 - 1485.
    • Sabin CA, Bofill M, Phillips AN, Elford J, Janossy G, Lee CA (1997). Relation between soluble CD30 levels measured soon after HIV seroconversion and disease progression in men with hemophilia. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 16(4), 279 - 283.
    • Phillips AN, Davey Smith G (1997). Viral load and combination therapy for human immunodeficiency virus. New England Journal of Medicine, 336(13), 958 - 959.
    • Adler MW, Phillips AN, Johnson AM (1997). Communicable Disease - Sexually Transmitted Diseases including AIDS. In Charlton J, Murphy M (Ed.), The Health of Adult Britain 1997 (pp. 1841 - 1994). : Government Statistical Service.
    • Mocroft A, Bofill M, Lipman M, Medina E, Borthwick N, Timms A, Batista L, Winter M, Sabin CA, Johnson M, Lee CA, Phillips A, Janossy G (1997). CD8+,CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 14(2), 158 - 162.
    • Cozzi-Lepri A, Phillips AN, Pezzotti P, Rezza G (1997). Is the clinical course of HIV infection changing? Study's censoring strategy may be source of bias. BMJ (Clinical Research Ed.), 315(7117), 1237 - .
    • Davey Smith G, Phillips AN (1997). Confounding. In Williams H, Strachan D (Ed.), Dermatological Epidemiology (pp. - ). : CRC Press Inc..
    • Davey Smith G, Egger M, Phillips AN (1997). Meta-analysis and data synthesis in medical research. In (Ed.), Oxford Textbook of Public Health (pp. - ). : Oxford University Press.
    • Cozzi-Lepri A, Sabin CA, Phillips AN (1997). Investigating temporal changes in the rate of HIV progression: challenges and limitations. AIDS, 11(13), 1647 - 1649.
    • Mocroft AJ, Lundgren JD, D'Arminio Monforte A, Ledergerber B, Barton SE, Vella S, Katlama C, Gerstoft J, Perdersen C, Phillips AN, Johnson AM (1997). Survival of AIDS Patients According to Type of AIDS-Defining Event. International Journal of Epidemiology, 26(4), 400 - 407.
    • Munoz A, Sabin CA, Phillips AN (1997). The incubation period of AIDS. AIDS, 11, S69 - S76.
    • Phillips AN, Mocroft AJ, Sabin CA, Cozzi-Lepri A (1997). Cross-sectional studies in AIDS pathogenesis: how far can they mislead us?. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 14(2), 153 - 157.
    • Sabin CA, Mocroft AJ, Bofill M, Janossy G, Johnson M, Lee CA, Phillips AN (1997). Survival after a very low (<5 x 106/1) CD4+ T-cell count in individuals affected with HIV. AIDS, 11(9), 1123 - 1127.
    • Madge S, Olaitan A, Mocroft AJ, Phillips AN, Johnson M (1997). Access to the medical care one year prior to diagnosis in 100 HIV-positive women. Family Practice, 14(3), 255 - 257.
    • Olaitan A, Mocroft AJ, McCarthy K, Phillips A, Reid W, Johnson M (1997). Cervical abnormality and sexually transmitted disease screening in human immunodeficiency virus-positive women. Obstetrics and Gynecology, 89(1), 71 - 75.
    • Adler M, Phillips A, Johnson A (1997). Communicable diseases: sexually transmitted diseases, including AIDS. In Charlton J, Murphy M (Ed.), The Health of Adult Britain 1841-1994 (pp. 21 - 29). : Stationery Office Books.
    • ALLIEGRO M, DORRUCCI M, PHILLIPS A, al. E (1997). Incidence and consequences of pregnancy in women with known duration of HIV infection. , 157(22), 2585 - 2590.
    • DORRUCCI M, PEZZOTTI P, PHILLIPS A, al. E (1997). Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. , 11(4), 461 - 467.
    • EGGER M, SMITH G, PHILLIPS A (1997). Meta-analysis: Principles and procedures. , 315(7121), 1533 - 1537.
    • MOCROFT A, YOULE M, MORCINEK J, al. E (1997). Survival after diagnosis of AIDS: A prospective observational study of 2625 patients. , 314(7078), 409 - 413.
    • PHILLIPS A, ERON J, BARTLETT J, al. E (1997). Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level CD4 lymphocyte count and the incidence of clinical disease in infected individuals. , 11(2), 169 - 175.
    • SABIN C, TELFER P, PHILLIPS A, al. E (1997). Hepatitis C virus infection in a human immunodeficiency virus-positive cohort in Hawaii - Reply. , 176(2), 542 - 543.
    • SMITH G, EGGER M, PHILLIPS A (1997). Meta-analysis - Beyond the grand mean?. , 315(7122), 1610 - 1614.
    • SMITH G, PHILLIPS A (1997). Intersalt data - Correction for regression dilution bias in Intersalt study was misleading. , 315(7106), 485 - 486.

    1996

    • PEZZOTTI P, PHILLIPS A, DORRUCCI M, al. E (1996). Category of exposure to HIV and age in the progression to AIDS: Longitudinal study of 1199 people with known dates of seroconversion. , 313(7057), 583 - 586.
    • OLAITAN A, MADGE S, MCCARTHY K, al. E (1996). Unrecognised HIV infection among gynaecology patients. , 103(5), 470 - 473.
    • PHILLIPS A (1996). Reduction of HIV concentration during acute infection: Independence from a specific immune response. , 271(5248), 497 - 499.
    • PHILLIPS A, ERON J, BARTLETT J, al. E (1996). HIV-1 RNA levels and the development of clinical disease. , 10(8), 859 - 865.
    • PHILLIPS A, SABIN C, ELFORD J, al. E (1996). Serum beta(2)-microglobulin at HIV-1 seroconversion as a predictor of severe immunodeficiency during 10 years of followup. , 13(3), 262 - 266.
    • PHILLIPS A, SMITH G, JOHNSON M (1996). Will we ever know when to treat HIV infection?. , 313(7057), 608 - 610.
    • SABIN C, PASI J, PHILLIPS A, al. E (1996). The use of intermediate-purity clotting factor concentrates and HIV disease progression in men with haemophilia. , 2(2), 78 - 81.
    • SABIN C, PASI K, PHILLIPS A, al. E (1996). Comparison of immunodeficiency and AIDS defining conditions in HIV negative and HIV positive men with haemophilia A. , 312(7025), 207 - 210.
    • SABIN C, PHILLIPS A, LEE C (1996). Arguments contradict the ''foreign protein-zidovudine'' hypothesis - Response. , 312(7025), 211 - 212.
    • SMITH G, PHILLIPS A (1996). Passive smoking and health: Should we believe Philip Morris's ''experts''?. , 313(7062), 929 - 933.
    • WALKER M, PHILLIPS A, SHAPER A, al. E (1996). Height and the risk of cardiovascular disease in women. , 144(7), 708 - 708.
    • Stephenson JM, Griffioen A, Woronowski H, Petruckevitch A, Keenlyside R, Johnson AM, Phillips AN, Anderson J, Melville R, Jeffries DJ, Norman J, Barton S, Chard S, Sibley K, Mitchelmore M, Brettle R, Morris S, ODornen P, Russell J, OveringtonHickford L, OFarrell N, Chappell J, Mulcahy RF, Moseley J, Lyons F, Welch J, Graham D, Fadojutimi M, Kitchen V, Wells C, Byrne G, Tobin J, Tucker L, Harindra V, Mercey DE, AllasonJones E, Campbell L, French R, Johnson MA, Reid A, Farmer D, Saint N, Olaitan A, Madge S, Forster G, Phillips M, Sampson K, Nayagam A, Edlin J, Nayagam A, Bradbeer C, deRuiter A, Hargreaves L, Doyle C (1996). The effect of HIV diagnosis on reproductive experience. AIDS, 10(14), 1683 - 1687.
    • Phillips AN, Lazzarin A, GonzalesLahoz J, Clumeck N, Glauser MP, Proenca R, Banhegyi D, Pedersen C, Lundgren JD, Johnson AM (1996). Factors associated with the CD4(+) lymphocyte count at diagnosis of acquired immunodeficiency. J CLIN EPIDEMIOL, 49(11), 1253 - 1258.
    • Phillips AN, Sabin CA, Elford J, Bofill M, Timms A, Janossy G, Lee CA (1996). Serum beta 2-microglobulin at HIV-1 seroconversion as a predictor of severe immunodeficiency during 10 years of followup.. J Acquir Immune Defic Syndr Hum Retrovirol, 13(3), 262 - 266.
    • Phillips AN, Lazzarin A, Gonzales-Lahoz J, Clumeck N, Glauser MP, Proenca R, Banhegyi D, Pedersen C, Lundgren JD, Johnson AM (1996). Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study Group.. J Clin Epidemiol, 49(11), 1253 - 1258.
    • Phillips AN, Wannamethee SG, Walker M, Thomson A, Smith GD (1996). Life expectancy in men who have never smoked and those who have smoked continuously: 15 year follow up of large cohort of middle aged British men. BMJ (Clinical Research Ed.), 313(7062), 907 - 908.
    • Pezzotti P, Phillips AN, Dorrucci M, Cozzi-Lepri A, Galai N, Vlahov D, Rezza G (1996). Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. HIV Italian Seroconversion Study Group. BMJ (Clinical Research Ed.), 313(7057), 583 - 586.
    • Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN (1996). Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS, 10(10), 1101 - 1105.
    • Mocroft A, Johnson MA, Phillips AN (1996). Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS, 10(10), 1057 - 1065. doi:10.1097/00002030-199609000-00001
    • Mercey D, Griffioen A, Woronowski H, Stephenson J, Anderson J, Melville R, Jeffries DJ, Norman J, Welch J, Graham D, Fadojutimi M, Forster G, Phillips M, Sampson K, Kitchen V, Wells C, Byrne G, Mercey DE, AllasonJones E, Campbell L, French R, Stephenson JM, Phillips AN, Keenlyside R, Johnson AM, Barton S, Chard S, Sibley K, Mitchelmore M, Bradbeer C, deRuiter A, Hargreaves L, Doyle C, OFarrell N, Chappell J, Johnson MA, Reid A, Farmer D, Saint N, Olaitan A, Madge S, Russell J, OveringtonHickford L, Brettle R, Morris S, ODornen P, Mulcahy F, Moseley J, Lyons F, Nayagam A, Edlin J, Tobin J, Tucker L, Harindra V (1996). Uptake of medical interventions in women with HIV infection in Britain and Ireland. GENITOURIN MED, 72(4), 281 - 282.
    • Bofill M, Mocroft A, Lipman M, Medina E, Borthwick NJ, Sabin CA, Timms A, Winter M, Baptista L, Johnson MA, Lee CA, Phillips AN, Janossy G (1996). Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS, 10(8), 827 - 834.
    • Phillips AN, Eron JJ, Bartlett JA, Rubin M, Johnson J, Price S, Self P, Hill AM (1996). HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group.. AIDS, 10(8), 859 - 865.
    • Pedersen C, Danner S, Lazzarin A, Glauser MP, Weber R, Katlama C, Barton SE, Lundgren JD, Clumeck N, DeWit S, Sommereijns B, Nielsen JO, Nielsen T, Jensen G, Skinhoj P, Bentsen K, Gerstoft J, Melbye M, Ranki A, Valle SL, Berlureau P, Dietrich M, Schwander S, Goebel FD, Kosmidis J, Stergiou G, Gouzia T, Papadopoulos A, Banhegyi D, Mulcahy F, Yust I, BenIshai Z, Bentwich Z, Sacks T, Maayan S, Vella S, Chiesi A, Ancarani F, Scalise G, Bertaggia A, Francavilla E, Calonghi G, Emilia R, Cargnel A, Arlotti M, Ciammarughi R, Rimini I, Colomba A, DeLalla F, Fassio P, Ferlini A, Fiaccadori F, Pasetti G, Giannelli F, Grillone W, Monforte AD, Mignani E, Andrea S, Nunnari A, Ortona L, Panichi G, Pauluzzi S, Piersantelli N, Ranieri S, Ricciardiello P, Roscioli B, Soranzo M, Hemmer R, Reiss P, Antunes F, GonzalezLahoz J, Polo R, Clotet B, Gatell J, Buira E, Miro J, Pehrson P, Luthy R, Ledergerber B, Olsson C, Glauser M, Hirschel B, Johnson A, Hawkes S, Phillips A, Barton S, Morcinek J, Pinching A, Coleman D, Gjorup I, Nieport C, Teglbjaerg L, Thornval A (1996). Epidemiology of cryptosporidiosis among European AIDS patients. GENITOURIN MED, 72(2), 128 - 131.
    • Mocroft A, Sabin CA, Phillips AN (1996). Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users relative to homosexual men. AIDS, 10(3), 344 - 345. doi:10.1097/00002030-199603000-00020
    • Sabin CA, Pasi KJ, Phillips AN, Lilley P, Bofill M, Lee CA (1996). Comparison of immunodeficiency and AIDS defining conditions in HIV negative and HIV positive men with haemophilia A.. BMJ, 312(7025), 207 - 210.
    • Sabin CA, Phillips AN, Lee CA (1996). Response: arguments contradict the "foreign protein-zidovudine" hypothesis.. BMJ, 312(7025), 211 - 212.
    • Davey Smith G, Phillips AN (1996). Inflation in epidemiology: "the proof and measurement of association between two things" revisited. BMJ (Clinical Research Ed.), 312(7047), 1659 - 1661.
    • UK Register of HIV Seroconverters Steering Committee (1996). The UK register of HIV seroconverters: methods and analytical issues. Epidemiology and Infection, 117(2), 305 - 312. doi:10.1017/S0950268800001485
    • Anderson J, Melville R, Jeffries DJ, Norman J, Welch J, Graham D, Fadojutimi M, Forster G, Phillips M, Sampson K, Kitchen V, Wells C, Byrne G, Mercey DE, Allason-Jones E, Campbell L, French R, Woronowski H, Griffioen A, Stephenson JM, Phillips AN, Keenlyside R, Johnson AM, Barton S, Chard S, Harindra V (1996). Ethnic differences in women with HIV infection in Britain and Ireland. The study group for the mrc collaborative study of HIV infection in women. AIDS, 10(1), 89 - 93.
    • Del Amo J, Petruckevitch A, Phillips AN, Johnson AM, Stephenson JM, Desmond N, Hanscheid T, Low N, Newell A, Obasi A, Paine K, Pym A, Theodore CM, De Cock KM (1996). Spectrum of disease in Africans with AIDS in London. AIDS, 10(13), 1563 - 1569.
    • Maini NK, Gilson RJ, Chavda N, Gill S, Fakoya A, Ross EJ, Phillips AN, Weller IVD (1996). Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourinary Medicine, 72(1), 27 - 31. doi:10.1136/sti.72.1.27
    • LEE C, SABIN C, PHILLIPS A, al. E (1996). Progression of hepatitis C virus and HIV infection in a group of haemophilic men infected with HIV for up to 16 years. , 93, 189 - 189.
    • LUNDGREN J, PHILLIPS A (1996). Factors associated with the development of Pneumocystis carinii pneumonia - Reply. , 22(4), 739 - 739.
    • MOCROFT A, YOULE M, GAZZARD B, al. E (1996). Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. , 10(10), 1101 - 1105.
    • PHILLIPS A (1996). Modeling HIV concentration during acute AIDS infection - Response. , 272(5270), 1961 - 1962.

    1995

    • LEE C, SAHIN O, PASI K, al. E (1995). IS HIV THE CAUSE OF AIDS - THE EFFECT OF INFECTION WITH HIV ON THE IMMUNE-SYSTEMS OF MEN WITH HEMOPHILIA-A AFTER CONTROLLING FOR CLOTTING FACTOR CONCENTRATE USAGE. , 73(6), 1458 - 1458.
    • SABIN C, ELFORD J, PHILLIPS A, al. E (1995). PROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONIA - ITS IMPACT ON THE NATURAL-HISTORY OF HIV-INFECTION IN MEN WITH HEMOPHILIA. , 1(1), 37 - 44.
    • PEAKMAN M, MAHALINGAM M, POZNIAK A, MCMANUS T, PHILLIPS A, VERGANI D (1995). Markers of immune cell activation and disease progression - Cell activation in HIV disease.
    • Mocroft A, Sabin CA, Phillips AN (1995). Percentage of CD4 lymphocytes and risk of AIDS. JAMA, 274(23), 1836 - . doi:10.1001/jama.274.23.1836
    • Dorrucci M, Pezzotti P, Phillips AN, Cozzi-Lepri AC, Rezza G (1995). Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. The Journal of Infectious Diseases, 172(6), 1503 - 1508.
    • Cozzi-Lepri A, Pezzotti P, Phillips AN, Petrucci A, Rezza G (1995). Clinical staging system for AIDS patients. The Lancet, 346(8982), 1103 - .
    • Sabin CA, Mocroft A, Phillips AN (1995). The use of CD4 counts as prognostic markers in HIV infection. AIDS, 9(10), 1205 - 1206. doi:10.1097/00002030-199510000-00021
    • MOCROFT AJ, JOHNSON MA, SABIN CA, YOULE M, PHILLIPS AN (1995). CLINICAL STAGING SYSTEM FOR AIDS PATIENTS - REPLY. LANCET, 346(8979), 911 - 911.
    • LUNDGREN JD, BARTON SE, LAZZARIN A, DANNER S, GOEBEL FD, PEHRSON P, MULCAHY F, KOSMIDIS J, PEDERSEN C, PHILLIPS AN, CLUMECK N, DEWIT S, SOMMEREIJNS B, NIELSEN JO, LUNDGREN J, NIELSEN T, JENSEN G, SKINHOJ P, BENTSEN K, GERSTOFT J, MELBYE M, RANKI A, VALLE SL, KATLAMA C, BERLUREAU P, DIETRICH M, SCHWANDER S, PAPADOPOULOS A, BANHEGYI D, YUST I, BENISHAI Z, BENTWICH Z, SACKS T, MAAYAN S, VELLA S, CHIESI A, ANCARANI F, SCALISE G, BERTAGGIA A, FRANCAVILLA E, CALONGHI G, CARGNEL A, ARLOTTI M, CIAMMARUGHI R, COLOMBA A, DELALLA F, FASSIO P, FERLINI A, FIACCADORI F, PASETTI G, GIANNELLI F, GRILLONE W, DARMINIO A, SACCO L, MIGNANI E, NUNNARI A, ORTONA L, PANICHI G, PAULUZZI S, PIERSANTELLI N, RANIERI S, RICCIARDIELLO P, ROSCIOLI B, SORANZO M, HEMMER R, BLOEMKOLK D, ANTUNES F, PROENCA R, GONZALEZLAHOZ J, MARTINEZBLANCO L, CLOTET B, GATELL J, BUIRA E, MIRO J, LUTHY R, LEDERGERBER B, OLSSON C, GLAUSER M, HIRSCHEL B, JOHNSON A, HAWKES S, PHILLIPS A, BARTON S, MORCINEK J, PINCHING A, COLEMAN D, GJORUP I, NIELSEN J, NIEPORT C, TEGLBJAERG L, THORNVAL A (1995). FACTORS ASSOCIATED WITH THE DEVELOPMENT OF PNEUMOCYSTIS-CARINII PNEUMONIA IN 5,025 EUROPEAN PATIENTS WITH AIDS. CLIN INFECT DIS, 21(1), 106 - 113.
    • MOCROFT AJ, JOHNSON MA, SABIN CA, LIPMAN M, ELFORD J, EMERY V, MORCINEK J, YOULE M, JANOSSY G, LEE CA, PHILLIPS AN (1995). STAGING SYSTEM FOR CLINICAL AIDS PATIENTS. LANCET, 346(8966), 12 - 17.
    • Phillips AN, Sabin CA, Mocroft A (1995). Serum HIV-1 RNA and routine patient monitoring. The Lancet, 345(8962), 1441 - . doi:10.1016/S0140-6736(95)92631-3
    • Phillips AN, Sabin CA, Mocroft A, Janossy G (1995). HIV results in the frame. Antiviral therapy. Nature, 375(6528), 195 - .
    • Sabin CA, Mocroft AA, Phillips AN (1995). The association between HIV phenotype, virus burden, codon 215 mutation and CD4 cell decline. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 9(1), 101 - 102. doi:10.1097/00042560-199505010-00018
    • LUNDGREN JD, BARTON SE, KATLAMA C, LEDERGERBER B, GONZALEZLAHOZ J, PINCHING AJ, PROENCA R, HEMMER R, PEDERSEN C, PHILLIPS AN (1995). CHANGES IN SURVIVAL OVER TIME AFTER A FIRST EPISODE OF PNEUMOCYSTIS-CARINII PNEUMONIA FOR EUROPEAN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME. ARCH INTERN MED, 155(8), 822 - 828.
    • Phillips AN, Mocroft A, Emery V, Janossy G, Johnson M (1995). Mathematical model of the effects of therapy and resistance to therapy in primary HIV infection. J ACQ IMMUN DEF SYND, 10, 83 - 83.
    • Sabin CA, Phillips AN, Lee CA, Janossy G, Emery V, Griffiths PD (1995). The effect of CMV infection on progression of human immunodeficiency virus disease is a cohort of haemophilic men followed for up to 13 years from seroconversion. Epidemiology and Infection, 114(2), 361 - 372. doi:10.1017/S095026880005799X
    • DORRUCCI M, PEZZOTTI P, PHILLIPS A, al. E (1995). COINFECTION OF HEPATITIS-C VIRUS WITH HUMAN-IMMUNODEFICIENCY-VIRUS AND PROGRESSION TO AIDS. , 172(6), 1503 - 1508.
    • LEE C, SABIN C, PHILLIPS A, al. E (1995). MORBIDITY AND MORTALITY FROM TRANSFUSION-TRANSMITTED DISEASE IN HEMOPHILIA. , 345(8960), 1309 - 1309.
    • MOCROFT A, JOHNSON M, SABIN C, al. E (1995). STAGING SYSTEM FOR CLINICAL AIDS PATIENTS. , 346(8966), 12 - 17.
    • PHILLIPS A (1995). THE EPIDEMIOLOGY OF HIV DISEASE IN MEN WITH HEMOPHILIA IN THE UK. , 1, 6 - 7.
    • PHILLIPS A, MOCROFT A, EMERY V, al. E (1995). Mathematical model of the effects of therapy and resistance to therapy in primary HIV infection. , 10, 83 - 83.
    • MOCROFT A, JOHNSON M, SABIN C, al. E (1995). CLINICAL STAGING SYSTEM FOR AIDS PATIENTS - REPLY. , 346(8979), 911 - 911.

    1994

    • EGGER M, NEATON J, PHILLIPS A, al. E (1994). CONCORDE TRIAL OF IMMEDIATE VERSUS DEFERRED ZIDOVUDINE. , 343(8909), 1355 - 1355.
    • PHILLIPS AN, SABIN CA (1994). CD4 COUNTS AS SURROGATE MARKERS FOR PROGRESSION TO AIDS. ANN INTERN MED, 120(1), 87 - 88.
    • LUNDGREN J, PEDERSEN C, NIELSEN J, al. E (1994). THE EFFICACY OF ZIDOVUDINE IS TIME-LIMITED - REPLY. , 272(13), 1001 - 1002.
    • LUNDGREN J, PHILLIPS A, PEDERSEN C, al. E (1994). COMPARISON OF LONG-TERM PROGNOSIS OF PATIENTS WITH AIDS TREATED AND NOT TREATED WITH ZIDOVUDINE. , 271(14), 1088 - 1092.
    • PHILLIPS A, SABIN C, ELFORD J, al. E (1994). T-LYMPHOCYTE HOMEOSTASIS AFTER HIV SEROCONVERSION. , 7(12), 1292 - 1293.
    • PHILLIPS A, SABIN C, ELFORD J, al. E (1994). USE OF CD4 LYMPHOCYTE COUNT TO PREDICT LONG-TERM SURVIVAL FREE OF AIDS AFTER HIV-INFECTION. , 309(6950), 309 - 313.
    • PHILLIPS A, SABIN C, MOCROFT A (1994). ACTIVE-DRUG INJECTING AND PROGRESSION OF HIV-INFECTION (VOL 8, PG 385, 1994). , 8(10), 1514 - 1514.
    • PHILLIPS A, SABIN C, SMITH G, al. E (1994). THE EUROPEAN-AUSTRALIAN-COLLABORATIVE-GROUP STUDY-017 OF ZIDOVUDINE VERSUS PLACEBO. , 8(8), 1185 - 1185.
    • PHILLIPS A, SMITH G (1994). CIGARETTE-SMOKING AS A POTENTIAL CAUSE OF CERVICAL-CANCER - HAS CONFOUNDING BEEN CONTROLLED. , 23(1), 42 - 49.
    • PHILLIPS A, SMITH G (1994). RISK-FACTOR EPIDEMIOLOGY. , 343(8897), 603 - 603.
    • PHILLIPS A, SMITH G (1994). SMALL NUMBERS AND POOR MEASUREMENTS - RESPONSE. , 47(8), 959 - 960.
    • SABIN C, LEE C, PHILLIPS A (1994). THE USE OF BACKCALCULATION TO ESTIMATE THE PREVALENCE OF SEVERE IMMUNODEFICIENCY INDUCED BY THE HUMAN-IMMUNODEFICIENCY-VIRUS IN ENGLAND AND WALES. , 157, 41 - 56.
    • SABIN C, PHILLIPS A (1994). THE EFFECT OF PREGNANCY ON HIV DISEASE PROGRESSION. , 7(3), 317 - 317.
    • SABIN C, PHILLIPS A, LEE C, al. E (1994). BETA-2-MICROGLOBULIN AS A PREDICTOR OF PROGNOSIS IN HIV-INFECTED MEN WITH HEMOPHILIA - A PROPOSED STRATEGY FOR USE IN CLINICAL CARE. , 86(2), 366 - 371.
    • SABIN C, PASI J, PHILLIPS A, al. E (1994). CD4+ COUNTS BEFORE AND AFTER SWITCHING TO MONOCLONAL HIGH-PURITY FACTOR-VIII CONCENTRATE IN HIV-INFECTED HEMOPHILIC PATIENTS. , 72(2), 214 - 217.
    • Cozzi-Lepri A, Pezzotti P, Dorrucci M, Phillips AN, Rezza G (1994). HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study. BMJ (Clinical Research Ed.), 309(6968), 1537 - 1542.
    • PHILLIPS A, SMITH GD (1994). CIGARETTE-SMOKING AND CERVICAL-CANCER - REPLY. INT J EPIDEMIOL, 23(5), 1100 - 1100.
    • Phillips AN, Pezzotti P, Cozzi-Lepri A, Rezza G (1994). CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study. AIDS, 8(9), 1299 - 1305.
    • Sabin C, Pasi J, Phillips A, Elford J, Janossy G, Lee C (1994). CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients.. Thromb Haemost, 72(2), 214 - 217.
    • Phillips AN, Sabin CA, Elford J, Bofill M, Janossy G, Lee CA (1994). Use of CD4 lymphocyte count to predict long-term survival free of AIDS after HIV infection.. BMJ, 309(6950), 309 - 313.
    • BIRD G, COOK R, DEANGELIS D, FAREWELL V, FIELDING K, FORE A, GORE S, KRAMER A, LEE C, MCNEIL A, PEZZOTTI P, PHILLIPS A, RABOUD J, REZZA G, SABIN C, SATTEN G, BRETTLE CR, HAMILTON B, POVEY S, RAAB G, RICHARDSON A, AIUTI F, ANGARANO G, BARBANERA M, CANESSA A, CASTELLI F, GAFA S, LAZZARIN A, MURATORI S, PRISTERA R, RICCHI E, SALASSA B, SINICCO A, TIRELLI U, VIALE P, ZACCARELLI M, BOFILL M, ELFORD J, JANOSSY G, GOEDERT J, YELLIN F, COATES R, CALZAVARRA L, REID S (1994). IMMUNOLOGICAL MARKERS OF AIDS PROGRESSION - CONSISTENCY ACROSS 5 HIV-INFECTED COHORTS. AIDS, 8(7), 911 - 921.
    • BIRD G, COOK R, DEANGELIS D, FAREWELL V, FIELDING K, FORE A, GORE S, KRAMER A, LEE C, MCNEIL A, PEZZOTTI P, PHILLIPS A, RABOUD J, REZZA G, SABIN C, SATTEN G, BRETTLE R, HAMILTON B, POVEY S, RAAB G, RICHARDSON A, AIUTI F, ANGARANO G, BARBANERA M, CANESSA A, CASTELLI F, GAFA S, LAZZARIN A, MURATORI S, PRISTERA R, RICCHI E, SALASSA B, SINICCO A, TIRELLI U, VIALE P, ZACCARELLI M, BOFILL M, ELFORD J, JANOSSY G, GOEDERT J, YELLIN F, COATES R, CALZAVARRA L, REID S (1994). IMMUNOLOGICAL MARKER PATHS FOR SEROCONVERSION - SINGLE DETERMINATIONS OF IMMUNOGLOBULIN-A AND BETA(2)-MICROGLOBULIN ARE NOT ADEQUATE TO ESTIMATE TIME OF HIV-INFECTION. AIDS, 8(7), 923 - 933.
    • PHILLIPS AN, ANTUNES F, STERGIOUS G, RANKI A, JENSEN GF, BENTWICH Z, SACKS T, PEDERSEN C, LUNDGREN JD, JOHNSON AM (1994). A SEX COMPARISON OF RATES OF NEW AIDS-DEFINING DISEASE AND DEATH IN 2554 AIDS CASES. AIDS, 8(6), 831 - 835.
    • LUNDGREN JD, PEDERSEN C, CLUMECK N, GATELL JM, JOHNSON AM, LEDERGERBER B, VELLA S, PHILLIPS A, NIELSEN JO, DEWIT S, SOMMEREIJNS B, NIELSEN T, JENSEN G, SKINHOJ P, BENTSEN K, GERSTOFT J, MELBYE M, RANKI A, VALLE SL, KATLAMA C, BERLUREAU P, DIETRICH M, SCHWANDER S, GOEBEL FD, KOSMIDIS J, STERGIOU G, GOUZIA T, PAPADOPOULOS A, BANHEGYI D, MULCAHY F, YUST I, BENISHAI Z, BENTWICH Z, SACKS T, MAAYAN S, CHIESI A, ANCARANI F, SCALISE G, BERTAGGIA A, FRANCAVILLA E, CALONGHI G, CARGNEL A, ARLOTTI M, CIAMMARUGHI R, COLOMBA A, DELALLA F, FASSIO P, FERLINI A, FIACCADORI F, PASETTI G, GIANNELLI F, GRILLONE W, LAZZARIN A, MONFORTE AD, MIGNANI E, NUNNARI A, ORTONA L, PANICHI G, PAULUZZI S, PIERSANTELLI N, RANIERI S, RICCIARDIELLO P, ROSCIOLI B, SORANZO M, HEMMER R, DANNER S, ANTUNES F, PROENCA R, GONZALEZLAHOZ J, MARTINEZBLANCO L, CLOTET B, BUIRA E, MIRO J, PEHRSON P, LUTHY R, OLSSON C, GLAUSER M, HIRSCHEL B, HAWKES S, BARTON S, MORCINEK J, PINCHING A, COLEMAN D (1994). SURVIVAL DIFFERENCES IN EUROPEAN PATIENTS WITH AIDS, 1979-89. BRIT MED J, 308(6936), 1068 - 1073.
    • Phillips AN, Sabin CA, Mocroft A (1994). Active drug injecting and progression of HIV infection. AIDS, 8(3), 385 - 386. doi:10.1097/00002030-199403000-00014
    • Sabin CA, Phillips AN, Lee CA, Elford J, Timms A, Bofill M, Janossy G (1994). Beta-2 microglobulin as a predictor of prognosis in HIV-infected men with haemophilia: a proposed strategy for use in clinical care.. Br J Haematol, 86(2), 366 - 371.
    • Lundgren JD, Pedersen C, Clumeck N, Gatell JM, Johnson AM, Ledergerber B, Vella S, Phillips A, Nielsen JO (1994). Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group. BMJ (Clinical Research Ed.), 308(6936), 1068 - 1073.
    • Lundgren JD, Phillips AN, Pedersen C, Clumeck N, Gatell JM, Johnson AM, Ledergerber B, Vella S, Nielsen JO (1994). Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA, 271(14), 1088 - 1092.
    • Phillips AN, Antunes F, Stergious G, Ranki A, Jensen GF, Bentwich Z, Sacks T, Pedersen C, Lundgren JD, Johnson AM (1994). A sex comparison of rates of new AIDS-defining disease and death in 2554 AIDS cases. AIDS in Europe Study Group. AIDS, 8(6), 831 - 835.
    • Phillips AN, Sabin CA, Elford J, Bofill M, Emery V, Griffiths PD, Janossy G, Lee CA (1994). Viral burden in HIV infection. Nature, 367(6459), 124 - 124. doi:10.1038/367124a0
    • LEPRI A, PEZZOTTI P, DORRUCCI M, al. E (1994). HIV DISEASE PROGRESSION IN 854 WOMEN AND MEN INFECTED THROUGH INJECTING DRUG-USE AND HETEROSEXUAL SEX AND FOLLOWED FOR UP TO 9 YEARS FROM SEROCONVERSION. , 309(6968), 1537 - 1542.

    1993

    • PHILLIPS AN, SABIN CA, BOFILL M, JANOSSY G, LEE CA (1993). CD8+ T-CELL COUNTS UP TO 10 YEARS FROM SEROCONVERSION. J ACQ IMMUN DEF SYND, 6(10), 1176 - 1177.
    • SABIN C, PHILLIPS A, ELFORD J, al. E (1993). THE PROGRESSION OF HIV DISEASE IN A HEMOPHILIC COHORT FOLLOWED FOR 12 YEARS. , 83(2), 330 - 333.
    • PHILLIPS AN, SMITH GD (1993). SMOKING AND HUMAN PAPILLOMAVIRUS INFECTION - CAUSAL LINK NOT PROVED. BRIT MED J, 306(6887), 1268 - 1269.
    • PHILLIPS AN, SABIN CA, BOFILL M, JANOSSY G, LEE CA (1993). ARE THERE 2 TYPES OF RESPONSE TO HIV. LANCET, 341(8851), 1023 - 1024.
    • Sabin C, Phillips A, Elford J, Griffiths P, Janossay G, Lee C (1993). The progression of HIV disease in a haemophilic cohort followed for 12 years.. Br J Haematol, 83(2), 330 - 333.
    • Maini M, Gilson RJC, Adolphus N, Fakoya A, Ross E, Phillips AN (1993). Normal range and sources of variability of CD4 counts in HIV-seronegative women and heterosexual men..
    • FRASER P, PHILLIPS A (1993). EMERGING PATTERNS OF HETEROSEXUAL HIV-INFECTION AND TRANSMISSION - CONFERENCE REPORT. , 4(6), 348 - 352.
    • JANOSSY G, BORTHWICK N, LOMNITZER R, al. E (1993). LYMPHOCYTE-ACTIVATION IN HIV-1 INFECTION .1. PREDOMINANT PROLIFERATIVE DEFECTS AMONG CD45R0 PLUS CELLS OF THE CD4 AND CD8 LINEAGES. , 7(5), 613 - 624.
    • LEE C, SABIN C, PHILLIPS A, al. E (1993). 13-YEAR FOLLOW-UP OF A HEMOPHILIC COHORT. , 69(6), 942 - 942.
    • LEE C, SABIN C, PHILLIPS A, al. E (1993). 13-YEAR FOLLOW-UP OF A HEMOPHILIC COHORT. , 84, 15 - 15.
    • PHILLIPS A, SABIN C (1993). ZIDOVUDINE IN ASYMPTOMATIC HIV-INFECTION. , 329(25), 1895 - 1895.
    • PHILLIPS A, SABIN C, ELFORD J, al. E (1993). ACQUIRED-IMMUNODEFICIENCY-SYNDROME (AIDS) RISK IN RECENT AND LONG-STANDING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-INFECTED PATIENTS WITH SIMILAR CD4 LYMPHOCYTE COUNTS. , 138(10), 870 - 878.
    • PHILLIPS A, SMITH G (1993). CONFOUNDING IN EPIDEMIOLOGIC STUDIES. , 306(6870), 142 - 142.
    • PHILLIPS A, SMITH G (1993). THE DESIGN OF PROSPECTIVE EPIDEMIOLOGIC STUDIES - MORE SUBJECTS OR BETTER MEASUREMENTS. , 46(10), 1203 - 1211.
    • SABIN C, PHILLIPS A (1993). THE RELATIVE EFFICACY OF ORAL DAPSONE AND NEBULIZED PENTAMIDINE AS PROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONIA. , 7(3), 440 - 440.
    • SABIN C, PHILLIPS A, ELFORD J, al. E (1993). THE INCIDENCE OF HIV-RELATED DISEASE IN A COHORT OF HEMOPHILIC MEN - NATURAL-HISTORY AND CHANGES SINCE THE INTRODUCTION OF PRE-AIDS TREATMENT. , 15(4), 241 - 251.
    • SABIN C, LEE C, PHILLIPS A (1993). NEW AIDS DEFINITION. , 341(8838), 178 - 178.
    • PHILLIPS AN, SABIN CA, ELFORD J, BOFILL M, LEE CA, JANOSSY G (1993). CD8 LYMPHOCYTE COUNTS AND SERUM IMMUNOGLOBULIN-A LEVELS EARLY IN HIV-INFECTION AS PREDICTORS OF CD4 LYMPHOCYTE DEPLETION DURING 8 YEARS OF FOLLOW-UP. AIDS, 7(7), 975 - 980.

    1992

    • PHILLIPS A (1992). STUDIES OF PROGNOSTIC MARKERS IN HIV-INFECTION - IMPLICATIONS FOR PATHOGENESIS. , 6(11), 1391 - 1394.
    • LEE CA, PHILLIPS AN, ELFORD J, GRIFFITHS P, BOFILL M, SWADEN L, JANOSSY G, KERNOFF PBA (1992). APPLICATIONS OF CD4 COUNTS IN A COHORT OF HIV-1 SEROPOSITIVE PATIENTS WITH HEMOPHILIA.
    • PHILLIPS A, NEATON J, COOK D, al. E (1992). LEUKOCYTE COUNT AND RISK OF MAJOR CORONARY HEART-DISEASE EVENTS. , 136(1), 59 - 70.
    • Bofill M, Janossy G, Lee CA, MacDonald-Burns D, Phillips AN, Sabin C, Timms A, Johnson MA, Kernoff PB (1992). Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis.. Clin Exp Immunol, 88(2), 243 - 252.
    • Phillips AN, Keenlyside R, Johnson AM (1992). The effect of antiviral therapy on the natural history of HIV infection. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 5(10), 1065 - 1066.
    • Phillips A, Johnson A (1992). Female-to-male transmission of HIV. JAMA, 268(14), 1855 - 1856.
    • BOFILL M, JANOSSY G, LEE C, al. E (1992). LABORATORY CONTROL VALUES FOR CD4 AND CD8 LYMPHOCYTES-T - IMPLICATIONS FOR HIV-1 DIAGNOSIS. , 88(2), 243 - 252.
    • PHILLIPS A (1992). CD4 LYMPHOCYTE DEPLETION PRIOR TO THE DEVELOPMENT OF AIDS. , 6(7), 735 - 736.
    • PHILLIPS A, ELFORD J, SABIN C, al. E (1992). PATTERN OF CD4+ T-CELL LOSS IN HIV-INFECTION. , 5(9), 950 - 951.
    • PHILLIPS A, LEE C, ELFORD J, al. E (1992). THE CUMULATIVE RISK OF AIDS AS THE CD4 LYMPHOCYTE COUNT DECLINES. , 5(2), 148 - 152.
    • PHILLIPS A, NEATON J, COOK D, al. E (1992). THE LEUKOCYTE COUNT AND RISK OF LUNG-CANCER. , 69(3), 680 - 684.
    • PHILLIPS A, SMITH G (1992). BIAS DUE TO MEASUREMENT IMPRECISION. , 339(8806), 1418 - 1419.
    • PHILLIPS A, SMITH G (1992). BIAS IN RELATIVE ODDS ESTIMATION OWING TO IMPRECISE MEASUREMENT OF CORRELATED EXPOSURES. , 11(7), 953 - 961.
    • PHILLIPS A, SMITH G (1992). COLLINEARITY AND IMPRECISION IN DIETARY MEASUREMENT. , 45(6), 681 - 682.
    • PHILLIPS A, SMITH G (1992). HIV-INFECTION AND SMOKING-BEHAVIOR. , 268(12), 1539 - 1540.
    • SABIN C, PHILLIPS A, ELFORD J, al. E (1992). PROGRESSION TO AIDS IN HIV-INFECTED PATIENTS WITH ORAL CANDIDIASIS OR HAIRY LEUKOPLAKIA. , 6(7), 750 - 751.
    • SMITH G, PHILLIPS A (1992). CONFOUNDING IN EPIDEMIOLOGIC STUDIES - WHY INDEPENDENT EFFECTS MAY NOT BE ALL THEY SEEM. , 305(6856), 757 - 759.
    • SMITH G, PHILLIPS A, NEATON J (1992). SMOKING AS INDEPENDENT RISK FACTOR FOR SUICIDE - ILLUSTRATION OF AN ARTIFACT FROM OBSERVATIONAL EPIDEMIOLOGY. , 340(8821), 709 - 712.
    • WEBSTER A, PHILLIPS A, LEE C, al. E (1992). CYTOMEGALOVIRUS (CMV) INFECTION, CD4+ LYMPHOCYTE COUNTS AND THE DEVELOPMENT OF AIDS IN HIV-1-INFECTED HEMOPHILIAC PATIENTS. , 88(1), 6 - 9.
    • McCormick PA, Morgan MY, Phillips A, Yin TP, McIntyre N, Burroughs AK (1992). The effects of alcohol use on rebleeding and mortality in patients with alcoholic cirrhosis following variceal haemorrhage.. J Hepatol, 14(1), 99 - 103.
    • BOFILL M, JANOSSY G, PHILLIPS AN, TIMMS A, MACDONALDBURNS D, JOHNSON MA, LEE CA (1992). NORMAL CONTROL VALUES FOR CD4 AND CD8 LYMPHOCYTES-T AND THEIR RELEVANCE FOR HIV-1 INFECTIONS.
    • PHILLIPS A, ELFORD J, SABIN C, al. E (1992). IMMUNODEFICIENCY AND THE RISK OF DEATH IN HIV-INFECTION. , 268(19), 2662 - 2666.

    1991

    • WALKER M, SHAPER A, PHILLIPS A, al. E (1991). STATURE AND THE RISK OF MYOCARDIAL-INFARCTION IN WOMEN. , 133(4), 411 - 412.
    • Phillips AN, Lee CA, Elford J, Janossy G, Timms A, Bofill M, Kernoff PB (1991). Serial CD4 lymphocyte counts and development of AIDS.. Lancet, 337(8738), 389 - 392.
    • BARRADAS M, MIKHAILIDIS D, PHILLIPS A, al. E (1991). ALBUMIN, HEMOSTASIS AND CARDIOVASCULAR-DISEASE. , 5(2), 131 - 131.
    • LEE C, PHILLIPS A, ELFORD J, al. E (1991). PROGRESSION OF HIV DISEASE IN A HEMOPHILIC COHORT FOLLOWED FOR 11 YEARS AND THE EFFECT OF TREATMENT. , 303(6810), 1093 - 1096.
    • PHILLIPS A, LEE C, ELFORD J, al. E (1991). MORE RAPID PROGRESSION TO AIDS IN OLDER HIV-INFECTED PEOPLE - THE ROLE OF CD4+ T-CELL COUNTS. , 4(10), 970 - 975.
    • PHILLIPS A, LEE C, ELFORD J, al. E (1991). P24 ANTIGENEMIA, CD4 LYMPHOCYTE COUNTS AND THE DEVELOPMENT OF AIDS. , 5(10), 1217 - 1222.
    • SMITH G, SHIPLEY M, PHILLIPS A (1991). ALCOHOL-CONSUMPTION AND RISK OF CORONARY HEART-DISEASE. , 303(6801), 521 - 521.
    • PHILLIPS A, SHAPER A (1991). SERUM-CALCIUM AND BLOOD-PRESSURE. , 5(6), 479 - 484.
    • PHILLIPS A, SMITH G (1991). HOW INDEPENDENT ARE INDEPENDENT EFFECTS - RELATIVE RISK-ESTIMATION WHEN CORRELATED EXPOSURES ARE MEASURED IMPRECISELY. , 44(11), 1223 - 1231.
    • PHILLIPS A, LEE C, ELFORD J, al. E (1991). MONITORING CD4 COUNTS IN HIV-INFECTION - REPLY. , 337(8749), 1108 - 1109.
    • SHAPER A, PHILLIPS A, POCOCK S, al. E (1991). RISK-FACTORS FOR STROKE IN MIDDLE-AGED BRITISH MEN. , 302(6785), 1111 - 1115.
    • SMITH G, PHILLIPS A (1991). SOCIOECONOMIC CONDITIONS AND ISCHEMIC-HEART-DISEASE. , 302(6768), 113 - 114.
    • PHILLIPS A, LEE C, ELFORD J, al. E (1991). SERIAL LYMPHOCYTE-CD4 COUNTS AND DEVELOPMENT OF AIDS. , 337(8738), 389 - 392.

    1990

    • SMITH GD, PHILLIPS A (1990). DECLARING INDEPENDENCE - WHY WE SHOULD BE CAUTIOUS. J EPIDEMIOL COMMUN H, 44(4), 257 - 258.
    • PHILLIPS A, SHAPER AG (1990). LIPID SCREENING. BRIT MED J, 301(6757), 928 - 928.
    • PHILLIPS A, SHAPER AG, WHINCUP PH (1990). SERUM-PROTEINS AND MORTALITY. LANCET, 335(8693), 858 - 858.
    • WALKER M, PHILLIPS A, SHAPER AG (1990). BLOOD CHOLESTEROL, SOCIAL-CLASS AND HEIGHT. J PUBLIC HEALTH MED, 12(2), 142 - 143.
    • LEE C, PHILLIPS A, ELFORD J, al. E (1990). 10-YEAR FOLLOW-UP OF HIV-INFECTION IN A HEMOPHILIC COHORT. , 75(4), 623 - 623.
    • PHILLIPS A, THOMPSON S, POCOCK S (1990). PROGNOSTIC SCORES FOR DETECTING A HIGH-RISK GROUP - ESTIMATING THE SENSITIVITY WHEN APPLIED TO NEW DATA. , 9(10), 1189 - 1198.
    • WHINCUP P, COOK D, PHILLIPS A, al. E (1990). ABO BLOOD-GROUP AND ISCHEMIC-HEART-DISEASE IN BRITISH MEN. , 300(6741), 1679 - 1682.
    • Elford J, Phillips A, Thomson AG, Shaper AG (1990). Migration and geographic variations in blood pressure in Britain.. BMJ, 300(6720), 291 - 295.

    1989

    • Phillips A, Lee CA, Elford J, Janossy G, Bofill M, Timms A, Kernoff PB (1989). Prediction of progression to AIDS by analysis of CD4 lymphocyte counts in a haemophilic cohort.. AIDS, 3(11), 737 - 741.
    • BURROUGHS AK, MCCORMICK PA, SIRINGO S, PHILLIPS A, SPRENGERS D, MCINTYRE N (1989). RANDOMIZED TRIAL OF LONGTERM SCLEROTHERAPY FOR VARICEAL REBLEEDING USING THE SAME PROTOCOL TO TREAT REBLEEDING IN ALL PATIENTS - FINAL REPORT. GUT, 30(10), A1506 - A1506.
    • BURROUGHS AK, MCCORMICK PA, SIRINGO S, PHILLIPS A, SPRENGERS D, MCINTYRE N (1989). PROSPECTIVE RANDOMIZED TRIAL OF LONG-TERM SCLEROTHERAPY FOR VARICEAL REBLEEDING USING THE SAME PROTOCOL TO TREAT REBLEEDING IN ALL PATIENTS - FINAL REPORT. HEPATOLOGY, 10(4), 579 - 579.
    • Burroughs AK, Hamilton G, Phillips A, Mezzanotte G, McIntyre N, Hobbs KE (1989). A comparison of sclerotherapy with staple transection of the esophagus for the emergency control of bleeding from esophageal varices.. N Engl J Med, 321(13), 857 - 862. doi:10.1056/NEJM198909283211303
    • Burroughs AK, Mezzanotte G, Phillips A, McCormick PA, McIntyre N (1989). Cirrhotics with variceal hemorrhage: the importance of the time interval between admission and the start of analysis for survival and rebleeding rates.. Hepatology, 9(6), 801 - 807.
    • ELFORD J, PHILLIPS A, THOMSON A, al. E (1989). MIGRATION AND GEOGRAPHIC VARIATIONS IN ISCHEMIC HEART-DISEASE IN GREAT-BRITAIN. , 1(8634), 343 - 346.
    • PHILLIPS A, POCOCK S (1989). SAMPLE-SIZE REQUIREMENTS FOR PROSPECTIVE STUDIES, WITH EXAMPLES FOR CORONARY HEART-DISEASE. , 42(7), 639 - 648.
    • PHILLIPS A, SHAPER A (1989). RELATIVE WEIGHT AND MAJOR ISCHEMIC-HEART-DISEASE EVENTS IN HYPERTENSIVE AND NORMOTENSIVE MEN. , 7, S391 - S391.
    • PHILLIPS A, SHAPER A (1989). SECONDARY PREVENTION OF CORONARY HEART-DISEASE. , 1(8640), 718 - 719.
    • PHILLIPS A, SHAPER A (1989). RELATIVE WEIGHT AND MAJOR ISCHEMIC HEART-DISEASE EVENTS IN HYPERTENSIVE MEN. , 1(8645), 1005 - 1008.
    • PHILLIPS A, SHAPER A, WHINCUP P (1989). ASSOCIATION BETWEEN SERUM-ALBUMIN AND MORTALITY FROM CARDIOVASCULAR-DISEASE, CANCER, AND OTHER CAUSES. , 2(8677), 1434 - 1436.
    • POCOCK S, SHAPER A, PHILLIPS A (1989). CONCENTRATIONS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, TRIGLYCERIDES, AND TOTAL CHOLESTEROL IN ISCHEMIC HEART-DISEASE. , 298(6679), 998 - 1002.
    • POCOCK S, SHAPER A, PHILLIPS A (1989). HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, TRIGLYCERIDES, AND ISCHEMIC HEART-DISEASE - A REAPPRAISAL. , 61(1), 106 - 107.
    • SHAPER A, PHILLIPS A, POCOCK S (1989). PLASMA-CHOLESTEROL, CORONARY HEART-DISEASE, AND CANCER. , 298(6684), 1381 - 1381.
    • SIRINGO S, MCCORMICK P, MISTRY P, al. E (1989). PROGNOSTIC IMPORTANCE - VARICEAL WHITE NIPPLE SIGN (PLATELET-FIBRIN PLUG) IN ACUTE VARICEAL BLEEDING. , 30(10), A1461 - A1461.
    • WALKER M, SHAPER A, PHILLIPS A, al. E (1989). SHORT STATURE, LUNG-FUNCTION AND RISK OF A HEART-ATTACK. , 18(3), 602 - 606.
    • Lee CA, Phillips A, Elford J, Miller EJ, Bofill M, Griffiths PD, Kernoff PB (1989). The natural history of human immunodeficiency virus infection in a haemophilic cohort.. Br J Haematol, 73(2), 228 - 234.

    1988

    • Pocock SJ, Shaper AG, Phillips AN, Walker M (1988). Prediction of men at high risk of heart attack and its relevance to pilots.. Eur Heart J, 9 Suppl G, 25 - 30.
    • MCCORMICK PA, MEZZANOTTE G, PHILLIPS A, MCINTYRE N, BURROUGHS AK (1988). VARICEAL BLEEDING - IMPORTANCE OF THE TIME INTERVAL BETWEEN ADMISSION AND STARTING POINT FOR ANALYSIS OF SURVIVAL AND REBLEEDING. GUT, 29(5), A719 - A719.
    • MACFARLANE P, PHILLIPS A, WALKER M, al. E (1988). BRITISH REGIONAL HEART-STUDY - AN ECG ASSESSMENT OF RISK. , 59(1), 136 - 136.
    • SHAPER A, PHILLIPS A, POCOCK S, al. E (1988). SYSTOLIC AND DIASTOLIC BLOOD PRESSURES IN PREDICTION OF HEART-ATTACKS AND STROKE. , 59(1), 97 - 97.
    • PHILLIPS A, SHAPER A, POCOCK S, al. E (1988). RISK-FACTORS IN PREDICTION OF HEART-ATTACKS IN MEN WITH PRE-EXISTING ISCHEMIC HEART-DISEASE. , 59(1), 100 - 100.
    • PHILLIPS A, SHAPER A, POCOCK S, al. E (1988). THE ROLE OF RISK-FACTORS IN HEART-ATTACKS OCCURRING IN MEN WITH PRE-EXISTING ISCHEMIC HEART-DISEASE. , 60(5), 404 - 410.
    • PHILLIPS A, SHAPER A, POCOCK S, al. E (1988). PARENTAL DEATH FROM HEART-DISEASE AND THE RISK OF HEART-ATTACK. , 9(3), 243 - 251.

    1987

    • POCOCK S, COOK D, SHAPER A, al. E (1987). SOCIAL-CLASS DIFFERENCES IN ISCHEMIC-HEART-DISEASE IN BRITISH MEN. , 2(8552), 197 - 201.
    • SHAPER A, PHILLIPS A, POCOCK S, al. E (1987). ALCOHOL AND ISCHEMIC-HEART-DISEASE IN MIDDLE-AGED BRITISH MEN - REPLY. , 294(6582), 1288 - 1289.
    • SHAPER A, PHILLIPS A, POCOCK S, al. E (1987). SYSTOLIC AND DIASTOLIC BLOOD PRESSURES IN THE PREDICTION OF HEART-ATTACKS AND STROKE. , 5(6), 764 - 764.
    • SHAPER A, PHILLIPS A, POCOCK S, al. E (1987). ALCOHOL AND ISCHEMIC-HEART-DISEASE IN MIDDLE-AGED BRITISH MEN. , 294(6574), 733 - 737.

    1986

    • BURROUGHS AK, DHEYGERE F, PHILLIPS A, DOOLEY J, EPSTEIN O, MCINTYRE N (1986). PROSPECTIVE RANDOMIZED TRIAL OF CHRONIC SCLEROTHERAPY TO PREVENT VARICEAL REBLEEDING USING THE SAME PROTOCOL TO TREAT BLEEDING - INTERIM ANALYSIS. GUT, 27(10), 1246 - 1247.
    • BURROUGHS AK, DHEYGERE F, PHILLIPS A, HOBBS KEF, MCINTYRE N (1986). PROSPECTIVE RANDOMIZED TRIAL OF ENDOSCOPIC SCLEROTHERAPY VERSUS ESOPHAGEAL STAPLE TRANSECTION FOR ACUTE VARICEAL BLEEDING - SINGLE INTERIM ANALYSIS. GUT, 27(10), 1266 - 1266.
    • BURROUGHS AK, DHEYGERE F, PHILLIPS A, HOBBS KEF, MCINTYRE N (1986). PROSPECTIVE RANDOMIZED TRIAL OF ENDOSCOPIC SCLEROTHERAPY VERSUS ESOPHAGEAL STAPLE TRANSECTION FOR ACUTE VARICEAL BLEEDING - INTERIM ANALYSIS. HEPATOLOGY, 6(5), 1152 - 1152.
    • BURROUGHS AK, DHEYGERE F, PHILLIPS A, DOOLEY J, EPSTEIN O, MCINTYRE N (1986). PROSPECTIVE RANDOMIZED TRIAL OF ELECTIVE SCLEROTHERAPY TO PREVENT VARICEAL REBLEEDING, USING THE SAME PROTOCOL TO TREAT BLEEDING - INTERIM ANALYSIS. HEPATOLOGY, 6(5), 1152 - 1152.
    • SHAPER A, POCOCK S, PHILLIPS A, al. E (1986). IDENTIFYING MEN AT HIGH-RISK OF HEART-ATTACKS - REPLY. , 293(6550), 818 - 818.
    • DHEYGERE F, BURROUGHS AK, PHILLIPS A, MCINTYRE N (1986). MULTIPLE LOGISTIC ANALYSIS OF PUGH CRITERIA FOR EARLY MORTALITY FROM VARICEAL BLEEDING - COMPARISON WITH OTHER MODIFIED CHILD CLASSIFICATIONS. GUT, 27(10), 1266 - 1266.
    • BURROUGHS AK, DHEYGERE F, PHILLIPS A, MCINTYRE N (1986). PREDICTIVE MODEL FOR EARLY FAILURE TO CONTROL VARICEAL BLEEDING. HEPATOLOGY, 6(5), 1153 - 1153.
    • POCOCK S, SHAPER A, PHILLIPS A, al. E (1986). HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL IS NOT A MAJOR RISK FACTOR FOR ISCHEMIC-HEART-DISEASE IN BRITISH MEN. , 292(6519), 515 - 519.
    • POCOCK S, SHAPER A, PHILLIPS A, al. E (1986). HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL IS NOT A MAJOR RISK FACTOR FOR ISCHEMIC-HEART-DISEASE IN BRITISH MEN - REPLY. , 292(6526), 1013 - 1014.
    • SHAPER A, POCOCK S, PHILLIPS A, al. E (1986). IDENTIFYING MEN AT HIGH-RISK OF HEART-ATTACKS - STRATEGY FOR USE IN GENERAL-PRACTICE. , 293(6545), 474 - 479.
    • SHAPER A, WALKER M, PHILLIPS A, al. E (1986). FAMILY HISTORY AS A RISK FACTOR FOR ISCHEMIC-HEART-DISEASE. , 7, 14 - 14.
    • DHEYGERE F, BURROUGHS AK, PHILLIPS A, MCINTYRE N (1986). MULTIPLE LOGISTIC ANALYSIS OF THE PROGNOSTIC VALUE OF PUGH CRITERIA FOR EARLY MORTALITY FROM VARICEAL BLEEDING - COMPARISON WITH OTHER MODIFIED CHILDS CLASSIFICATIONS. HEPATOLOGY, 6(5), 1152 - 1152.

    1985

    • SHAPER A, POCOCK S, WALKER M, al. E (1985). RISK-FACTORS FOR ISCHEMIC HEART-DISEASE - THE PROSPECTIVE PHASE OF THE BRITISH REGIONAL HEART-STUDY. , 39(3), 197 - 209.
    • POCOCK S, SHAPER A, PHILLIPS A, al. E (1985). HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL, ALCOHOL INTAKE AND ISCHEMIC HEART-DISEASE. , 53(1), 102 - 102.

    • Castro H, Dunn DT, Cane P, et al (). Persistence of transmitted HIV drug resistance mutations.
    • Samri A, Lampe F, Autran B, Phillips AN, Goh L, El Habib R, Theofan G, Kinloch S, the QUEST Core and Study Group (). Multifunctional HIV-1 specific CD4 and CD8 T cell responses during a therapeutic immunization study (QUEST) in HAART-Treated acutely-infected (PHI) subjects - abstract H-116.
    • McDonnell J, Haddow L, Daskalopoulo M, Lampe F, Speakman A, Gilson R, Phillips A, Sherr L, Wayal S, Harrison J, Antinori A, Maruf P, Schembri A, Johnson M, Collins S (). Minimal cognitive impairment in HIV positive men who have sex with men (MSM) in the United Kingdom: comparison with the general population and HIV negative MSM.. JAIDS: Journal of Acquired Immune Deficiency Syndromes, , - .
    • BANSI LK, BENZIE AA, PHILLIPS AN, al. E (). Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?.
    • EMERY S, NEUHAUS JA, PHILLIPS AN, al. E (). Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study..
    • ANGUS B, LAMPE F, TAMBUSSI G, al. E (). TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals..